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ABSTRACT  
   
With the number of internationally-run clinical drug trials increasing, the double 
standards between those in developed nations and those in developing nations are being 
scrutinized under the ethical microscope. Many argue that several pharmaceutical 
companies and researchers are exploiting developing nation participants. Two issues of 
concern are the use of a placebo control when an effective alternative treatment exists and 
the lack of drug availability to the country that hosted the clinical trial should the 
experimental drug prove effective. Though intuitively this seems like an instance of 
exploitation, philosophically, exploitation theories cannot adequately account for the 
wrongdoing in these cases. My project has two parts. First, after explaining why the 
theories of Alan Wertheimer, John Lawrence Hill, and Ruth Sample fail to explain the 
exploitation in clinical drug research, I provide an alternative account of exploitation that 
can explain why the double standard in clinical research is harmful. Rather than craft a 
single theory encompassing all instances of exploitation, I offer an account of a type, or 
subset, of exploitation that I refer to as comparative exploitation. The double standards in 
clinical research fall under the category of comparative exploitation. Furthermore, while 
many critics maintain that cases of comparative exploitation, including clinical research, 
are mutually beneficial, they are actually harmful to its victims. I explain the harm of 
comparative exploitation using Ben Bradley's counterfactual account of harm and Larry 
May's theory of sharing responsibility. The second part of my project focuses on the 
"standard of care" argument, which most defenders use to justify the double standard in 
clinical research. I elaborate on Ruth Macklin's position that advocates of the "standard of 
care" position make three faulty assumptions: placebo-
ii 
standard, the only relevant question responsive to the host country's health needs is "Is 
the experimental product being studied better than the 'nothing' now available to the 
population?", and the only way of obtaining affordable products is to test cheap 
alternatives to replace the expensive ones. In the end, I advocate moving towards a 
universalizing of standards in order to avoid exploitation. 
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Chapter 1: THE PROBLEM 
Introduction 
 In the past two decades, clinical drug research run abroad has dramatically 
increased.  From 1990 to 1999, the number of countries hosting research involving 
human subjects jumped from twenty-nine to seventy-nine, the largest growth occurring in 
Russia, Eastern Europe and Latin America.1  By 2004, the Food and Drug Administration 
(FDA) estimated that those drug companies petitioning for FDA approval for new 
products were launching over sixteen hundred new trials overseas every year.2  Of the 
141, 132 trials registered on ClinicalTrials.gov from 2000 to February 2013, only forty-
one percent of the studies were run only in the United States.  Six percent were run both 
inside and outside of the United States, and forty-three percent were only run outside of 
the United States.3 
 Several factors have generated the migration abroad, particularly to “low-cost” 
countries.  Throughout this dissertation, those countries shall be referred to as developing 
countries.  The primary motivator for moving drug trials abroad has been to cut costs.  
Thomas Fogarty, inventor and founder of Mountain View’s Fogarty Institute for 
Innovation, stated that many companies are looking at regions where labor costs are 
drastically lower, such as Paraguay, Argentina, and Mexico.  He states, “[y]ou can find 
people there who are well-trained in their work and do follow-up with patients.  It’s an 
                                                
1 Ruth Macklin, Double Standards in Medical Research in Developing Countries 
(Cambridge: Cambridge University Press, 2004), 7. 
2 Sonia Shah, The Body Hunters: Testing New Drugs on the World’s Poorest Patients 
(New York: The New Press, 2006), 7. 
3 “Trends, Charts, and Maps,” ClinicalTrials.gov, last reviewed August 2012, 
http://www.clinicaltrials.gov/ct2/resources/trends. 
2 
affordable process in those places.”4  With the process of bringing a new drug to market 
costing up to $1 million, venture-backed companies want to save as much money as 
possible in order to maximize profits gained from the new drug.5  GlaxoSmithKline’s 
CEO in 2004 claimed $200 million a year in savings due to the relocation of around thirty 
percent of its trial business to “low-cost” countries such as Poland and India.   
 While cheaper labor and resources accounts for part of that cost, the increased 
speed at which they are able to run trials accounts for the other.  Trial participants are 
often hard to find.  In 2006, trouble finding participants led to an average 4.6 months lost 
per trial.6  In 2002, it was reported that less than four percent of cancer patients, who 
generally have the most to gain from experimental treatments, volunteer for trials.7  
While recruitment is slow in the United States, recruitment abroad is much more rapid.  
When little healthcare exists in a country, people leap at an opportunity to receive 
treatment.  For example, Quintiles was able to find 3,000 volunteers in South Africa for 
an experimental vaccine study in just nine days.8  For many clinical trials are the only the 
participants only way to have modern medical care as either their country lacks the 
resources for modern medical care or the participants cannot afford it as they have no 
insurance.  As Laxminarayn Bhat, founder and CEO of San Jose-based Reviva 
                                                
4 David Goll, “Clinical trials move overseas to speed process, save money,” Silicon 
Valley Business Journal, April 13, 2012, accessed April 17, 2013, 
http://www.bizjournals.com/sanjose/print-edition/2012/04/13/clinical-trials-move-
overseas-to-speed.html?page=all. 
5 Goll, ““Clinical trials move overseas to speed process, save money.” 
6 Beasely, "Recruiting," 2006, quoted in “Clinical Trial Facts & Figures,” The Center for 
Information & Study on Clinical Research Participation, accessed April 17, 2013, 
http://www.ciscrp.org/professional/facts_pat.html. 
7 Shah. The Body Hunters, 4. 
8 Shah. The Body Hunters, 9. 
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Pharmaceuticals Inc., explains, “[h]ere in the U.S., most people have insurance, so it’s 
difficult to get volunteers. . .  If you can get one or two patients, you’re doing well.  If 
you go to Russia or some places in Asia, where people are paying for health care out of 
pocket, it’s much easier to find people to participate in trials.”9    
 Moreover those participants in developing nations are less likely to complain and 
drop out of a trial.  In 2003, Vijai Kumar, head of a New Delhi-based industry trial 
center, boasted that they have retained 99.5 percent of subjects enrolled.10  John 
Wurzlemann, MD recounts a study completed in both the United States and Russia in 
which venograms were used.  Venograms require patients to have a surgically inserted 
intravenous catheter to administer contrast-heightening chemicals so that x-rays could be 
more easily read.  The invasive venogram had been largely replaced by noninvasive CT 
scans and MRIs in the United States.  The portion of the study in Russia not only 
received more patients, but patients were very willing to have the venogram procedure as 
no other alternative existed.11   
 An additional financial advantage is that researchers are able to run placebo 
control trials in developing nations that they would not otherwise be able to in developed 
nations.   In those cases, a placebo control could not be used because an alternative 
proven treatment exists on the market in developed worlds.  To run a placebo control 
when an alternative exists and is available in that country is considered unethical, 
particularly by the FDA.  However, if the drug is not available on the market, such as in 
many developing nations, than it has been permissible to use a placebo control.  By 
                                                
9 Goll, ““Clinical trials move overseas to speed process, save money.” 
10 Shah. The Body Hunters, 9. 
11 Shah. The Body Hunters, 9. 
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permissible, I mean that the trials that use a placebo control in those instances - where the 
alternative treatment is not available in that nation - have passed FDA inspection.  As will 
be discussed at length in Chapter 3, the FDA passes placebo control trials faster than 
active control trials.  That is because trials with a placebo control have efficacy data that 
is more readily acceptable for the FDA.  As we shall see, there is much debate as to 
whether an active control trial can produce the efficacy data that placebo controls do.   
There are high costs associated with delay of a drug’s release on a market.  In 2008, it 
was estimated that a pharmaceutical company loses $8 million each day that a drug 
release on the market is delayed.12  As a result, companies want to pass through the FDA 
approval process as fast as possible, which means providing them with the type of data 
they are most ready to accept, which has historically been placebo control data. 
 There are also scientific advantages of running trials in developing nations.  
Subjects in developing nations have significantly less access to healthcare than in other 
more industrialized nations.  As a result, they are exposed to fewer drugs than subjects in 
industrialized nations.  This yields more reliable results for the experimental drug, as 
there is little worry about the experimental drug interacting with others.  As one industry 
spokesperson is quoted as saying, “[y]ou want patients with no other disease states and 
no other treatments.  Then you can say relatively clearly that whatever happens to those 
patients is from the drug.”13 
                                                
12 Beasely, "Recruiting," 2008, quoted in “Clinical Trial Facts & Figures,” The Center for 
Information & Study on Clinical Research Participation, accessed April 17, 2013, 
http://www.ciscrp.org/professional/facts_pat.html. 
13 Sonia Shah, “Globalizing Clinical Research,” The Nation (July 1, 2002): 23, quoted in 
Ruth Macklin, Double Standards in Medical Research in Developing Countries 
(Cambridge: Cambridge University Press, 2004), 7. 
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 With the increase in drug trials, one might assume that the developing world is 
getting healthier; however, that is not the case.  Americans have been getting healthier.  
Between 1965 and 1996 death rates from blocked arteries dropped by seventy-four 
percent, from heart disease by sixty-two percent, and from hypertension by twenty-one 
percent.14  The Center for Disease Control reports that the death rate in the United States 
has dropped by sixty percent between 1935 and 2010.15  They also reported that in 2010 
the top five leading causes of death were heart disease, cancer, chronic lower respiratory 
disease, stroke, and accidents.  The developing world, on the other hand, is not getting 
healthier.  The top five causes of death for low-income countries are, in order, lower 
respiratory infections, diarrheal diseases, HIV/AIDS, ischaemic heart disease, and 
malaria.16  Many of the diseases leading to death in the developing world have been 
minimized in the developed world.  For example in 2000, more than one million people, 
mostly children, died of Malaria in Africa, whereas only 1200 were diagnosed with 
Malaria in the United states, most occurring in immigrants or travelers.17  Because the 
market for infectious and tropical diseases is small, little money is spent on researching 
those diseases.  As Alan Wertheimer notes, ninety percent of the global research budget 
is spent on illnesses that cause ten percent of the world’s disease burden; whereas, ten 
                                                
14 Shah. The Body Hunters, 44. 
15 Donna L. Hoyert,“75 years of mortality in the United States,” 1935-2010 NCHS Data 
Brief, 88 (Hyattsville, MD: National Center for Health Statistics, 2012), accessed April 
17, 2013, http://www.cdc.gov/nchs/data/databriefs/db88.htm. 
16 “The top 10 causes of death,” World Health Organization, updated June 2011, 
http://www.who.int/mediacentre/factsheets/fs310/en/index.html. 
17 Macklin, Double Standards in Medical Research in Developing Countries, 9. 
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percent of the global research budget is spent on illnesses affecting ninety percent of the 
world’s population.18 
 The increasing exportation of clinical research to developing nations, which best 
serves the needs of the developed world, demands higher scrutiny under the ethical 
microscope.  Many argue that researchers and pharmaceutical companies are exploiting 
developing nations.  Particularly, one questions the conduct of researchers and 
pharmaceutical companies when different standards are used in a developing nation 
versus a developed nation.  On the face of it having two standards for conducting clinical 
research trials, one with much more lax standards, seems like widespread exploitation, 
exploitation theories cannot adequately account for the wrongdoing in these cases.  That 
is because it seems as if the victims in the case of clinical trials are benefitting rather than 
being harmed as they have the opportunity to be receive healthcare that they would 
otherwise not receive.  The literature refers to cases of exploitation where the victim 
benefits as mutually beneficial exploitation.  Mutually beneficial exploitation is a source 
of difficulty for many exploitation theories because it is difficult to understand why it is 
morally wrong. 
 In this dissertation, I argue that while existing theories may not be able to explain 
the exploitative nature of the double standards in clinical research, researchers and 
pharmaceutical companies are exploiting developing nations.  Specifically, I argue that 
clinical research is a type of exploitation I call “comparative exploitation.”  While 
instances of comparative exploitation, like clinical research, may seem mutually 
                                                
18 Alan Wertheimer, Rethinking the Ethics of Clinical Research: Widening\ the Lens 
(Oxford Scholarship Online, 2010), 7, accessed April 17, 2013, 
http://lib.myilibrary.com.ezproxy1.lib.asu.edu?ID=294138. 
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beneficial, they are actually harmful to its victims.  Moreover, I will also contend that the 
traditional response to charges of exploitation, the “standard of care” response, fails to 
justify the double standards.  While considering the exploitative nature of clinical 
research in developing nations, I will look at two particular issues - placebo-controlled 
trials and the availability of the experimental drug should it be proven effective.   
 In the rest of this chapter, I will offer background information on clinical research 
and set up the problem of exploitation in developing nations.  After offering information 
on the developed versus developing country distinction and the history of guidelines 
regulating clinical research, I will explain the double standard between trials in developed 
nations and developing nations.  Specifically, once I explain two case studies, I will 
explore the issues of placebo controls, drug availability, and consent.  I will, then, explain 
why exploitation is the appropriate model for this situation.  Finally, I will briefly explain 
the topics of the remaining chapters. 
 
Developed versus Developing 
 The terms “developed” and “developing” are terms typically used to compare 
nations’ economic levels, with developed countries at the higher wealthier levels and 
developing at the lower poorer levels.  Developed nations are also often called 
“industrialized,” as opposed to “industrializing” to indicate the process of becoming an 
industrialized economy, or “non-industrialized.”  Of the 158 nations that are members of 
8 
the World Trade Organization, about two-thirds are self-proclaimed as developing,19 and 
34 nations of that two-thirds are recognized as least-developed countries.20   
 Despite their widespread use, there is not hard and fast line distinguishing 
between developed, developing and least developed nations.  Rather than a 
categorization, it seems that the distinctions ought to be more of a sliding scale with 
developed and least developed at opposite ends so as to reflect the distinctions between 
nations.  There is a trend, however, when discussing specific countries to label Western 
Europe, North America, Japan Australia, and New Zealand as developed and label all 
others as developing.  There is a lot of controversy concerning these labels.  For example, 
is China a developed or a developing nation?  If it is a developing nation, than ought it to 
be categorized under the same label as more economically impoverished nations, such as 
Ethiopia?  Ruth Macklin argues that, particularly for evaluating the research enterprise, 
the categorization depends on which features of the country we wish to talk about.  She 
explains, 
 [i]t is appropriate to lump together countries that are resource-poor, since neither 
 the government nor the majority of citizens can afford medical treatments that 
 become largely available to residents of wealthier countries once research is 
 concluded.  It is appropriate to lump together countries that have few trained 
 scientists and little experience of conducting biomedical research.  And it is 
 appropriate to lump together countries that lack ethical guidelines for research and 
 have little or no capacity for conducting ethical review of research conducted 
 there by industry or by scientists from industrialized countries.21 
 
                                                
19 “Understanding the WTO: Developing Countries,” World Trade Organization, 
accessed April 17, 2013, 
http://www.wto.org/english/thewto_e/whatis_e/tif_e/dev1_e.htm. 
20 “Understanding the WTO: The Organization,” World Trade Organization, accessed 
April 17, 2013, http://www.wto.org/english/thewto_e/whatis_e/tif_e/org7_e.htm. 
21 Macklin, Double Standards in Medical Research in Developing Countries, 10. 
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Macklin has picked out the relevant characteristics of comparison that clinical research 
ethics literature discusses.  Thus, those are the factors I will rely on when comparing 
developing and developed nations throughout this dissertation.  At its core, the chief 
distinction between the two is, as Macklin describes, in developed nations the majority of 
the population has the opportunity to access successful products of research and the 
majority of the population in developing nations do not have that opportunity.22 
 
Guidelines 
 Throughout the dissertation I will make reference to specific guidelines that 
regulate international research conducted on human subjects.  In chapter 4 on the 
“standard of care” debate, I analyze three specific sets of guidelines: the Declaration of 
Helsinki, the Council for International Organizations of Medical Sciences, and the FDA.  
Here I will give a brief background to the development of the guidelines and their 
purposes. 
 
Declaration of Helsinki 
 In June 1964, the World Medical Association at a meeting in Helsinki adopted a 
code of ethics on human experimentation, known as the Declaration of Helsinki. The 
original Declaration of Helsinki has roots in the Nuremberg Code - a code of ethics on 
human experimentation emerging from the exposure of horrific experiments on 
                                                
22 Macklin, Double Standards in Medical Research in Developing Countries, 11 
10 
concentration camp prisoners at the 1947 Nuremberg trials. 23  In 1975 the first revision 
of the Declaration was made and was signed by the United States and thirty-four other 
countries.  As Sonia Shah describes, the revised Declaration urged  
 voluntary informed consent, the use of independent ethics committees, and that 
 investigators prioritize, their subjects’ well-being above all other concerns, 
 including ‘the  interests of science and society.’ In the interests of justice, the 
 declaration suggested, research subjects should be assured of access to the best 
 health interventions identified in the study, and that their societies enjoy a 
 ‘reasonable likelihood’ of benefiting from the results of the experiment.24 
 
 Minor revisions were made to the Declaration in 1983, 1989, and 1996.  In 2000, 
the World Medical Association made another major revision to the Declaration.  While 
retaining the primacy of the individual, the 2000 revision increased awareness of public 
health needs.  Specifically, the revision removed the distinction between “therapeutic” 
and “non-therapeutic” research.  That distinction was premised on most medical research 
being “therapeutic,” meaning it is intended to benefit the research subject.  The 2000 
revision, on the other hand, contends that the purpose of research is the advancement of 
knowledge for the benefit of future patients.  That purpose and its limitations for the 
health needs of subjects are demonstrated through double-blinded clinical trials.  The 
2000 revision also added an entirely new concept; researchers and sponsors had a 
responsibility to provide benefits to populations.  Though the nature of those benefits is 
                                                
23 Robert V. Carlson, Kenneth M. Boyd, and David J. Webb, “The revision of the 
Declaration of Helsinki: past, present, and future,” British Journal of Clinical 
Pharmacology, 57, no. 6, (June 2004):  696. 
24 Shah. The Body Hunters, 75-76. 
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not specified, as John R Williams argues, the addition adds a public-health component to 
research ethics.25 
 In 2008, the Declaration was revised again in order to incorporate new 
requirements relating to the registration of clinical trials and the reporting of their results.  
The purpose of those requirements is to reduce publication and reporting bias, which will 
provide reliable evidence for decision-making.  This addition represents the medical 
community’s firm commitment to transparency to help rebuild trust in medical research, 
which had been damaged by controversies.26  Those include the use of placebo-controlled 
trials, the standard of care argument, and post-trial obligations in research in developing 
countries.   
 
The Council for International Organizations of Medical Sciences (CIOMS) 
 In 1949, the World Health Organization (WHO) and the United Nations 
Educational Scientific and Cultural Organization (UNESCO) formed CIOMS, an 
international, non-governmental, non-profit organization.  With its over 55 international, 
national and associate member organizations as of 2010, it represents many of the 
biomedical disciplines, national academies of sciences and medical research councils.  
CIOMS’ main objectives are: 
• To facilitate and promote international activities in the field of biomedical 
sciences, especially when the participation of several international associations 
and national institutions is deemed necessary; 
                                                
25 John R Williams, “The Declaration of Helsinki and public health,” Bull World Health 
Organ 86, no. 8 (August 2008): 650-651. 
26 Karmela Krieza-Jefric and Trudo Lemmens, “7th Revision of the Declaration of 
Helsinki: Good News for the Transparency of Clinical Trials,” Croatian Medical Journal 
50, no. 2 (April 2009): 105. 
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• To maintain collaborative relations with the United Nations and its specialized 
agencies, in particular WHO and UNESCO 
• To serve the scientific interests of the international biomedical community in 
general 
• To achieve its objectives, CIOMS has initiated and coordinates the following 
main long term programs: [Bioethics; Health Policy, Ethics and Human Values - 
An International Dialogue, Drug Development and Use; International 
Nomenclature of Diseases].27 
 
 In the late 1970s, CIOMS, in association with WHO, began its work on ethics 
related to biomedical research.  Its goal was to establish guidelines that would explain 
how the ethical principles concerning biomedical researching involving human subjects, 
as laid out in the Declaration of Helsinki, should be applied, especially in developing 
nations.  This led to CIOMS publishing the Proposed International Ethical Guidelines 
for Biomedical Research involving Human Subjects in 1982.  Those guidelines were 
revised in the early 1990s, leading to two sets of guidelines: in 1991, International 
Guidelines for Ethical Review of Epidemiological Studies; and, in 1993, International 
Ethical Guidelines for Biomedical Research Involving Human Subjects.   
 Those guidelines covered mainly when a comparator could be used other than the 
established effective therapy and clinical trials with external sponsors and investigators 
that were conducted in developing nations.   However, there were ethical situations for 
which CIOMS had no guidelines, particularly the perceived need for low-cost, 
technologically appropriate, public-health solutions in developing nations.  That was 
especially true for HIV/AIDS treatments or vaccines that developing nations could not 
                                                
27 “About Us,” Council for International Organizations of Medical Sciences, accessed 
April 17, 2013, http://www.cioms.ch/index.php/2012-06-07-19-16-08/about-us. 
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afford.  As a result, in 2002 the CIOMS updated its International Ethical Guidelines for 
Biomedical Research Involving Human Subjects to reflect those issues.28    
 
United States’ Guidelines 
 Prior to 1972, there was little formal federal legislature or guidelines reviewing 
researchers’ experimentation protocols or obtaining subject consent.  Congress passed 
legislation in 1962 requiring subject consent for any study seeking FDA approval for new 
drugs; however, the legislation was largely ineffective because it allowed for exceptions 
when obtaining consent was “not feasible” or was not in the best interest of the subject.29  
Subsequently, in 1966, a directive was issued by the Surgeon general stating that “clinical 
researcher would be supported only if the judgment of the investigator would be subject 
to prior review by the institutional associates concerning the issues of: (1) the rights and 
welfare of research subjects; (2) the appropriateness of the methods used to assure 
informed consent; and (3) the risk and medical benefits of the investigation.30  There 
were later revisions of that policy that required assurances that investigations complied 
with community laws and gave “due consideration to pertinent ethical issues.”31  While 
the review committees were typically comprised of scientists and physicians by 1969, the 
                                                
28 “International Ethical Guidelines for Biomedical Research Involving Human Subjects,” 
Council for International Organizations of Medical Sciences, accessed April 17, 2013, 
http://www.cioms.ch/images/stories/CIOMS/guidelines/guidelines_nov_2002_blurb.htm. 
29 Jesse A. Goldner, “An Overview of Legal Controls on Human Experimentation and the 
Regulatory Implications of Taking Professor Katz Seriously,” in The Ethics and 
Regulation of Research with Human Subjects, ed. Carl H. Coleman, Jerry A Menikoff, 
Jesse A. Goldner, and Nancy Neveloff Dubler (Newark: LexisNexis, 2005), 51-52. 
30 Goldner, “An Overview of Legal Controls on Human Experimentation and the 
Regulatory Implications of Taking Professor Katz Seriously,” 52. 
31 Goldner, “An Overview of Legal Controls on Human Experimentation and the 
Regulatory Implications of Taking Professor Katz Seriously,” 52. 
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guidelines required that committee membership reflect diverse backgrounds and that 
members be competent in the ways of “institutional regulations, relevant law, standards 
of professional practice, and community acceptance.”  The Department of Health, 
Education and Welfare, in May 1974 passed regulations requiring that no committee 
could be comprised in its entirety of members from a single professional group or 
institution employees. 32 
 That same year, the U.S. Senate passed the National Research Act of 1974 that 
established the Institutional Review Board and the National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Researcher.  In order to 
protect the rights of human subjects, the Institutional Review Board was set to review 
both biomedical and behavioral human subject research that is conducted or sponsored by 
the Federal Government. While the requirement only applies to federally-funded 
research, other institutions such as universities, medical schools, and research hospitals 
have “negotiated” these assurances with the federal government, promising to conform 
with the regulations and applying them to all research no matter the source of funding.   
 The National Commission’s task was to identify basic ethical principles that 
would underlie the conduct of research involving human subjects and provide guidelines 
that could apply to such research.  From this charge, the National Commission issued the 
1979 Belmont Report (the Report).  The Report identified three philosophical principles, 
which are relevant to human subject research: respect for persons, beneficence, and 
                                                
32 Goldner, “An Overview of Legal Controls on Human Experimentation and the 
Regulatory Implications of Taking Professor Katz Seriously,” 52. 
15 
justice.33  As the Report argues, respect for persons, minimally, encompasses two ethical 
convictions “first, that individuals should be treated as autonomous agents, and second 
that persons with diminished autonomy are entitled to protection.  The principle of 
respect for persons thus divides into two separate moral requirements: the requirement to 
acknowledge autonomy and the requirement to protect those with diminished 
autonomy.”34 
 While “beneficence”, as the Report points out, is usually understood as acts of 
kindness or charity that go beyond strict obligation, the Report intends beneficence to be 
understood as a stronger obligation.  Expressions of beneficence, the Report argues, can 
be understood as the following two rules: “(1) do not harm and (2) maximize possible 
benefits and minimize possible harms.”35 
 The Report understands justice in in multiple senses, including “fairness in 
distribution,” “what is deserved,” and “equals ought to be treated equally.”  It argues that 
an injustice occurs when “some benefit to which a person is entitled is denied without 
good reason or when some burden is imposed unduly.”36  While, it does not argue for one 
specific theory of justice, it does maintain that in light of events such as the Tuskegee 
                                                
33 Goldner, “An Overview of Legal Controls on Human Experimentation and the 
Regulatory Implications of Taking Professor Katz Seriously,” 52-53. 
34 The National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research, “The Belmont Report: Ethical principles and guidelines for the 
protection of human subjects of research,” April 18, 1979, accessed April 17, 2013, 
http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. 
35 The National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research, “The Belmont Report: Ethical principles and guidelines for the 
protection of human subjects of research,” 
36 The National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research, “The Belmont Report: Ethical principles and guidelines for the 
protection of human subjects of research,” 
16 
syphilis study and Nazi experiments on concentration camp prisoners that justice is 
relevant to research involving human subjects.  
 
FDA 
 The FDA’s primary responsibility, as assigned by Congress, is to determine when 
certain types of treatments - such as drugs, devices, and biologics - can be marketed in 
the United States.    As part of that responsibility, the FDA must decide on what threshold 
of evidence is required, along with the types of studies that can produce that evidence, to 
prove that a new treatment is safe and effective for treating a particular medical problem.  
Once a study has been approved by the FDA to be conducted, the results must be 
presented to an expert panel that makes recommendations to the FDA on whether the 
treatment is safe and effective.37 
 Prior to 2000, the FDA largely incorporated the principles of the Declaration of 
Helsinki into its guidelines.  However, the FDA was unhappy with the revisions of the 
Declaration between 2000 and 2004. During that time, the FDA referred to the 1989 
version of the Declaration, which the World Medical Association considered invalid.  
The FDA was reacting, in particular, to the addition of two paragraphs (29 and 30), which 
if adopted by the FDA, there would be a limit on the use of placebos in drug trials and an 
increase in responsibilities of trials sponsors toward research participants.3839  In 2008, 
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the FDA took a further step and “removed all reference to the Declaration in its approval 
requirements for drugs and biological products studied outside of the United States.”40  
Instead, the FDA adopted the International Conference on Harmonisation Good Clinical 
Practice as its new regulatory standard, justifying its decision by arguing that it was 
harmonizing its regulations with a global standard.41    
 
The Problem 
 In order to understand the ethical concerns of clinical drug trials. Let us look at 
two specific trials that are popular in clinical research literature: AZT and surfaxin. 
 
AZT 
 The debate over international clinical trial standards sparked in the early 90’s.   In 
1994 the New England Journal of Medicine published the results of the AIDS Clinical 
Trials Group Study 076.  The study demonstrated that the drug zidovudine (AZT) 
reduced the rate of transmission of HIV from pregnant women to their newborn infants 
by two thirds.42  By 1997, AZT was associated with a fifty percent decrease in HIV 
transmission in the United States; however, the potential of AZT was unrealized in 
                                                                                                                                            
39 There will be extensive discussion of those paragraphs in chapter 4 
40 Annette Rid and Harald Schmidt, "The 2008 Declaration of Helsinki—First among 
Equals in Research Ethics?," The Journal of Law, Medicine & Ethics 38, no. 1 (2010): 
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41 Michael Goodyear, Trudo Lemmens, Dominique Sprumont, and Godfrey B. Tangwa, 
“The FDA and the Declaration of Helsinki: A New Rule Seems to Be More About 
Imperialism than Harmonisation,” British Medical Journal 338 (2009): 1157. 
42 Zidovudine’s brand name is Retrovir and was formerly called azidothymidine [AZT].  
Zidovudine may also be abbreviated as (ZDV) Most of the literature refers to this drug as 
AZT, which is what I will refer it throughout the remainder of this dissertation. For more 
information, see http://www.rxlist.com/retrovir-drug.htm. 
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developing nations, especially in Asia and sub-Saharan Africa, primarily because of 
AZT’s high cost.43  AZT was originally released on the market as Retrovir in 1987 as a 
treatment for AIDS by a company that would later become a part of GlaxoSmithKline.  
Even though a sizable public investment had gone into the development of AZT, the 
company charged AIDS patients $8,000 for a year’s worth of treatment.44   
 In an effort to find a less expensive treatment, clinical trials were run to test less 
expensive interventions to prevent perinatal transmission of HIV- such as lowering the 
dose of AZT given, decreasing the number of doses a patient took of AZT, and testing 
alternative interventions.  In September 1997, Peter Lurie, Sidney Wolfe, and Marcia 
Angell published articles in the New England Journal of Medicine criticizing on ethical 
grounds the design of those trials.   Lurie and Wolfe identified eighteen randomized, 
controlled trials to prevent perinatal transmission of HIV - two in the United States and 
sixteen in developing nations.45   The total number of women involved in the trials was 
over 17,000.  In the two trials in the United States, the patients in all the study groups had 
unrestricted access to AZT and other antiretroviral drugs.  In fifteen of the sixteen 
conducted in developing nations, some or all of the patients were not provided with the 
antiretroviral drugs.  Those studies used a placebo control, rather than an active control.  
In a placebo control, the control group is given a placebo; in an active control, the control 
group is given the best available proven therapy.  The sixteenth trial in developing 
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nations was an active-controlled trial (an equivalency study) run in Thailand by Marc 
Lallemant, a researcher at the Harvard School of Public Health.  Lallmant tested three 
shorter regimes of AZT compared to the full regimen used in the AIDS Clinical Trials 
Group Study 076.  The Harvard study’s research question is “Can we reduce the duration 
of prophylactic [AZT] treatment without increasing the risk of perinatal transmission of 
HIV, that is, without compromising the demonstrated efficacy of the standard ACTG 
[AIDS Clinical Trials Group] 076 [AZT] regimen?” 
 Those using a placebo control argue that the placebo-controlled trials provide the 
best option for scientifically valid assessment for alternative regimens, and provide the 
only appropriate research design - answering the question “Is the shorter regimen better 
than nothing?”  Officials and researchers further defend the placebo control by arguing 
that those patients in the control are being treated at least according to the standard of 
care in their home country, which consists of unproven regimens or no treatment at all.   
 Lurie and Wolfe condemn the fifteen placebo controls studies.  They argue that 
the hundreds of infants in the placebo control needlessly contracted HIV.  The active 
control studies, they contend, would yield more useful results without putting infants at 
risk.  Moreover, the standard of care justification is fundamental misunderstanding the 
concept of standard of care.  Lurie and Wolfe maintain that it ought to be based on 
alternative treatments and previous clinical data, but in developing countries, the standard 
of care is wrongly based on economically determined policies of governments that cannot 
afford the drug companies’ prices.  On those grounds, Lurie and Wolfe argue that the 
double standard for using a placebo control in developing nations versus the active 
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control in developed is unethical.  They promote developing a single international 
standard of ethical research.46 
 Marcia Angell supports Lurie and Wolfe’s conclusions.  She argues that it is only 
ethical to use placeboes when no known effective treatment is available with which to 
compare a potential new treatment.  The justification for the use of placebo controls in 
those fifteen AZT studies, Angell contends, is reminiscent to those used in the Tuskegee 
Study of Untreated Syphilis.  In the Tuskegee Study, 412 poor African-American men 
with untreated syphilis were followed and compared to 204 men free of the disease from 
1932 to 1972 in order to determine the natural history of syphilis.  There were numerous 
ethical violations in the study.  Participants did not provide informed consent.  They were 
also denied the best available treatment.47  In the beginning that only meant being denied 
heavy metal treatment, which was the standard treatment at the time.  In the 1930s and 
early 1940s of the 71 survivors, only about thirty reported receiving some kind of heavy 
metal treatment.48 However, later on penicillin became widely available and was well 
known to be highly effective against syphilis, but the study continued without providing 
penicillin to the infected participants.  Investigators justified the denial of treatment by 
arguing that because the participants were poor they would not have been treated 
anyways.  The researchers argued that they were merely observing what would have 
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happened had there been no study at all.  That, Angell argues, is very similar to the 
standard of care justification; “[w]omen in the Third World would not receive 
antiretroviral treatment anyway, so the investigators are simply observing what would 
happen to the subjects’ infants if there were no study.” 49 
 Lurie, Wolfe, and Angell’s articles were controversially received, particularly by 
the pharmaceutical industry, and the debate was ignited.  They brought light to an 
ethically gray area of clinical research that had not previously received the attention it 
deserved.  When is it ethical to use a placebo?  Is a double standard between research in 
the developed and developing world ethically justified?  Almost twenty years later, 
progress has been made, but little consensus still exists. 
  
Surfaxin 
 Respiratory distress syndrome (RDS) is a common disease in premature infants 
that is potentially fatal.  It is caused by insufficient surfactant, a protein fluid that helps 
enable proper lung inflation and aeration, in the lungs. The standard treatment is 
surfactant therapy, which has produced a thirty-four percent decrease in neonatal 
mortality in randomized trials in the Western world.  There are four surfactants approved 
by the FDA since 1990 - Exosurf, Survanta, Infasurf, and Curosurf.  Despite the proven 
reduction, as of 2008, RDS is the fourth leading cause of infant mortality in the United 
States and is responsible for up to half of all infant mortality in developing countries as 
they do not have access to surfactant therapy or ventilation support.  While surfactant 
therapy has been approved for use in Latin America, it is too expensive (U.S. $1,000-
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$2,400 per child) for it to be a viable option for most infants, where the per capita ranges 
from U.S. $60 - $140. 
 In 2000, Discovery Labs, a private U.S. drug company, planned a Phase III trial to 
demonstrate the efficacy of a new surfactant called Surfaxin, and deliberated with the 
FDA about an acceptable trial design.  Initially, Discovery Labs proposed an equivalency 
study or active-controlled trial comparing Surfaxin to Survanta.  While the FDA would 
have accepted an active-controlled trial comparing Surfaxin to Exosurf as proof of 
Surfaxin’s effectiveness, the FDA, based on previous surfactant studies, did not think a 
trial of Surfaxin against Survanta would yield data that would support the approval of 
Surfaxin.   
 After deliberations, a multi-center, double blind, randomized, two-arm, placebo-
controlled trial was proposed, which would involve 650 premature infants with RDS in 
Bolivia.  Half of those infants would be receiving a placebo.  The hospitals chosen for the 
study did not have surfactant therapy available for the treatment of RDS.    The sponsor 
did agree to provide endotracheal tubes, ventilators, and antibiotics for all study 
participants.  A team of American neonatologists was proposed to be sent to supervise the 
trial and help trail local health care personnel.  The principal target market for the drug 
was the U.S. and Europe, but no plan was offered by the sponsor to market in Latin 
America.  There were negotiations between the sponsor and participating hospitals to 
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make Surfaxin available to them at a reduced cost if it proved efficacious, but no firm 
agreement was reached.50 
 In 2001, the Public Citizen Health Research Group learned of the proposed 
Surfaxin trial, and managed to obtain several FDA internal memos.  The internal FDA 
meeting where they discussed the Surfaxin trial was entitled “Use of placebo controls in 
life-threatening diseases: is the developing world the answer?”51  That title stirs 
controversy when combined with one internal memo that Public Citizen obtained where 
the FDA acknowledged that “conduct of a placebo controlled surfactant trial for 
premature infants with RDS is considered unethical in the USA.”  The FDA documents 
also state that some hospitals in countries where the study was proposed have access to 
surfactants, but are completely unavailable at other hospitals.     
 On February 22, 2001, Public Citizen wrote a letter to Tommy Thompson, 
Secretary of the US Department of Health and Human Services.  The letter contained the 
following: 
 [p]articularly because the FDA approved another surfactant (Infasurf) in 1998 on 
 the basis of studies performed between 1991 and 1993 in which all infants were 
 treated with a presumably effective drug and none were given placebo, we call on 
 you to immediately put a stop to plans for this unethical and exploitative study in 
 its present design.  The study is unethical because it violates the principle that 
 placebos not be employed when there exists a standard treatment that may reduce 
 or prevent harm, improve health or prolong life.  If the study produces findings 
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 that are beneficial to patients in wealthier countries but the drug is not widely 
 available in the countries in which it was tested, an additional dimension of 
 unethical behavior will have been added.  For the study to take place ethically, all 
 infants must be provided with a treatment either known or expected to be 
 effective; a comparison of the new surfactant to an already approved one would 
 therefore be acceptable.52 
 
Despite having supporters for the original design, six weeks later, Public Citizen 
announced that Discovery Labs had redesigned the trial using an active control versus a 
placebo.53 
 
Double Standards: Placebo-Controlled Trials (PCTs) and Drug Availability 
 Those two trials highlight two of the most popular ethical complaints on clinical 
research in developing nation: the use of a PCT and the host nation’s lack of availability 
of the experimental drug should it prove effective.   Let us look at each issue in turn.   
 In both the AZT and the Surfaxin trial, the chief objection was that a placebo 
control was being used when known effective treatment existed.  They were even 
available on the market for use and purchase in developed countries, specifically the 
United States and Europe.  However, they were not readily available in the country in 
which the trials were being run or were proposed to be run in.54 Thus, while a PCT might 
be unethical to run in a developed nation where the drug is available, supporters of PCTs 
argue that it is ethical for those same trials to be run in a developing nation where the 
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drug is not available.  That is, the placebo is not any worse than the no treatment the 
developing nation participants would be receiving if they were not enrolled in the trial.   
 There are many reasons I will discuss throughout this dissertation on why the 
double standard on PCTs is ethically troubling, but one in particular is its violation of 
equipoise.    As Dr. Benjamin Freedman describes equipoise, 
 [t]here is widespread agreement that ethics requires that each clinical trial begin 
 with an honest null hypothesis.  In the simplest model testing a new treatment B 
 on a defined patient population P for which the current accepted treatment is A, it 
 is necessary that the clinical investigator be in a state of genuine uncertainty 
 regarding the comparative merits of treatments A and B for population P.  If a 
 physician knows that these treatments are not equivalent, ethics requires that the 
 superior treatment be recommended. . . I call this state of uncertainty about the 
 relative merits of A and B “equipoise.”55 
 
Freedman argues that equipoise is ethically necessary in all clinical research, including 
placebo-controlled trials, and between all arms of a trial, otherwise the trial ought to be 
designed to exclude the inferior treatment.  If equipoise has been disturbed, the trial may 
have to be terminated with all subjects, both current and previously enrolled, receiving 
the superior treatment.56  
 Freedman also distinguishes between theoretical and clinical equipoise.  
Theoretical equipoise, which is conceptually odd and ethically irrelevant, exists when the 
overall evidence for two alternative treatments is exactly balanced.57  Clinical equipoise, 
which is ethically relevant, exists under the following circumstances: 
 ...there is a current or imminent conflict in the clinical community over what 
 treatment is preferred for patients in a defined population P.  The standard 
 treatment is A, but some evidence suggests that B will be superior... Or there is a 
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 split in [the] clinical community, with some clinicians favoring A and others 
 favoring B.  Each side recognizes that the opposing side has evidence to support 
 its position, yet each still thinks that overall its own view is correct.  There 
 exists ... an honest professional disagreement among expert clinicians about the 
 preferred treatment.  A clinical trial is instituted with the aim of resolving this 
 dispute.58 
 
Given this understanding of clinical equipoise, Freedman proposes the following formal 
conditions under which a trial may be run ethically: 
 at the start of the trial, there must be a state of clinical equipoise regarding the 
 merits of the regimens to be tested, and the trial must be designed in such a way 
 as to make it reasonable to expect that, if it is successfully concluded, clinical 
 equipoise will be disturbed.  In other words, the results of a successful clinical 
 trial should be convincing enough to resolve the dispute among clinicians.59 
 
 Under Freedman’s account of clinical equipoise, using PCTS in developing 
nations when an existing treatment exists violates clinical equipoise, as it is already 
known prior to the trial that the placebo is worse than the standard treatment.  As 
Franklin G. Miller and Howard Brody argue, “[w]hat makes it ethical to conduct [a 
random-controlled trial] comparing a new treatment with a standard treatment, but not 
with a placebo, is that experts in the  clinical community are uncertain or in a state of 
disagreement about whether the new treatment is as good as or better than standard 
therapy.”60 
 
It is possible for researchers to not violate clinical equipoise in developing nation trials.  
Researchers can use an active-controlled trial (ACT), where the control group is giving 
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the standard treatment that exists, assuming that they are uncertain about whether the 
active control is better or worse than their experimental drug.  Lallmant used an ACT, as 
did Discovery Labs after redesigning the Surfaxin trial. 
 In chapter 4, I will further engage the equipoise debate and analyze the ethical 
underpinnings of using PCTs in developing nations.  For now, it is only important to 
understand that there is a double standard regarding PCTs and clinical equipoise for trials 
in developing nations and trials in developed nations. 
 The second major ethical critique of clinical trials in developing nations is 
researchers and pharmaceutical companies not making the experimental drug available to 
the host nation at an affordable rate should the drug be proven effective.  In 2000, the 
World Health Organization developed Millennium Development Goals (MDG) - goals 
which they wanted to accomplish by 2015.61  MDG 8 is to develop a global partnership 
for development, part of which is to provide access to affordable essential medicines in 
developing countries in cooperation with pharmaceutical companies.  The MDG Gap task 
force in its recent report found that in the public sector, generic medicines are only 
available in 38.1% of facilities and cost 250% more on average than the international 
reference price.  In the private sector, those same generic medicines are available at 
63.3% of facilities and on average cost 610% more than the international reference 
price.62  In a survey of over 40 mainly low-income and middle-income countries, generic 
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medicines were only available at 44% of health facilities in the public sector and 65% of 
health facilities in the private sector.63   
 With such little drug availability and continuing health problems, developing 
nations are desperate to have access to low-cost medicines and research.  However, as 
demonstrated in the AZT and Surfaxin case, there is little effort on part of the 
pharmaceutical companies to provide the tested drug at a reasonable price. Rather, than 
lowering the price, they test the drug at lower doses to see if it is effective so that they 
can sell that lower dose at a lower price to developing nations, as was the case with AZT.  
If the trial takes place in the developed world, drug availability is not an issue as the 
primary target market for the experimental market is the developed world.  This topic, 
including the feasibility of providing the drugs at lower prices, will be discussed in 
further detail in chapter 4. 
 What is particularly disturbing about the use of PCTs and the lack of drug 
availability is that developing nations are undertaking all the risk while the developed 
world is the primarily beneficiary from the research which violates the principle of justice 
in the Belmont Report.   As will be discussed in chapter 4, international and U.S. federal 
guidelines call on researchers to balance the risks and benefits to the patients.  Yet, the 
risk undergone by developing nations is high, especially when a placebo versus an active 
control is used, with little benefit received from the research or drug availability.  
Moreover, developed nations have access to the drug and the research from the trial 
without any of the medical risks associated with the trial.  Furthermore, there is not 
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strong justification, be it scientific or ethical, for the double standard beyond financial 
benefit and efficiency on the part of the researchers and pharmaceutical companies.64  In 
other words, developing nations are being exploited as pharmaceutical companies and 
researchers are using the countries’ lack of resources and health needs to gain. 
  
Consent 
 Though I will not be considering problems with consent within my analysis of 
exploitation and the double standards in international research, it is a large enough 
problem to warrant some discussion as part of the background information.  In general, 
be it in a developing nation or developed nation, there are problems with informed 
consent.  In seeking consent, the FDA requires researchers to provide the following basic 
elements potential participants:65 
 (1) A statement that the study involves research, an explanation of the purposes of 
 the research and the expected duration of the subject’s participation, a description 
 of the procedures to be followed, and identification of any procedures which are 
 experimental. 
 (2) A description of any reasonably foreseeable risks or discomforts to the 
subject. 
 (3) A description of any benefits to the subject or to others which may reasonably 
 be expected from the research. 
 (4) A disclosure of appropriate alternative procedures or courses of treatment, if 
 any, that might be advantageous to the subject. 
 (5) A statement describing the extent, if any, to which confidentiality of records 
 identifying the subject will be maintained and that notes the possibility that the 
 Food and Drug Administration may inspect the records. 
 (6) For research involving more than minimal risk, an explanation as to whether 
 any compensation and an explanation as to whether any medical treatments are 
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 available if injury occurs and, if so what they consist of, or where further 
 information may be obtained. 
 (7) An explanation of whom to contact for answers to pertinent questions about 
 the research and research subjects’ rights, and whom to contact in the event of a 
 research- related injury to the subject. 
 (8) A statement that participation is voluntary, that refusal to participate will 
 involve no penalty or loss of benefits to which the subject is otherwise entitled, 
 and that the subject may discontinue participation at any time without penalty or 
 loss of benefits to which the subject is otherwise entitled.66 
 
 Few researchers, however, check a patient’s understanding of those elements. As 
Shah describes, 
 [f]ew researchers... ever bother to verify whether their subjects do, in fact, 
 understand.  It  wouldn’t be difficult.  Medical researchers routinely double-check, 
 duplicate, and  re-analyze nearly every other aspect of clinical trials by means of a 
 profusion of journal articles, conferences, workshops, and lectures.  “Relentless 
 scrutiny of details” could be said to be the research industry’s motto.  But in the 
 area of informed consent, an atypical atmosphere of ‘don’t ask, don’t tell’ 
 prevails.67 
 
In a study published in 2001, while over half of researchers agreed that verifying 
subjects’ understanding of experiments is a good idea, only 16% have done so in their 
own trials.68 
 Verification is increasingly important as few patients fully read and comprehend 
informed-consent documents, as they tend to be too long with a difficult degree of 
readability.  In July 2011, a study published in the Journal of Internal Medicine reviewed 
124 informed-consent forms in 21 HIV clinical trials sponsored by the National Institute 
of Health’s Division of AIDS.  It found that the forms were typically written above the 
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ninth-grade reading level and were longer than twenty-two pages.69  As Nancy Kass, lead 
author of the study, describes, “[v]ery few people are going to sit down and read a 
document that’s that long and the goal is to have people understand.  The whole reason 
for putting [informed  consent] in writing is with the belief that someone will read it.  The 
longer it is, the less likely people are to read it all the way through, and then you have 
defeated your own purpose.”70 
 That problem is compounded in developing nations where there is not only 
potentially language barrier but also a cultural barrier.  In many developing nations there 
is a lack of familiarity or understandings of western medicine, scientific research, and 
basic concepts of modern science.  In a report by the National Bioethics Advisory 
Commission, analysts point out that in some African languages, not only are there are no 
words for “science” or “research,” but there is no concept to explain “placebo” or 
“experiment.”  As the same word for “science” is often also used for “medicine,” analysts 
argue that many adult subjects have no understanding of the difference between being a 
research subject and receiving medical treatment.71   
 Moreover, there are difficulties in getting developing nations subjects to sign the 
informed consent documents.  In a study published in 2001, M Upvall and S Hashwani of 
Aga Khan University in Pakistan compared informed consent procedures in Pakistan and 
Swaziland.  According to their study, researchers had to jump through many hoops 
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created by tribal hierarchy and corrupted bureaucracy in order to obtain informed 
consent.  At times, they had to ask the husbands of wives or village elders first.  
Researchers also struggled to contact subjects, as some do not have telephones or 
permanent addresses.  Some are even afraid to sign their names.72   
 In addition to practical difficulties in obtaining and verifying informed consent, 
there are several philosophical questions.  What constitutes informed consent? Are we 
respecting patients’ autonomy if we are unable to achieve 100% informed consent?  If 
total informed consent is achieved, does that nullify any concern over wrongdoing 
concerning the double standards in clinical practices between developing and developed 
nations?  This last question represents one of responses to charges of exploitation in 
developing nations.  Some argue that if one consents to the act, it is either not exploitative 
or the wrongdoing of the transaction is nullified.  I argue that even if fully we achieve 
total informed consent, pharmaceutical companies and researchers are exploiting 
developing nation participants, and that is harmful to those participants.  In chapter 4, I 
look specifically at the consent justification.  As a result, I will not be engaging the 
consent debate and will assume total informed consent throughout this dissertation. 
 
Why Exploitation? 
 Exploitation is the correct model for understanding the wrongdoing imposed by 
pharmaceutical companies and researchers on developing nations for three reasons.   
First, in a minimal sense, Jennifer S. Hawkins argues that exploitation means to “take 
advantage” of someone or something.  That includes both moralized and non-moralized 
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senses of exploitation.  In the moralized sense, which is the sense we are concerned with, 
that interaction of ‘taking advantage’ must be unfair or morally problematic in some 
sense.73  Based on this minimal sense, pharmaceutical companies and researchers seem to 
be exploiting developing nation participants in clinical drug trials.  They are using the 
participants’ vulnerable circumstances - lack of access to health care and existing 
treatment - to offer them less than developed nation participants for the sake of benefit - 
money, efficiency, etc.  One party is benefitting through the use of another.  For it to be 
exploitative, that use must be unfair or morally problematic.  It seems unfair, as they are 
not receiving the same benefits that they would receive if they were living in the 
developed world.  With a minimal depth understanding of exploitation, then, it intuitively 
seems that clinical trials in developing nations are exploitative.   
 Second, as Hawkins and Ezekiel J Emanuel argue, exploitation provides a model 
that unifies many research concerns into a single ethical issue.  Those concerns, as 
discussed, include study design, specifically over the choice of control, drug availability, 
informed consent, and the balance of risks and benefits for patients.74  Though different 
in consequences, all stem from a single interaction, or rather a single set of interactions, - 
the drug trial.  No matter what form the research takes or where it is located, “all research 
‘uses’ the participants to gain information that, hopefully, will improve the health of 
                                                
73 Jennifer S. Hawkins, “Research Ethics, Developing Countries, and Exploitation: A 
Primer,” in Exploitation and Developing Countries: The Ethics of Clinical Research, ed. 
Jennifer S. Hawkins and Ezekiel J. Emanuel. (Princeton: Princeton University Press, 
2008), 44. 
74 Jennifer S. Hawkins and Ezekiel J. Emanuel. “Introduction: Why Exploitation?,” in in 
Exploitation and Developing Countries: The Ethics of Clinical Research, ed. Jennifer S. 
Hawkins and Ezekiel J. Emanuel. (Princeton: Princeton University Press, 2008), 10-13. 
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others whether directly or indirectly through additional research.”75  Since all concerns 
with developing nation clinical research stems from that ‘use,’ it seems natural to 
categorize them under a single moral umbrella.  Exploitation is wide enough to 
encompass all of those issues.  While it is possible to understand each concern as a 
different moral wrong; however, this only complicates the task of understanding the 
moral wrong in clinical research, which is both theoretically and practically unattractive 
if there is to be timely policy changes.  
 Third, the language of exploitation runs heavily in the clinical trial literature 
particularly on the topic of developing nations.  In their critique of the AZT trial, Lurie 
and Wolfe state, 
 [r]esidents of impoverished, postcolonial countries, the majority of whom are 
 people of color, must be protected from potential exploitation in research.  
 Otherwise, the abominable state of health care in these countries can be used to 
 justify studies that could never pass ethical muster in the sponsoring country [my 
 italics].76 
 
Harold T. Shapiro and Eric M Meslin call for safeguards in clinical research; 
 [a]n important additional safeguard is needed to avoid the exploitation of 
 potentially vulnerable populations in developing countries - namely clinical trials 
 sponsored or regulated by U.S. groups should be limited to those that are 
 responsive to the host  country’s health needs [my italics].77 
 
George J Annas and Michael A Grodin similarly argue, 
 unless the interventions being tested will actually be made available to the 
 impoverished  populations that are being used as research subjects developed 
 countries are simply exploiting them in order to quickly use the knowledge gained 
                                                
75 Hawkins and Emanuel, “ Introduction: Why Exploitation?,” 12. 
76 Lurie and Wolfe. “ Unethical Trials of Interventions to Reduce Perinatal Transmission 
of the Human Immunodeficiency Virus in Developing Countries," 855. 
77 Harold T. Shapiro and Eric M. Meslin, "Ethical issues in the design and conduct of 
clinical trials in developing countries," The New England journal of medicine 345, no. 2 
(2001): 139. 
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 from the clinical trials for the developed countries’ own benefit. . . . The central 
 issue in doing research with impoverished populations is exploitation [my 
 italics].78 
 
This language continues throughout the literature.  Exploitation is the field’s chosen lens 
through which to view the problems.  
 While there are benefits, accepting exploitation as the model of moral wrong 
doing has its negatives.  Specifically, exploitation is a diffuse and vague concept.  There 
are moral and non-moral examples of exploitation.  For example, to say that an athlete 
exploits his talent to throw the football farther than anyone else to win a game is to use 
exploitation in the non-moral sense.  That is, the athlete’s action is not morally 
worrisome.79  Moreover, there is little agreement as to what constitutes exploitation or 
why exploitative actions are morally bad.   
 The double standard in clinical research is particularly troubling for exploitation 
theories as it appears that patients are better off having been exploited by the trial than 
they would have been had the trial not taken place.  Pharmaceutical companies and 
researchers make this argument in defense of the double standard.  As seen particularly in 
the AZT case, even with a placebo control patients have a chance of getting the actual 
experimental drug and will receive medical care, which they would not have had 
otherwise.  It seems as if, on balance, patients are benefiting rather than being harmed.  
                                                
78 George J Annas and Michael A Grodin, “Human Rights and Maternal-Fetal HIV 
Transmission Prevention Trials in Africa,” American Journal of Public Health 88 (1998): 
560-563 at 561 quoted in Jennifer S. Hawkins and Ezekiel J. Emanuel. “Introduction: 
Why Exploitation?,” in in Exploitation and Developing Countries: The Ethics of Clinical 
Research, ed. Jennifer S. Hawkins and Ezekiel J. Emanuel. (Princeton: Princeton 
University Press, 2008), 12. 
79 Hawkins and Emanuel, “ Introduction: Why Exploitation?,” 13. 
36 
Explaining how this instance of exploitation, which seems to be mutually beneficial for 
both the researchers and the patients, is morally bad.  This will be the topic of Chapter 2. 
 
The Remaining Chapters 
 There are four additional chapters after this one.  In “Chapter 2: What is 
exploitation?”  I examine existing theories of exploitation.  Specifically, I will look at the 
theories of Alan Wertheimer, John Lawrence Hill, and Ruth Sample, who offer the best 
explanations for how exploitation might be mutually beneficial but still be morally 
wrong.  The goal of this chapter is not to discuss why exploitation is harmful, but rather 
discuss what exploitation is.  After discussing why each does not meet the challenge of 
explaining exploitation of clinical research developing nations, I will offer my own 
theory.  Rather than offering a theory of all exploitation, I will identify and develop a 
type of exploitation, which I call comparative exploitation.  I argue that the double 
standard in clinical research is an example of comparative exploitation.  
 In “Chapter 3: How Comparative Exploitation is Harmful” I argue that cases of 
exploitation that seem to be mutually beneficial, like clinical trials in developing nations, 
are actually harmful to the victims.  I have two main arguments as to why they are 
actually harmful.  First, I argue that the assumption that the victim is benefitting rather 
than being harmed relies on the standard counterfactual account of harm.  I contend that 
under the standard account, the wrong counterfactual question is being asked when 
determining if harm occurred.  Rather, I rely on Ben Bradley’s account, which changes 
the counterfactual question to one where harm in comparative exploitation can more 
easily be understood.  Second, I argue that even under the standard counterfactual 
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account of harm, exploitation that is thought to be mutually beneficial is actually harmful 
because it creates a climate of harm under which increases the likelihood that the victims 
will get harmed. 
 “Chapter 4: Standard of Care” analyzes the standard of care debate.  The standard 
of care argument is one offered by supporters of the double standard in international 
researcher.  They argue that when guidelines say “best therapeutic method available” that 
means the best available in the host country, not in any country.  Thus, they are justified 
when they use a placebo control in countries where the existing medical alternative is not 
available in the host country.  Within this chapter, I argue against the standard of care 
response, particularly analyzing the concerns over the use of placebo-controlled trials and 
the availability of the experimental drug should it prove effective.  I contend that the 
participants from developing nations be treated the same as those in developed nation.      
 Finally, in “Chapter 5: Conclusion” I will conclude the dissertation and examine 
one final issue.  Alan Wertheimer argues that though clinical research in developing 
nations may be exploitative, we should allow the exploitation to continue otherwise 
pharmaceutical companies and researchers will not continue to conduct clinical trials in 
the developing world.  I argue that we cannot allow exploitative drug trials to continue. 
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Chapter 2: WHAT IS EXPLOITATION? 
 
Introduction 
 Exploitation theories vary as widely as they are numerous.80  Many suggest that 
exploitation requires that the exploiter has a net gain while the exploited party has a net 
loss.  For example, Allen Buchanan argues that “to exploit a person involves the harmful, 
merely instrumental utilization of him or his capacities, for one’s own advantage or for 
the sake of one’s own ends.”81  Judith Farr Tormey contends that “[e]xploitation 
necessarily involves benefits or gains of some kind to someone... Exploitation resembles 
a zero-sum game, viz what the exploiter gains, the exploitee loses; or, minimally, for the 
exploiter to gain, the exploitee must lose.”82  The problem with such theories is that there 
are plenty of cases of exploitation where the exploited party gains overall rather than 
loses.  Consider child labor.  Often children are forced to work in factories in order to 
earn an income for their families.  If they do not work they may die of starvation, thus it 
is to their benefit that they work.  Yet, we still maintain that companies who hire child 
                                                
80 Much of the exploitation literature that examines specific moral problems does not 
discuss the Marxist tradition in depth.  I suspect that is because the moral situations 
discussed do not often fit within an economic framework, and there is a fear that an 
overarching concept of exploitation would be too vague and unable to fully grasp the 
moral wrongness.  For the sake of narrowing my project and honing in on the specific 
moral complaints of clinical drug trial, I have decided not to include the Marxist tradition 
in this chapter.  Marxism is not discussed in much of the literature on exploitation in 
clinical drug trials.   
81 Allen Buchanan quoted in Alan Wertheimer, "Exploitation," The Stanford 
Encyclopedia of Philosophy, edited by Edward N. Zalta, (2008), updated July 24, 2008, 
http://plato.stanford.edu/archives/fall2008/entries/exploitation/. 
82 Judith Farr Tormey quoted in Alan Wertheimer, "Exploitation," The Stanford 
Encyclopedia of Philosophy, edited by Edward N. Zalta, (2008), updated July 24, 2008, 
http://plato.stanford.edu/archives/fall2008/entries/exploitation/. 
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laborers are exploiting the children.  This type of exploitation, where the exploited party 
gains, is called mutually advantageous exploitation. 
 It can be argued that clinical drug trials in developing nations are an example of 
mutually advantageous exploitation.  It is to the participants’ benefit to participate in the 
trial where even though a placebo is used; they have a chance of receiving medication or 
compensation.  If they do not participate, they have zero chance of receiving any kind of 
treatment.  However as in the child labor case, the consensus is that the trial participants 
are being exploited.   An account is needed to explain how these sorts of cases classify as 
exploitation and what moral wrong is being done to the exploited parties.  
 In this chapter my goal is to analyze existing accounts of exploitation and then 
offer my own account.  While there are many theories of exploitation, I will only discuss 
the theories of Alan Wertheimer, John Lawrence Hill, and Ruth Sample.  I have chosen 
those theories for their popularity, plausibility, and for their vastly different approaches to 
the problem of mutually advantageous exploitation.  This chapter will not explore why 
exploitation is morally wrong, but rather focus on why certain situations are categorized 
as exploitation.83   While all three approaches offer plausible accounts for exploitation, 
they fall short in their explanative force of the moral wrong done by the double standards 
in clinical research.  In the introduction I explained why exploitation is the correct 
framework for the double standards between developed nations and developing nations’ 
                                                
83 As suggested in the Chapter 1, I will argue in Chapter 3 that the victims of exploitation 
from clinical drug trials are harmed rather than benefitting.  Thus, clinical drug trials are 
mistakenly labeled as mutually advantageous.  However, I believe one of the reasons for 
their mislabeling is because existing theories of exploitation do not adequately explain 
why the double standard is exploitative.  The goal of this chapter is to off a theory that 
explains why the double standard in clinical research between developing nations and 
developed nations is exploitative. 
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clinical trials, and this chapter will explain why specific theories of exploitation are 
failing this case.   After discussing the obstacles of those three approaches, I will offer my 
own account.  My own account is not a full theory of exploitation, but rather an account 
of a specific type of exploitation, which I call “comparative exploitation”.   
 I have made some assumptions that I want to clarify.  First, many theories of 
exploitation including the ones discussed in this chapter argue that if there is a defect in 
consent then the interaction is exploitative.  While defects in consent are a concern for 
mutually beneficial exploitation, including clinical drug trials as discussed in the 
introduction, I want to examine the clinical drug trial cases under the best of 
circumstances.  Thus, for the sake of this chapter, I assume no defects in consent for trial 
participants.  Second, in describing the happenings between the exploiter and the 
exploited party, I will use the words transaction and interaction interchangeably.  This 
terminological use is consistent with what is found in the literature.  No deeper meaning 
is meant by using one world over another.  Third, for clarity’s sake through this chapter, I 
will reference the hypothetical example of A exploits B.  Thus when I refer to A, I mean 
the exploiter, and when I refer to B, I mean the exploited party.  
 
Wertheimer 
 In an early formulation of exploitation, Wertheimer categorizes a transaction as 
exploitative if A takes unfair advantage of B.  Note that Wertheimer defines exploitation 
in terms of fairness rather than harm.  In doing so, he is able to craft two sub-categories 
of exploitation: harmful exploitation and mutually advantageous exploitation.  In harmful 
exploitation A gains from a transaction or action that is harmful to B, where harm is 
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defined in terms of an appropriate baseline; whereas, in mutually advantageous 
exploitation A unfairly gains or gains in an excessive amount from a transaction that is 
beneficial to B.   Whether A unfairly or excessively gains is determined by the same 
baseline used in harmful exploitation.84  Moreover, in order for a mutually advantageous 
transaction to be wrongfully exploitative, the outcome must be in some way unfair to B.  
Wertheimer admits that mutually advantageous exploitation can be understood as a form 
of harmful exploitation in so far as the transaction is evaluated by reference to a fairness 
baseline.85 
  Critical to both types of exploitation is that A must gain at least ex ante, if not 
also ex post.  That is, a transaction cannot be exploitative if A did not at least believe he 
was going to gain from the transaction prior to actually transacting with B.  It may be the 
case that unforeseen circumstances prevented A from receiving a benefit, but the 
transaction may still be exploitative.86  Suppose a pharmaceutical company exploits me 
by testing a new drug on me without my consent that has harmful consequences to my 
health.  Ex ante the company would have benefited by proving the drug effective and 
selling it on the market.  However, if that new drug does not prove effective and the 
company chooses to no longer use it (no ex post benefit), I have still been exploited by 
the company.   A also need not intend to exploit B in order for A to exploit B.  A may 
exploit B if A thinks the transactions is fair ex ante or is unaware of the effects of the 
transaction on B.87 Wertheimer further clarifies that A’s gain need not be financial and A 
                                                
84 Alan Wertheimer, Exploitation (Princeton: Princeton University Press, 1996), 207. 
85 Wertheimer, Exploitation, 22. 
86 Wertheimer, Exploitation, 209. 
87 Wertheimer, Exploitation, 209. 
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need not exploit B for personal gain.  A could exploit B on behalf of a third party C.  This 
later case, Wertheimer classifies as mediated exploitation.88 
 In order to determine the baseline of fairness for transactions, Wertheimer refers 
to the Best Alternative to a Negotiated Agreement (BATNA); 
 [a] party’s BATNA is a course of action, for example, to do nothing or to transact 
 with another party.  A BATNA has a value to each party.  Call it the reservation 
 value. With reference to that reservation value, each party determines his or her 
 reservation price, a price that is just equal to the reservation value, the minimum 
 threshold value that he or she is prepared to accept for entering into an 
 agreement.89   
 
If A receives more than the reservation price, then A has gained from the transaction. 90  
 Wertheimer distinguishes between two notions of reservation price: actual 
reservation price and A’s morally justified reservation price.  An agent’s actual 
reservation price is a counterfactual in two ways.  First, it is the minimum price that the 
agent would accept, and second, it is a function of the agent’s general knowledge of the 
market and the reservation price of the other agent involved in the transaction.91  On the 
other hand, the morally justified reservation price is the baseline used to understand an 
agent’s gain.  The morally justified reservation price is often no less than the actual 
reservation price but it need not be.  Wertheimer intends it to be a baseline not a ceiling.92   
 The morally justified reservation price is the fair price for a transaction.  Fairness 
does not dictate that all of the parties involved in the transaction must gain equally.93  
Rather, Wertheimer suggests agents should utilize hypothetical markets to determine fair 
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91 Wertheimer, Exploitation, 212. 
92 Wertheimer, Exploitation, 211-213. 
93 Wertheimer, Exploitation, 223. 
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prices.  The hypothetical market price is the “accepted baseline price that was set by a 
‘fairly conducted market...in the absence of fraud, monopoly, or coercion.’”94  
Wertheimer uses the following example to motivate his use of hypothetical market price.  
Consider two friends, A and B.  A wants to sell her house to B and B wants to buy A’s 
house.  Both parties want to transact at a fair price so as to avoid taking unfair advantage 
of the other.  How do A and B determine a fair price of the house?  Using Wertheimer’s 
hypothetical market framework, the two friends should determine the price produced by a 
fair competitive market.95   
 Wertheimer admits that the hypothetical market model does not inherently reflect 
a deep principle of justice.   However, he finds the model attractive because, as 
Wertheimer describes, 
 ...it does reflect a crucial moral dimension of the relationship between the parties 
 to the transaction.  The competitive market price is a price at which neither party 
 takes special unfair advantage of particular defects in the other party’s decision- 
 making capacity or special vulnerabilities in the other party’s situation.  It is a 
 price at which the specific parties to this particular transaction do not receive 
 greater value than they would receive if they did not encounter each other.  It may 
 or may not be a ‘just price,’ all things considered, but it may well be a 
 nonexploitative price, for neither party takes unfair  advantage of the other 
 party.96 
 
 Moreover in a perfectly competitive market, there are no important differences in 
bargaining power between A and B.  Wertheimer does assume that there is a bargaining 
range between A and B; “for where there can be no bargaining, there cannot be an 
                                                
94 Wertheimer, Exploitation, 231. Wertheimer is quoting Raymond de Roover, “The 
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95 Wertheimer, Exploitation, 230. 
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inequality in bargaining power.”97  That is, because A and B bargain when it comes to the 
terms of a transaction, there must be a difference in bargaining power.  Although, there is 
no inequality in bargaining power if A’s and B’s reservation prices are roughly 
equidistant from the bargain price.  Consider the example of B who needs to buy food 
from A.  B may feel an injustice as B is on a tight budget and would like to pay less for 
food than what A is charging.  Similarly, A may have liked to have charged B more for 
food, but was prevented from doing so by the market.  “So,” Wertheimer argues, “despite 
the fact that there are important objective and phenomenological inequalities between A 
and B [such as A being a big firm and B being a lowly individual], there is no inequality 
of bargaining power...”98 In other words, because the price that B ended up paying for the 
food was between the price that B wanted to pay and the price A wanted to charge, there 
is no inequality in bargaining power according to Wertheimer.   
 Based on that analysis, Wertheimer believes that to say that B has a bargaining 
weakness “is simply another way to state that B’s reservation price is higher than some 
norm or is likely to generate a price that is much greater than the cost to A or what might 
be A’s reservation price in the absence of B’s vulnerability or other competitors.”99  
Wertheimer goes on to argue that bargaining weakness do not equate an inequality of 
bargaining power; “vulnerabilities are interactive.  Although B’s vulnerability creates 
opportunities for A, B can use those very opportunities as a lever against A.  Once the 
situation is redefined in this way, there is no obvious inequality of bargaining power 
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between the parties. . .”100 What Wertheimer is suggesting is that a transaction is not 
necessarily exploitative if there is a difference in bargaining power.  While I agree that a 
difference in bargaining power does not necessitate exploitation, if the difference in 
bargaining power is too great, the transaction can become exploitative.  I will further 
explain that idea in detail further on.  Additionally, Wertheimer is vague as to how B can 
leverage his vulnerabilities against A.   In fact, as I will argue, there are situations where 
B’s vulnerabilities are so great that B has no bargaining power.  In those cases, A is 
easily able to exploit B. 
 Wertheimer’s explanation of A exploits B if and only if A takes unfair advantage 
of B, seems intuitively correct, and I accept that part of his argument.  However, 
Wertheimer’s unpacking of “unfair advantage” in terms of a hypothetical competitive 
market is problematic.   Ruth Sample makes that argument.  Sample agrees with 
Wertheimer that exploitation does not necessarily involve harm, coercion, an unequal 
distribution of the social surplus of an interaction, or unequal bargaining power; however, 
she disagrees with Wertheimer’s claim that “exploitation occurs when one pays a 
nonstandard price for the object of a transaction.”101  Such a claim, according to Sample, 
produces some counterintuitive results.  She offers the example of the wealthy tourist 
visiting a poor nation, where the average daily income is one dollar.  Within the market 
of that nation, the fair value of a pineapple is five cents.  The tourist is offered the 
pineapple for a price of twenty-five cents.  Even though the tourist has a hunch that the 
locals pay a lower price, the tourist buys the pineapple at twenty-five cents.  Has the 
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tourist been exploited?  Sample argues that despite paying five times the market value for 
the pineapple, the tourist has not been morally wronged.  She explains, 
 [e]ven if the vendor earns much more than a subsistence wage - say, five dollars 
 per day - I am inclined not to chastise her for exploitation, but to congratulate 
 her for her enterprising activities, especially when no dishonesty is involved and 
 the transaction is not of a Good Samaritan sort.  It simply does not seem generally 
 wrong to charge a nonstandard price for something.102 
 
 I share Sample’s intuition.  Perhaps a motivation for that intuition is the inference 
that the tourist is wealthy and may be from a country where the fair market price of a 
pineapple is three dollars.  If the tourist would generally pay three dollar for a pineapple, 
it seems odd to say that she has been exploited when paying twenty-five cents.  Which 
market is to govern the fair price of the pineapple, the tourist’s home country or the 
visiting country?  If it is the visiting country, then it seems that the tourist should be able 
to fly in and buy a lifetime supply of pineapples at twenty-five cents and return home 
with them.  She would still be paying five times the fair market value as dictated by the 
visiting country, but is paying substantially less than the fair market value of the 
pineapple in her home country.  In that scenario, it seems that the tourist is exploiting the 
pineapple sellers of the visiting country.  The tourist could be paying them more but is 
taking advantage of their need to sell at a price lower than the tourist’s home country.   
If the home country’s market is to determine fair value, then consider this example:  the 
tourist actually originates from an even poorer country where the fair market value of 
pineapples is one cent.  Even if the tourist buys the pineapple at market value of the 
visiting country, five cents, then the tourist would be exploited as he is paying more than 
the fair value of the pineapple in his home country.  Simply put, Wertheimer’s analysis of 
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hypothetical markets to set the baseline for fairness over simplifies a very complex 
system, which is made even more complicated since wealth varies so greatly between 
communities. 
Moreover, Sample argues that rather than articulating what it is for a transaction 
to be fair, and then choosing a system, which conveys that fairness, the hypothetical 
market system seems to be a convention chosen without any regard as to whether it is 
genuinely fair.  She explains, 
 ...it is clear that this is an understanding of exploitation as failure to adhere to a 
 convention.  It says that in the context of a market for a given object, paying the 
 standard (i.e., normal) price, when there is a competitive market for the object, 
 would make the transaction, ceteris paribus, nonexploitative.  But why should we 
 accept this?  It may be true that the law regards transactions as fair when they 
 meet this standard (hence the  doctrine of unconscionable contracts), but that is not 
 the same as showing that they are fair and that they do not exploit.  Competitive 
 market prices are set by supply and demand, and if a person has a monopoly on a 
 resource - such as employment - this may drive demand and thus prices up.103 
 
To illustrate her point, Sample points out the labor situation in the Pacific Rim countries.  
In that region, laborers outnumber capitalists, so that the market price for labor is 
relatively low.   Many have the intuition that those laborers are being exploited and yet 
under Wertheimer’s account the fair market price is being met.104   
 Here is another example to bolster Sample’s point.  In some of those Pacific Rim 
countries, children are a part of the work force.  The children’s wages are necessary in 
order to keep their families afloat financially, and they are being paid in accordance with 
what the market in those countries dictates.  Both sides in the transaction, the children 
(along with their families) and the capitalists, are benefitting.  Yet we call such factories 
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sweat shops, and believe to a very certain degree that those children are being exploited.  
As Sample explains, Wertheimer’s theory cannot account for the exploitation and moral 
wrong done in those cases. 
 Both of Sample’s points highlight an obstacle with Wertheimer’s account.  When 
there are two different fair market prices, how does one determine what is the most fair 
market value?  What reason is there for choosing one price over the other?  Without any 
additional guideline for fairness, any chosen market price would be chosen arbitrarily.  
Furthermore if an additional principle of fairness for exploitative transactions is needed, 
why rely on hypothetical markets at all?  As Sample points out, Wertheimer has not 
offered any reasoning as to why hypothetical markets are the best convention for 
determining fair transactions.  Rather hypothetical markets seem to complicate the 
matter. 
 The Pacific Rim laborers, particularly the children workers, examples mirror the 
problem of clinical drug trials in developing nations.  Both the researchers and trial 
participants are gaining after the interaction.  The trial participants, like the laborers, are 
not in a position where they cannot interact.  With more laborers than employers, there is 
a financial strain forcing laborers to accept low paying jobs, and similarly, in many cases 
trial participants do not have access to any health care.  A drug trial is better than no 
treatment whatsoever.  Thus, like the laborers example, the clinical drug trial problem 
poses problems for Wertheimer’s account.   
 To determine the fairness of the transaction between the researchers and trial 
participants, according to Wertheimer, “we must measure the fairness of their gains 
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against a normative standard as to how much the parties ought to gain.”105  That 
normative standard, as discussed, is determined by a hypothetical market.  However, that 
framework does little to offer a standard of fairness for a clinical transaction.  First, it 
suffers from the same criticism as in the pineapple example.  Does one use the 
hypothetical market modeling the conditions of the host country that have virtually no 
health resources available for the general public or the conditions of the researcher’s 
country where more medication and health services are available?  Second, the 
interaction between the researchers and the trial participants is not a typical transaction 
involving commodities.  The participants’ bodies, health, and well-being are at the center 
of the interaction.  With such high stakes for the participants, an economic-based concept 
of hypothetical competitive market does not seem to be the appropriate mechanism for 
determining fairness.  
 Wertheimer does recognize the pitfalls of relying on the hypothetical market 
model and tweaks his theory of exploitation in Rethinking the Ethics of Clinical 
Research: Widening the Lens.   His new formulation defines a transaction as exploitative 
if B receives less from (or pays more for) the interaction than is required by a plausible 
principle of fairness.  Wertheimer admits that he is unable to offer an unproblematic 
principle of fairness that adequately explains the unfairness of mutually beneficial 
transactions.  Thus, for the sake of argument, he argues, “that some mutually 
advantageous transactions are unfair by reference to an appropriate normative 
                                                
105 Alan Wertheimer, “Exploitation in Clinical Drug Trials.” in Exploitation and 
Developing Countries: The Ethics of Clinical Research. edited by Jennifer Hawkins and 
Ezekiel J. Emanuel, (Princeton: Princeton University Press, 2008), 73. 
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standard.”106  Unfortunately, this new formulation does not solve our earlier problem as to 
what the normative standard of fairness ought to be for clinical drug trials. 
 When specifically addressing the exploitative nature of clinical drug trials, 
Wertheimer does not believe that the critics of the clinical drug trials have proven why 
the distribution of benefits between the parties is unfair.107  First, he argues that in some 
cases, it is unclear who the beneficiaries of the transaction are.  In private research, 
clearly the pharmaceutical companies gain in profit; however, the study could be run by a 
not-for-profit organization such as the National Institute for Health, in which case the 
beneficiary is unclear. Wertheimer says that you could claim that the scientists gain, but it 
seems that the intended indirect beneficiaries of the trial are the trial participants.108   I 
agree with Wertheimer.  Trial participants are intended indirect beneficiaries, but I would 
also contend that in both the trials run by private companies and not-for-profit 
organizations, the community from which the company and organization originate, the 
developed world, is also an intended beneficiary.  After the trial is run, as previously 
discussed, the developed world gains the majority of benefit over the developing world.  
Thus, it seems only fair that when considering the distribution of benefits, if we consider 
the benefits of both parties. 
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 Second, Wertheimer argues that it is possible to interpret investigators as offering 
fair ex ante packages to trial participants through placebo-controlled trials.  Prior to 
entering the trial, the participants had zero percent chance of receiving beneficial 
treatment.  Those odds increase upon entering the trial.  If only half of the participants 
receive the actual medicine, whereas the other half receive a placebo, the odds for all 
participants of receiving beneficial treatment has increased from zero to fifty percent.  
Additionally, even those who are receiving the placebo are receiving all around better 
care than they would have if they had not entered the trial. 109 While I agree that that the 
participant does have some ex ante benefit from entering the trial, that does not mean that 
the benefit is fair and thus the overall transaction fair and nonexploitative.  Consider the 
following example:  my sister and I do the same amount of chores, but I receive $10 for 
my work, but my sister only receives $5.  Even though my sister does receive more 
benefit, $5, doing the chores than had she not done the chores and received $0, her 
benefit is still unfair as she only received half the amount of money I received for doing 
the same amount of work. 
 One might make the following objection.  My sister and I are employees of Al.  
Suppose Al is required by law to pay me twice as much as my sister for the same amount 
of work.  That is, Al is left with two choices; either (A) offer my sister and me $5 and 
$10 respectively or (B) offer us nothing.  Also suppose that both my sister and I are better 
off with option A than B.  Under these circumstances, it is not clear that option A is 
unfair or exploitative.  While it is clear that it is unfair to treat those who are alike in all 
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morally relevant aspects differently when treating them alike is an option, it is far less 
clear that it is unfair to treat those that are alike in all morally relevant aspects differently 
when treating them alike is not feasible or if treating them alike makes them better off.110  
 This objection confuses the source of the unfairness.  Even though the law 
prevents Al from paying my sister and me equal amounts does not mean that the unequal 
payment is fair.   Al is not the source of the unfairness as he does not necessarily intend 
to be unfair to my sister and me, but rather the law that requires me to receive twice as 
much is.  The law, in treating my sister and me differently when we ought to be treated 
similarly, is unfair, and thus, every instance of the law being enacted is an unfair example 
of that law.   If we are to place feasibility as a limit on fairness in transactions, the 
question of fairness becomes more of a practical issue than a normative one.  
Additionally, in the cases of mutually beneficial exploitation that I am looking at - 
clinical drug trials and child labor - there are no strict laws that prevent the exploiter from 
transaction with the victims in a fair and moral manner.  In fact, as was discussed in the 
introduction and will be examined in further length in chapter 4, for clinical drug trials, 
the legal standard promotes equal treatment for individuals who are alike in all morally 
relevant aspects.  So while this objection may be of concern for other exploitative 
situations, it does weigh heavily in this instance.   
 Third, Wertheimer dismisses the argument that clinical trials in developing 
nations are exploitative because they serve the interests of the wealthy nations.  Citizens 
of wealthy nations have medical needs.  He argues, “the issue is not the legitimacy of the 
interests that are being served, but whether those who serve those interests are being 
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treated fairly.”111  For example, if Oriental rug makers were treated fairly, we would not 
say they are being exploited just because they are providing goods for affluent 
westerners112.  Wertheimer’s example is dis-analogous to the case of clinical drug trials.  
There is a difference between a person who makes a good and a person who is allowing 
their body to be tested on for medical purposes.  The trial participant is taking on much 
greater personal risk than the person knitting oriental rugs.  For a participant to take on a 
great risk only to have that benefit wealthy nations versus this own community is an 
important factor in determining whether the risk for the participant is warranted.  
Moreover, many participants are unaware that their participation in the trial will not 
benefit their community as much as wealthy nations.  If trial participants believe their 
community is one of the major intended beneficiaries, then it seems that participants are 
not fully aware of the terms of the transaction to which they consenting. 
 Furthermore, understanding wealthy nations as the intended beneficiaries is 
important to the exploitation debate because of the double standards that exist between 
the trials run in those wealthy nations and those run in developing nations.  If developing 
nations are serving the interests of wealthy nations, do they not at least deserve the same 
conditions as the trial participants from those wealthy nations assuming it is feasible to do 
so?  If developing nation participants are only serving the needs of their own community, 
then one might be able to justify the different standards.  But since both trials in 
developing and developed nations have the same beneficiary, it seems that the terms 
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should be the same in both cases.  This will be discussed in further detail in the chapter 
on standard of care.113 
 
Hill 
 Hill argues that exploitation concerns a psychological disparity rather than an 
economic or social disparity.  Though economic and social inequalities may exist 
between the two parties involved in an exploitative transaction, it is the psychological 
vulnerability between the two that qualifies the transaction as exploitative.  To 
demonstrate that intuition, Hill uses the example of a college student who entices her 
college professor into a sexual relationship for a better grade.  While the student has a 
lower social position, she is exploiting a weakness of the teacher.114 
 In order for a transaction to be exploitative in the legally relevant sense, according 
to Hill, the following five conditions must be met.  The transaction must, 
 1) consist of an offer of benefit, never a threat 
2) which is made intentionally, knowingly or recklessly on the part of the offeror, 
such that it is likely to involve, implicate or take advantage of; 
3) a psychologically recognized vulnerability or weakness on part of the offeree; 
4) where the vulnerability or weakness characteristically results in a significant 
impairment of the rational-emotional capacity of the individual; 
5) that the offer actually has the effect of impairing the rational-emotional 
capacity of the offeree; 
6) such that, but for the impairment of this capacity, the offeree would not have 
accepted the offer.115 
 
 Let us look at each of those conditions in turn.  First, the transaction must consist 
of an offer of benefit, never a threat.  This emphasis on benefit over threat serves to 
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distinguish exploitation from coercion.  Coercion often involves a threat of harm to B if B 
does not comply with the terms of the transaction.  Additionally, Hill notes, that the offer 
to B need not be objectively beneficial; “many offers are considered exploitative in part 
precisely because the offer of benefit is illusory.”116   
 Second, the offer is made intentionally, knowingly or recklessly on the part of the 
offeror, such that it is likely to involve, implicate or take advantage of.  This condition 
mandates the intent of the offeror to exploit.  Hill rightly frames the standard of intent 
objectively rather than subjectively.  That is there are two criteria for intent: “the offeror 
must act voluntarily and the act must be performed with the desire to, or with substantial 
certainty that the act will in fact bring about some specific consequence.”117  Hill also 
quite rightly includes cases of recklessness where A was in a position to have the 
consequences of his interaction with B and should have known them before engaging in 
the interaction.  Concerning the latter half of the statement, “likely to involve, implicate 
or take advantage of,” Hill does not mean that A must necessarily create a cognitive 
impairment (though his definition of exploitation does encompass those cases), but A 
may merely take advantage of a pre-existing condition.  That is,  
 the offeror must subjectively know, or there must be substantial certainty, given 
 what the offeror knows or should know about the offeree’s situation, that the offer 
 will undermine the rational capacities of the offeree.  The offeror must, therefore, 
 act in conscious disregard of the likelihood of exploitation.118 
 
 Third, the offeror is taking advantage of a psychologically recognized 
vulnerability or weakness on part of the offeree.  By vulnerability Hill means, “a 
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disposition of personality or circumstance of life that serves to hamper the rational-
emotive process, such as severe depression, grief, guilt, fear or physiological 
addiction.”119  Key to Hill’s notion of vulnerability is their resulting in an internal 
psychological state that interferes with one’s reasoning processes. There are several 
situations that do not necessarily but can result in vulnerabilities, such as poverty, 
political oppression or social alienation.  While Hill recognizes that it can be difficult to 
determine when said situations create a vulnerability, what is important for his concept is 
that vulnerability require more than “mere credulity, gullibility, curiosity, or naiveté.” 120  
 Hill’s explanation for vulnerability is unsatisfying.  If theorists are unable to 
clearly identify the circumstances under which B’s circumstances in life create a 
vulnerability, then to what extent can we hold A accountable for knowledge of B’s 
vulnerability?  I am not suggesting there are not cases of exploitation where A did not 
intentionally exploit B but recklessly engaged in the transaction.  However, A’s epistemic 
burden seems too high given the gray area Hill portrays.  Rather than simplifying 
exploitation's complexities, Hill has shifted the complexity to the concept of 
vulnerability.    
 Fourth, the vulnerability or weakness characteristically results in a significant 
impairment of the rational-emotional capacity of the individual.    In order to prove that 
volitional states can affect one’s ability to reason, Hill looks at three different types of 
examples.  First, volitional states affect beliefs.  Consider a man drowning in a lake with 
no hope of rescue.  The only thing within reach that may help him is a piece of straw.   
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Under normal circumstances, that man believes a piece of straw is not strong enough to 
support his weight and allow him to pull himself ashore.   However, under his current 
circumstances, Hill argues, it would not be surprising to find the man grasping at that 
straw to try to prevent his drowning.  That is because the man’s fear of death and 
drowning merits his trying to use the straw to save himself, or as Hill argues given the 
circumstances the man now has the belief, as improbable as it may be, that the straw 
might save him. 121   
 Volitional states also affect one’s values.  Consider the example of a person who 
values property rights.  That person believes that it is immoral to steal.  However, if that 
person were starving or was unable to feed her children, she would very likely steal food 
in order to feed herself and/or her children.  While in other circumstances, upon seeing a 
loaf of bread, said person may reason that it is wrong to steal, so I will not steal the bread.  
However, in a situation in which she is starving, her values may change, and she may 
reason that it is not wrong to steal the bread because I am starving.  This shows a change 
in her reason due to a change in her values originating from a volitional state.122 
 Finally, volitional states affect one’s behavior.  He appeals to people’s erratic 
behavior during times of emergency.  Often times when an emergency arises, such as a 
burning building, a person choking, etc., some people panic and do not act rationally.  
The emergency circumstances affect one’s ability to reason and act accordingly, such as 
calling 911.123  Despite his examples, Hill admits the practical difficulty of giving a full 
account of the psychological analysis of rational decision-making.  Rather, he relies on 
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tort law in suggesting that “a particular decision will be deemed “rational” if it would be 
made by a reasonable person in the subject’s circumstances.”124  Thus, if a person acts 
differently than a reasonable person would, the person is not acting rationally.   
 While Hill is able to offer examples of ways in which volitional states can affect 
our rationality, I have the same worry as explained under the third condition.  Hill does 
not offer a full enough account that would allow A to determine if B is vulnerable and if 
that vulnerability is affecting B’s decision-making.  If we rely on his “reasonable man 
standard,” I am still at a loss a loss as to what characteristics define the reasonable man, 
and to what extent A should have knowledge of what a reasonable man is.  Furthermore, 
what if it is unclear what the reasonable man would do?  Often on controversial issues, 
such as stem cell research and clinical drug trials, it is unclear what the reasonable action 
is.  Consider the following scenario:  A and a bystander C disagree on what the 
reasonable man would do.   A thinks B is acting reasonably and C does not.  Thus A 
thinks he is not exploiting B but C thinks he is.  How are we to determine who is correct?  
If we are to accept Hill’s account of exploitation, we must develop clearer standards for 
what it means to act rationally in a given situation. 
 Let us look at the fifth and sixth conditions together.  The fifth condition is that 
the offer actually has the effect of impairing the rational-emotional capacity of the 
offeree, and the sixth is that but for the impairment of this capacity, the offeree would not 
have accepted the offer.   Important to note that from those conditions we can rule out 
cases where A intends to exploit B but there is no actual effect.  Exploitation requires A 
actually influencing B, and B acting in a way that would be different from how they 
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would have acted without cognitive impairment.  It is also important to notice that Hill’s 
account does not discuss B’s position after the interaction.  That is, B could be left better 
off after the transaction and still have been exploited.125 
 Hill’s theory does effectively account for some exploitative scenarios that other 
theorists, such as Wertheimer, cannot.  Consider the following case: a dance studio 
convinces a lonely, depressed widow she has dance talent and should purchase $50,000 
worth of dance lessons.  In order to pay for the lessons, she must sell everything she 
owns, including her home.126  Has the widow been exploited?  Perhaps, she is not being 
charged a higher price than any other dance and was pursued to the same degree that any 
other potential dance student would be.  Given those conditions, Wertheimer’s theory 
struggles to classify this situation as exploitative.  However, intuitively, it seems that the 
dance studio is exploiting the widow.  Hill’s account has the explanative force behind 
that intuition.  Because she is depressed and lonely, the widow is psychologically 
vulnerable, which is affecting her rational decision-making processes.  The dance studio 
is taking advantage of that psychological vulnerability whether it be intentional or 
recklessly when they allow her to sell all of her belongings and spend $50,000 on dance 
lessons.  Had she not been depressed and lonely, the widow may not have made the same 
decision.   
 How might Hill, then, explain the intuition of exploitation in clinical drug trials?  
If pharmaceutical companies are exploiting the developing world participants, it is 
because the participants are psychologically vulnerable which is interfering with their 
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ability to rationally consent to participation in the trial.  That psychological vulnerability 
arises from their lower socioeconomic position.  That is, because the participants are 
poorer without access to healthcare, their desire for medical care overrides their 
rationality in deciding to enter a trial. However, if we believe the participants to be 
rationally consenting to the trial, then a psychological vulnerability is not interfering with 
their decision-making processes, which means, according to Hill they are not being 
exploited. 
 While Hill’s account may have weight with cases like the dance studio and 
widow, I reject that idea that in order for a transaction to be exploitative, the exploited 
party’s rationality must be called into question.  There are several instances of 
exploitation where it seems that the exploited party, B, has entered into the transaction 
rationally.  Let us say that B is dying of dehydration and will die within the hour if he 
does not drink a glass of water.  A, who is not dying of dehydration, has a glass of water 
and will give B the glass of water for $20.  B, having $20, buys the glass of water from A 
and lives.  A has clearly taken advantage of B’s situation in order to make $20.  Does this 
mean B had a psychological vulnerability that created a psychological disability, which 
affected his ability to rationally make a decision?  No.  There is no evidence that B has 
psychological disability.  Rather it seems that B was acting quite rationally.  If B did not 
pay $20 for the glass of water and died, many would think that B would have been acting 
irrationally.  One’s life is surely worth more than $20.  The situation is similar for clinical 
drug trials.  Given a choice between no health care and perhaps certain death or entering 
a trial that offers a chance of a survival, though the conditions of the trial may not be 
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optimal, it seems that the rational decision would be to enter the trial.  However, that 
rational consent does not dismiss the exploitative nature of the trials.  
 
Sample 
 Rather than appealing to fairness, Sample places lack of respect at the center of 
exploitation.  She argues that exploitation “involves interacting with another being for the 
sake of advantage in a way that degrades or fails to respect the inherent value in that 
being.”127 The consequences of that disrespect are connected to the exploitative act but 
need not be constitutive of it.  That is, while some exploitative acts are harmful in and of 
themselves, exploitation may also be mutually beneficial.128   
 Sample identifies three broad categories for ways in which we may disrespect a 
person’s value.  We fail to respect a person by (1) neglecting what is necessary for that 
person’s well-being or flourishing, (2) taking advantage of an injustice done to him, and 
(3) commodifying an aspect of that person’s being that ought not be commodified.  In 
each category, there is a lack of respect for human value that motivates the charge of 
exploitation.129 
 Similar to other theorists, Sample believes that A must gain from the transaction 
with B in order for the transaction to be exploitative.  A need not have intent to exploit 
for the act to be exploitative.  Sample observes three ways in which exploitation may be 
unintentional: A may believe that B is not deserving of respect; A may be mistaken about 
what respect requires; and A may be mistaken in what it takes to fulfill a requirement of 
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respect.  In other words, even if A either has mistaken beliefs or is ignorant of what it 
takes to respect an individual, she can still be held morally responsible for exploiting 
B.130   
 Sample, also, pays particular attention to cases of exploitation where the 
transaction is the best available option to B and A is not obligated to interact with B.131 In 
such cases, Sample argues that B is vulnerable to A, and that vulnerability takes the form 
of need.  By need, Sample means “not only those objects necessary for physical survival, 
but also conditions of purposeful employment, the prerequisites of psychological well-
being, and constraints on interaction that are necessary for self-respect.”132  When A 
exploits B under those circumstances, A is using B’s need for the sake of advantage in a 
way that fails to respect B.  Though the needs of others do not automatically obligate us 
to provide for them, Sample argues that the needs of others do constrain how we interact 
with them.    That is, “[i]f we can interact with persons so that their basic needs are taken 
into account through the transaction, we ought to.”133  If, for whatever reason, the 
mutually beneficial transaction is unable to provide for those needs, the transaction is not 
exploitative. 134  
 According to Sample’s theory, pharmaceutical drug companies are exploiting trial 
participants because if they are in a position to provide for the participants’ basic needs, 
particularly medical care, then drug companies ought to provide for those needs.  That is, 
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they should make available the drugs on the market in developed nations through active 
control trials and provide the tested drug at an affordable rate if the trial is successful.  
Those two items serve to provide for the trial participants health needs.  To not do so, 
under Sample’s lens, is to treat the trial participants for the sake of advantage in a way 
that is degrading to their inherent value. 
 Sample’s account is successful in identifying one way in which mutually 
beneficial exploitative transactions are morally wrong.  They disrespect and/or degrade a 
person’s inherent value.  Her theory is particularly apt in cases of interpersonal 
exploitation.  Consider the following scenario: A and B are parents of a child.  A and B 
know that grandparents C and D, having paid for A’s college tuition, will not allow the 
child to go without a college education.  A and B also know that C and D have enough 
sayings to pay for the child’s college tuition, though they may need to give up some 
retirement activities.  A and B, thus, decide to spend their savings on traveling rather than 
saving up for their child’s education.135  Because relationships vary in character and 
complexity, finding a standard by which to gauge fairness is difficult.  It also seems that 
in paying for the college tuition, the grandparents are acting rationally toward the child 
who is in need of education.  Yet the scenario seems to leave a morally bad taste in one’s 
mouth.  Sample is able to characterize the moral wrongness of the college tuition 
example.  She asserts, 
 [t]he parents A and B ... are taking advantage of the family ties of the grandparents 
 C and  D, whose love of their grandchild ensures that they will make tremendous 
 sacrifices to see that the child is educated.  Their morally praiseworthy 
 sentimental attachment is a vulnerability that is being used to the advantage of the 
 parents, to the detriment of the grandparents’ financial well-being.  It is degrading 
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 to have one’s generosity not only go unreciprocated, but be preyed upon.  It 
 cheapens the value of intimacy to use it in this way.136 
 
However, her account seems to blur the lines between exploitation and other forms of 
wrong doing, which in turn complicates the exploitation debate. 
 Like many other philosophers, including Wertheimer and Hill, Sample defines 
exploitation using the phrase “taking advantage.”  When A exploits B, A is takes 
advantage of B.  It is unclear what that phrase entails.  The Oxford English Dictionary 
defines to take (the) advantage as “to take an opportunity provided by favourable 
circumstances; to avail oneself of a person or thing. Freq. in negative sense: to seize an 
opportunity of unfairly profiting by a person or thing, esp. sexually.”  The latter portion 
of the definition seems to be what philosophers are intending.  However, “to seize an 
opportunity of unfairly profiting by a person or thing” is too broad of a phrase.  That is, 
we cannot use that phrase to define exploitation as other harms that are not exploitative 
are encompassed by it.137    
 Consider the sexual connotation of to take advantage of.  To say that A takes 
advantage of B sexually, usually connotes some form of rape.  It is easy to see how when 
A rapes B, A is seizing an opportunity of unfairly profiting by a person or a thing.  A 
seized an opportunity to gain power and pleasure through unfair treatment of B.138 While 
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A did harm B, it would seem odd in this situation to say that A exploited B.139  A similar 
situation arises when examining other forms of wrongdoing.  If A and B are business 
partners and A murders B in order to keep B’s share of the profits, clearly A has unfairly 
profited by killing B, an act which is degrading to B’s value, but would we say that A has 
exploited B?140 Even if A is serial killer and murders B for the sheer thrill of killing, it is 
reasonable to describe A as unfairly profiting, in the form of personal pleasure, from 
killing B, an act which degrades B’s value.  But yet again, that seems to suggest under 
Sample’s perspective that murder is a case of exploitation.   
 One could simply bite the bullet and accept that such a broad interpretation of 
exploitation demands that some harmful acts be considered exploitation that otherwise 
may not seem to be exploitation.141  I question whether in doing so we are not 
fundamentally misunderstanding the nature of exploitation as a unique harm, which 
requires tailored policies to prevent.  More practically, a wide notion of exploitation 
complicates the establishment of laws and standards to prevent exploitation.  For 
example, pharmaceutical companies have utilized the vagueness of the phrase “best 
proven prophylactic, therapeutic, and diagnostic method available” in the Declaration of 
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Helsinki to justify the use of a placebo when a known effective treatment exists.  That 
issue will be discussed in further detail in the standard of care chapter. 
 
Exploitation in Clinical Drug Trials 
 Each of the three theories is better able to account for some difficult cases of 
exploitation but not all.  Wertheimer successfully explains the exploitative natures of 
transactions where clear standards of fairness exist.  For example, the tow company who 
charges a stranded motorist $100 more than fair market value because he is the only tow 
company available to help.  Hill’s theory gives explanative force to cases where A treats 
B no differently than he might treat any other person in the same circumstances but an 
error in B’s judgment during the transaction triggers a charge of exploitation.  Recall the 
case of the dance studio convincing a widow to spend $50,000 on dance lessons.  Sample 
captures the moral wrongness of exploitation that does not seem overtly harmful or unfair 
such as in interpersonal exploitation between two family members.  However, no one 
theory is fully able to account for all categories and instances in which we apply the label 
of exploitation.  Perhaps the difficulty with achieving a single overarching concept of 
exploitation is that the contexts in which we use the word “exploit” vary widely.  Joel 
Feinberg makes that variation apparent in his breakdown of exploitation.  At the broadest 
category, exploitation has two senses: non- pejorative and pejorative.  Non-pejorative 
exploitation refers to opportunities and resources, such as to take advantage of a talent or 
of an environmental resource.    In this sense, the exploiter is always a person.  Pejorative 
exploitation refers to a kind of injustice and moral evil.  It involves “a relation between 
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two or more persons or groups, and ... can involve morally altered relationships among 
three or even four parties.”142 .  
 Feinberg further breaks down pejorative exploitation into coercive and non-
coercive.  Coercive exploitation is when A forces B to act in a way that is beneficial to A, 
and non-coercive exploitation is when A takes advantage of B’s traits or circumstances to 
gain either with B’s consent or without regard to B’s choice at all.143  From both the 
coercive and non-coercive categories, Feinberg identifies nine cases of wrongful 
exploitation: coercive forcing deceiving, or manipulating-the-incompetent; unequal 
contest; freeloading and similar cheating; manipulated benevolence; petard-boisting; 
unproductive cashing in; pandering; harmless parasitism and passive unjust 
enrichment.144 
 I am neither agreeing nor disagreeing with Feinberg’s categorization, though I do 
find it to be the most complete in the literature.  I am merely demonstrating the breadth of 
cases that fall under the exploitation umbrella.  If simply identifying the ways in which 
we use the term exploitation is so complex, the task of connecting them in a single 
unified theory is even more daunting.  I am inclined to think that maybe exploitation’s 
wide range is in part due to our erroneously using the same word to describe different 
types of wrongdoing.  That is, the moral wrongness of a painter who charges a couple 
double for painting the outside of their house because he knows that the couple is 
extremely wealthy does not seem to be of the same type of moral wrongness when 
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pharmaceutical drug companies knowingly use different ethical standards for trial 
participants in developing nations in order to put their drugs on the market faster and at 
higher prices.  How akin is the college tuition case of exploitation to companies hiring 
children overseas so that they may pay lower wages?    
 Moreover, no existing theory adequately accounts for exploitation in clinical drug 
trials.  As a result, policy standards remain vague on what constitutes exploitation, which 
allows pharmaceutical companies to find loopholes and justify inadequate treatment of its 
trial participants.  In order to provide a practical theoretical background from which 
policy can be drawn, my goal is not to offer a single unified theory of exploitation.  
Rather I offer a concept of exploitation tailored to the wrongness of clinical drug trials in 
developing nations.  My concept shall be a type or subset of exploitation, which I call 
comparative exploitation.  To offer an analogy, if exploitation were a tree, comparative 
exploitation would be a branch on that tree.  There is a common thread or family 
resemblance between the types of exploitation, but I am not trying to identify what that 
thread is.  I merely want to fully develop a theory of my one branch.  
 I suggest looking at the harm done in clinical drug trials and child labor through a 
comparative lens.  When we say A exploits B, it must be possible for A to not exploit B.  
Moreover, the question of what it is for A to not exploit B may be proven empirically.  
Maybe A has interacted in the same manner with another person C on another occasion, 
and that interaction was not exploitative. When an empirical comparison is not available, 
the question becomes theoretical.  We could imagine what a nonexploitative interaction 
between A and B would look like given some moral framework.  If we were unable to 
find either an empirical or theoretical alternative where A is able to interact with B, or 
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someone like B, in a nonexploitative matter, that would mean it would be logically 
impossible for A to not exploit B.  Since it is impossible for A to act otherwise, then we 
would not be able to hold A morally culpable for her actions.  However, we hold 
exploiters accountable for their actions all the time, which means we presuppose that A 
could have acted differently.   Perhaps the key to understanding some types of 
exploitation is by comparing A’s exploitative interaction with A’s empirical or theoretical 
nonexploitative interaction. 
 Given that comparative lens, I propose the following necessary conditions for 
comparative exploitation: A exploits B in interaction I if  
 1. A does x to B in interaction I; and 
 2. there is a possible world in which C exists such that (1) B and C ought to be 
 treated equally; (2) if A and C engage in I under similar circumstances, A does 
 not do x to C; and (3) it is feasible for A to not do x to B.145    
This is not intended to be a sufficient definition of comparative exploitation.  I am merely 
identifying necessary conditions.   
  In more difficult cases of identifying the exact reasons why the interaction 
between A and B is exploitative, it may be easier to identify C and the differences 
between the two interactions. The addition of (1) under 2 is in order to ensure that the 
interactions between B and C are alike and ought to be treated alike.  If B and C ought 
not to be treated equally than some of the differences in A’s actions towards B and C may 
                                                
145 It is possible that B and C are the same person.  In an empirical comparison, A and B 
might have had the same kind of interaction but it was nonexploitative.  We could thus 
compare the current exploitative interaction with the nonexploitative one. In a theoretical 
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be morally justified and not be reasons why the interaction with B is exploitative.  I want 
to isolate the exact differences that make a nonexploitative interaction exploitative. 
  Moreover, C in many cases exists in the actual world.  However, as suggested, if a 
theoretical comparison is made then C exists in a near possible world.  Suppose some 
god-like creature enslaves and exploits the entire human race and does not interact with 
anyone else but the human race.  While there is not a being with whom the god-like 
creature interacts with in a nonexploitative way, we can conceive of what such an 
interaction would be like, and identify the differences between that interaction and the 
one between the creature and humans.  Then we can determine what humans deserve in 
order to achieve a nonexploitative interaction with the creature. 
 Furthermore, the addition of (3) under 2 is to rule out cases where it not possible 
for A to not do x.  That is, on every possible world A does x.  For example, it may be the 
case that on every possible world where her character and dispositions remain the same 
that my mom pays me twice as much as my sister to do chores.  Thus, it is not possible 
for her to not to do.  This example would not be a case of comparative exploitation as it 
fails (3), though it may be exploitation of a different kind.  Recall that I am not offering a 
theory of exploitation in total, but rather offering a theory of a specific subset of 
exploitation. 
 For clinical drug trials, the C is the trial participants in the developed world.  As 
described in the last section, much of the charge of exploitation arises from the double 
standards between trials in developed versus developing countries.  That is, in developing 
nations, pharmaceutical companies unnecessarily use placebo-controlled trials versus 
active control, and do not share the benefits of research, such as selling the new drug at 
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an affordable rate.  Those are required of pharmaceutical companies in developed 
countries.   
 Trial participants in developed nations are also C because the developed world is 
the primary intended beneficiary if the trial drug proves successful.  Favorable risk-
benefit ratio is a common ethical requirement in many clinical trial doctrines including: 
the Nuremberg Code, the Declaration of Helsinki, the Belmont Report, and the Council 
for International Organizations of Medical Sciences guidelines.146  The requirement, as 
summarized by Ezekiel J. Emanuel, David Wendler, and Christine Grady, states, 
“[clinical research can be justified only if, consistent with the scientific aims of the study 
and the relevant standards of clinical practice, 3 conditions are fulfilled: the potential 
risks to individual subjects are minimized, the potential benefits to individual subjects are 
enhanced, and the potential benefits to individual subjects and society are proportionate 
to or outweigh the risks.”147  Pharmaceutical companies are violating the third condition 
in developing nations.  Trial participants are taking on all the risk and receiving very few 
benefits, which developed nations receive.  If those taking on the risk are being exploited 
and those gaining the benefits are profiting, it seems natural to ask what the interaction 
would look like if those benefiting took on the risks.  That is the ideal situation as 
proposed by the favorable risk-benefit ratio.  Hence why the developed nation seems to 
be the appropriate C of comparison. 
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 Thus, the pharmaceutical companies are exploiting participants in developing 
nations because they are treating them unequally as compared to participants from 
developed nations.  Note that I am assuming (1) - that trial participants from both nations 
ought to be treated equally.    Pharmaceutical companies argue just the opposite; they 
ought not to be treated equally because they are not like cases.  That is at the core of the 
standard of care debate and will be discussed at length in a later chapter.  For the sake of 
argument, allow me the assumption of (1) for now. 
 I am not trying to argue that clinical drug trials even in the most optimal 
conditions available through the current standards in developed nations are not 
exploitative.  It could be the case that trial participants in developed nations are also 
being exploited.  Maybe it is the case that in order for a participant to not be exploited, 
they must be written a $1 million check, which they are currently not receiving.  Under 
those conditions, if the disparity between trials in developed and developing trials did not 
exist, all participants in all locations would be exploited because they are not receiving 
that check.  That is a different kind of exploitation than the one I am identifying.  The 
type I am identifying, which I will call comparative exploitation, derives from the 
unequal treatment of like cases for the sake of benefit.  Put another way, if A exploits B 
in interaction I, then A treats B less equally than A has treated, treats, or would treat C in 
interaction I for the sake of benefit.   
 Combined with the first formulation, I offer the following definition of 
comparative exploitation:  A exploits B in interaction I iff  
 1. A does x to B in interaction I; and 
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 2. there is a possible world in which C exists such that (1) B and C ought to be 
 treated equally; (2) if A and C engage in I under similar circumstances, A does 
 not do x to C; (3) it is feasible for A to not do x to B; and 
 3. A treats B less equally than A has treated, treats, or would treat C in interaction 
 I for the sake of benefit. 
 Comparative exploitation can also explain other situations.  Consider the case of 
Bob and his two employees Mary and Susan.  Mary and Susan have the same type of 
position at the same level and make the same amount of money.  Mary, however, is able 
to do twice the amount of work as Susan.  Bob, knowing that Mary is the more reliable 
employee, gives Mary twice as much work as Susan.  This often leads Mary to working 
longer hours than Susan, but Mary is not paid any more than Susan even though it is 
feasible for Bob to do so.  Since Bob has Mary doing twice the amount of work as Susan, 
he does not need to hire a third employee to pick up the slack, which saves him money.  
Intuitively, it seems that Bob is exploiting Mary and her work ethic.   
 Comparative exploitation can explain why Bob is exploiting Mary Let us consider 
condition 1: there is a possible world in which C exists such that (1) B and C ought to be 
treated equally; (2) if A and C engage in I under similar circumstances, A does not do x 
to C; (3) it is feasible for A to not do x to B, then A exploits B.   A is Bob.  B is Mary, 
and Susan is C. As Mary and Susan have the same type of position at the same level, they 
ought to be treated equally, which satisfies (1).  (2) is satisfied since Bob interacts as a 
boss the same way as he does Mary, and yet he is not exploiting Susan.  (3) is stipulated 
in the example; Bob does has the financial means to pay Susan more. 
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 Condition 2 states A treats B less equally than A has treated, treats, or would treat 
C in interaction I for the sake of benefit.  Bob is treating Mary less equally than Susan 
since he gives Mary more work, and he benefits from doing so by saving money.  Both 
conditions are met.  We now have a clearer picture of why the interaction between Bob 
and Mary is exploitative. 
 There are other instances of comparative exploitation including some child labor 
situations and Wertheimer’s example of a slave owner who treats two slaves the same but 
one slave, who is able to do more work, seems exploited over the other.148  I am not 
trying to give an exhaustive list of such cases, but rather offer theoretical model for 
classifying more difficult examples.   
Conclusion 
 In this chapter I have argued that the exploitation theories offered by Wertheimer, 
Hill, and Sample are unable to account for why the clinical trial double standards 
between developing and developed nations are exploitative.  Rather than offering a full 
account of exploitation, I have identified a type or subset of exploitation, which I call 
comparative exploitation.  Comparative exploitation is able to explain why the double 
standards in clinical research are exploitative.  In the next chapter, I will explain why 
comparative exploitation is harmful. 
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Chapter 3: How Comparative Exploitation is Harmful 
 
Introduction 
 In the last chapter, I offered a definition for a specific type of exploitation, 
comparative exploitation, which relies on unequal treatment for the sake of benefit.  
Comparative exploitation provides the explanatory force behind claims of exploitation in 
clinical drug trials in developing nations.  In this chapter I will explore the moral 
wrongness of comparative exploitation.  A majority of the literature frames moral 
wrongness in terms of harm the exploitee suffers.  That framework provides a unique 
challenge not only for some cases of comparative exploitation but more generally cases 
of mutually beneficial exploitation.  In cases labeled as mutually beneficial exploitation, 
both the exploiter and exploitee seem to be left better off than they would have been had 
the exploitative interaction not occurred.  However, in this chapter I will argue that those 
cases are not mutually beneficial and the exploitees are actually being harmed in those 
cases.149   
 Rather than creating a new framework with which to evaluate the moral 
wrongness of comparative exploitation, I will engage the harm debate.  In place of 
arguing for the correct or best harm theory, my goal is to adapt the harm framework 
found in the clinical drug trials literature to account for harm in comparative exploitation.  
The harm framework most found in the literature is the counterfactual comparison 
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account of harm.  That is, an action or research is harmful if it leaves the patient or 
subject worse off than they would have been had the action or research not taken place.  
The first part of the chapter argues that the traditional counterfactual comparison should 
be rejected in favor of an alternative counterfactual comparison as argued for by Ben 
Bradley.  First, I will lay out the traditional counterfactual account of harm as explained 
by Matthew Hanser, Hanser’s objections to that theory, and explain how under this model 
mutually beneficial exploitation does not seem harmful.  Second, I will explore an 
alternative concept of the counterfactual account of harm as constructed by Bradley.  I 
will then explain how Bradley’s account successfully answers Hanser’s objections.  
Finally, I will use Bradley’s account to explain how mutually beneficial exploitation, 
particularly mutually beneficial comparative exploitation, is harmful. 
 The second half of this chapter focuses on how mutually beneficial comparative 
exploitation can still be viewed as harmful even under the traditional counterfactual 
account.  To accomplish that, I rely on Larry May’s notion of shared responsibility.  After 
describing his theory and its application to racist attitudes, I will argue that acts of 
exploitation, even if they are mutually beneficial, create of a climate of harm that 
increases the likelihood that the exploited party will be exploited again which in turn 
increases their chances of being harmed.   
 As a reminder, PCT continues to refer to placebo-controlled drug trials, A refers 
to the exploiter, B the exploitee, and C refers to the person A interacts with 
nonexploitatively. 
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Harm and Counterfactual Questions 
 Comparative exploitation cases that are mutually beneficial do not seem harmful 
as the victim benefits more than they would have had the exploitative interaction not 
occurred.  Consider the proposed Surfaxin drug trial.  One can argue that all participating 
infants, including those who would receive the placebo, benefit from such a trial.  As 
Thomas Pogge writes, 
 one might even say that all infants enrolled in the study benefit, because they all 
 have their survival prospects boosted by a 50 percent chance of receiving Surfaxin 
 treatment.  In this way the Surfaxin trial is like a compulsory public vaccination 
 program.  Even if such a program causes medical complications for a few children 
 each year, it does save thousands of lives by preventing epidemics.  Assuming it  
is not known which children will suffer complications, the program can be 
 justified to all children on the ground that it improves the health prospects of 
 each.  Participation in the vaccination program is in each child’s best interest ex 
 ante.  And so is enrollment in the Surfaxin trial.150 
 
The comparison being made in this passage by Pogge is between the consequences of the 
infants being enrolled in the study with the consequences of not enrolling in the trial.   
 Examining the potential consequences of the interaction having not taken place is 
a counterfactual question and is often the basis for determining if harm occurs.  Such a 
method assumes a state-based account of harm.  That is, “to suffer harm is to be put into 
(or is perhaps simply to be in) a certain sort of bad state or condition.”151  Many state-
based accounts are comparative, where to suffer a harm is “to be put into a certain sort of 
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comparatively bad state - a state that is worse for one than some relevant alternative 
state.”152  
 One such comparative account is the counterfactual comparison: “to suffer a harm 
is to come to be worse off than one otherwise would have been.”153  In clinical drug 
trials, such as in the Surfaxin trial, one could make the argument that the patients in 
developing nations are not being harmed because they are better off than they would have 
been had the trial not taken place.    For example, in the AZT trials, the chance of 
receiving the lower dose of AZT and not being placed in the placebo control group, no 
matter how low the probability, is better than not entering the trial and having zero 
chance of receiving medication. Matthew Hanser analyzes the counterfactual account of 
harm, and ultimately, dismisses it as the appropriate lens through which to view harm.  In 
an effort to be charitable to counterfactual account defenders, Hanser provides the 
following formulation of the counterfactual comparison of harm: “a person suffers harm 
if and only if there occurs an event e such that had e not occurred he would have been 
better off in some respect for some interval of time.”154  Hanser adds the phrase “in some 
respect” in order to avoid the following counter example: a soldier in war loses his foot, 
but in doing so he avoids losing both of his arms.  The counterfactual account might say 
that the soldier was not harmed because had he not lost his foot, he would have lost both 
arms.  However, the losing of a foot is still a harm.  Thus by adding “in some respect” we 
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can say that the soldier would have been better off with respect to his foot had the event 
that took his foot not occurred.155   
  Additionally, Hanser adds “for some interval of time” to that construction of the 
counterfactual account to avoid the six million dollar man counterexample.  On the 
fictional television show The Six Million Dollar Man, the title character shatters his legs 
in an accident, and is given ‘bionic” replacements that function better than his original 
legs ever could.  While the six million dollar man suffers a tremendous amount to begin 
with, eventually he is actually better off than he was originally.  Does this mean that he 
was not harmed by the event that caused him to lose his legs?  No, he was in fact worse 
off for an interval of time, hence the addition of the phrase. 156  
 Under this conception, it seems that mutually beneficial comparative exploitation 
is not harmful.  Particularly for clinical drug trials, often times the alternative to entering 
the trial is no treatment whatsoever.  Had the infants not entered into the Surfaxin drug 
trial, they would have been worse off as they would not have had a fifty-percent increase 
in survival.  At no interval of time would the infants have been better off had the drug 
trial not occurred because any chance of treatment is better than guaranteed zero 
treatment.  Additionally, in no respect do they seem to be made worse off.   
 There are reasons, however, to reject the counterfactual comparison account of 
harm.  Hanser identifies several problems with the counterfactual comparison theory.  I 
will focus on two of his arguments.  First, consider preemptive harms.  Imagine the 
following scenario: George wants to burglarize Fred’s store.  George thinks that the 
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burglary will go more smoothly if Fred is not there.  George decides to go to Fred’s house 
and break his legs so that Fred cannot go to the store the next day.  As soon as George 
gets to Fred’s house he finds that Fred’s legs have already been broken by Fred’s loan 
shark.  According to the counterfactual account, the loan shark did not harm Fred because 
had he not broken Fred’s legs then George surely would have.  Thus, as Hanser contends 
there is no event such that Fred would have been better off had it not occurred.157 
However, it does seem that the loan shark did harm Fred.   
 Hanser does offer a potential revision for the counterfactual supporter.  Perhaps, 
we ought to compare the world where the loan shark breaks Fred’s leg with a world 
where the loan shark does not break Fred’s leg and no relevantly similar event takes 
place.  The new construction is written as “someone suffers harm if and only if there 
occurs an event such that he would have been better off, for some period of time and in 
some respect, had neither that event nor any relevantly similar event occurred.”158  
However, this new account is still problematic.  We are now saying that Fred suffered a 
harm because he would have been better off had both the loan shark not broken his legs 
and George not set out to break his legs.  From the comparative standpoint, it is both of 
those factors taken together that come to Fred as a harm.  However as Hanser points out, 
that seems wrong, as the loan shark and George did not jointly harm Fred.  Only the loan 
shark harmed Fred.  Thus, it seems that even the revised counterfactual account 
misidentifies the harm done to Fred.159 
                                                
157 Hanser “The Metaphysics of Harm,” 34. 
158 Hanser “The Metaphysics of Harm,” 435. 
159 Hanser “The Metaphysics of Harm,” 436. 
81 
 Hanser’s second problem with the counterfactual account is the excessive 
multiplication of harms.  Suppose that Claire shoots Harry, which paralyzes Harry from 
the waist down.  Hanser argues that there is a series of casual events within this action: 
Claire pulls the trigger, the gun goes off, the bullet enters Harry’s body, and Harry 
becomes paralyzed.  According to the counterfactual account, Harry is in a distinct 
harmed state relative to each of those events.  That is, “he is worse off than he would 
have been had [Claire] not pulled the trigger; he is worse off than he would have been 
had the gun not gone off; he is worse off than he would have been had the bullet not 
entered his body; and he is worse off than he would have been had he not become 
paralyzed.  Each of these events, then, comes to him as a separate harm.”160  This seems 
to be the wrong way to describe the situation for Hanser.  There are not four distinct 
harms, but one harm with several causal antecedents.  An acceptable theory of harm, 
according to Hanser, ought to be to isolate harms from their causal antecedents. 
 
Ben Bradley: A different Counterfactual theory 
 While the counterfactual comparison theory seems weak given Hanser’s 
objections, Ben Bradley’s construction strengthens the position and, I believe, answers 
Hanser’s objections.  Bradley argues that in order to understand the value of an action, 
whether it be of good or of bad value, we appeal to what would have happened if it had 
not been obtained.   That appeal relies on the counterfactual conditional: “if X were to 
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have happened, Y would have happened.”161  Because of philosophers such as David 
Lewis and Robert Stalnaker, we, often, interpret those counterfactual conditionals by 
relying on notions of possible worlds.   “According to this view,” Bradley writes, “to say 
that if X were to have happened, Y would have happened is to say that at the closest 
possible world in which X happens, Y happens.”162  In determining closeness of possible 
worlds, Bradley adopts Lewis’ theory that closeness is determined by similarity.  That is, 
one possible world is closer to the actual world than another possible world if it is more 
similar to the actual world.  Moreover, Bradley thinks of possible worlds as a complete 
story about the universe: a maximally consistent set of propositions.  As he describes, 
 [t]here is one such story corresponding to the actual world; the story it tells is the 
 story of the actual history of our whole universe form beginning to end.  But there 
 are many alternative stories.  Some of these are similar to the actual story in 
 certain respects.  The  most similar world where X does not happen must different 
 form ours not only with respect to whether X happens, but also with respect to the 
 consequences of X’s happening or not.163 
 
 To demonstrate this similarity relation, Bradley uses the example of Lee Harvey 
Oswald shooting JFK.  The closest possible world where Oswald does not shoot JFK 
does not go on like the actual world did after the shooting, and it is also not a world 
where instead of being shot, at the exact say moment JFK suddenly dies of a devastating 
head injury even for no reason.  That latter world is fundamentally not like the actual 
world because in the actual world no one suddenly gets a devastating head injury for no 
reason.  Rather, Bradley argues, “the closest world is a world where he proceeds along in 
the motorcade waving to the spectators... (and alternative historians tell us what happens 
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after that).”164  Thus, the closest possible world to the actual world had an event not 
happened has a great many things different from the actual world. 
 Identifying the closest possible world is not always a determinate matter.  It can 
depend, as Bradley notes, on what features of the actual world we wish to keep fixed or 
on a similarity relation of our choosing.  Furthermore, if we want to know what the 
closest possible world looks like had an event not occurred, must that closest possible 
world be exactly like the actual world right up until the event occurs? Or, can some of the 
history before the event occurs be different?  Bradley considers the example of a woman 
dying at time t after a year-long struggle with cancer.  What is the closest possible world 
where she does not die at time t?  There are several choices we might choose, including: a 
world where she dies the next day, a world where she did not get cancer a year ago, a 
world where her cancer had gone into remission, or a world where she was completely 
cured.  If we hold the past fixed, the first option of a world where she dies the next day 
would most likely be the closest possible world; however, any of the others are 
possibilities if we allow the past to vary.  Before we can determine “what would have 
happened” we must decide what should stay fixed and what should vary.165   
 Returning to value of an action, recall that Bradley argues that in order to 
determine the value of an action for a person we compare how things actually went for 
that person and compare that with how things would have gone had that event not 
happened.  Based on his interpretation of counterfactuals, that means comparing the 
actual world to the closest possible world where the event did not occur.  Given that the 
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closest possible world depends on the similarity relation of our choosing, then the value 
of an action must also be relativized to that similarity relation.166  From this analysis, 
Bradley offers the following principle 
 Difference-Making Principle (DMP): The value of event E, for person S, at world 
 w, relative to similarity relation R = the intrinsic value of w for S, minus the 
 intrinsic value  for S of the most R-similar world to w where E does not occur.167 
 
Recognizing the close relationship between badness of an event and a concept of harm, 
Bradley creates a version of DMP for harm, which he calls the Difference-Making 
Principle of Harm (DMPH).   Bradley states, “I am inclined to say that something is bad 
for a person if and only if it harms her; thus an event harms a person if and only if it 
makes things go worse for that person that they would have gone otherwise.”168  I suspect 
that Bradley intends the formulation of DMPH to be something like this: 
 Difference-Making Principle of Harm (DMPH): Event E is harmful for person S 
 at world w, relative to similarity relation R, if the intrinsic value of w for S is 
 worse or less than the intrinsic value for S of the most R-similar world to w where 
 E does not occur. 
 
Bradley’s conception of the counterfactual comparison of harm solves for Hanser’s 
objections 
 
Preemptive Harm 
 Recall that Hanser’s preemptive harm objection concerns cases where the 
consequences to the victim seem inevitable even if the event had not occurred, the case of 
George, Fred, and Fred’s loan shark.  Bradley believes DMP can solve for such scenarios.  
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He considers the case of the young pedestrian.  A young man absentmindedly steps off 
the curb into the path of a bus, and is killed instantly and painlessly.  During his autopsy, 
it is discovered that the young man had a cerebral aneurysm that would have burst within 
the week and killed the young man had he not been killed by the bus.169   
 As Hanser would argue, it seems that DMP would entail that the young 
pedestrian’s death was not very bad for him as he was deprived of very little life.  What 
world is the most similar possible world in which the young pedestrian does not die at 
that exact moment, ti?  Bradley states, “[t]ypically, it is a world in which the past as of t1 
(or shortly before ti) is completely similar to the actual past as of ti, so that if he had not 
died at ti, he would still have died of an aneurysm shortly after t1 anyway.  To suppose 
that he  would not have had an aneurysm in the first place would be to make a gratuitous 
historical change.”170 
 
 However, not all changes of the past before the young pedestrian's death are 
gratuitous.  Bradley considers possible answers to the question, “was the young 
pedestrian’s death at t1 bad?”  Answer #1 is yes; it was very bad.  Because he was a 
young man at t1 he would have been better off dying at a much later time.  Answer # 2 is 
yes, but it was not very bad.  That is because he would have died within a week anyways 
from an aneurysm.  Both of these answers, along with many others, could be correct 
depending on the context, according to Bradley.  While we might initially feel a pull to 
Answer #1 right after the young pedestrian’s death, after the autopsy, we may feel a pull 
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to Answer #2.  However, it is still possible for us to feel a stronger pull to Answer #1 
after the autopsy.  171 
 Bradley contends that our feeling pulled in different directions is because of the 
vagueness of the question.  We can have different comparisons in the mind at the same 
time, which correspond to different similarity relations.  The world that is most similar to 
the actual world where the young pedestrian does not die at ti could be several possible 
worlds.  Sometimes it is the world where he dies only a week later, but sometimes it may 
be the one where he dies a long time after ti, even if that means some ‘backtracking’ 
counterfactuals come out true (e.g. had he not died at ti, he would not have had an 
aneurysm before ti).  Answer #2 may be the right answer if we are asking if the young 
pedestrian’s death at ti was bad for him given that he had an aneurysm.  In that context, 
we are using a similarity relation that counts facts about the very recent past as being very 
important in determining similarity.  This answer emphasizes the cause of death.  Answer 
#1 may be right if we are asking if it was bad for young pedestrian’s to die at ti rather 
than in old age.  In that context, the similarity relation does not count facts about the 
recent past as important.  The closest possible world is one in which he dies much later.  
This answer emphasizes the timing of death.  Traditionally, we are more concerned with 
the timing of death versus the cause of death when determining how bad someone’s death 
is.  Thus, when determining the closet possible world, we do not care if the past events 
remained fixed because doing so would requires us to fix the cause of death.172 
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 Let us return to George, Fred, and Fred’s loan shark.  When Hanser argues that 
Fred’s loan shark did not harm Fred because had the loan shark not broken Fred’s leg, 
George surely would have, he is relying on one type of similarity relation.  That is, 
Hanser assumes that the closest possible world is one in which the past is held fixed.  As 
Bradley points out, adopting that similarity relation emphasizes the cause of Fred’s injury 
versus the timing.  Another closest possible world could be one in which the past is not 
held fixed, and we assume in that world neither the loan shark nor George harm Fred.  
Hanser argues that to change the past is to change the question.  He argues that to take 
both the loan shark and George’s actions into account seems to suppose that they are 
jointly harming Fred.  However, I think Bradley is right.  Hanser is placing the emphasis 
on the cause of the bad thing that happened to Fred, which is only one similarity relation.  
He is asking the question, “was it bad for the loan shark to break Fred’s leg, given that 
George was going to break Fred’s leg thirty minutes later?”   One could also ask the 
question “was it bad for Fred to have his leg broken versus not having it broken at all?”    
At the very least there seems no reason to prefer Hanser’s question over my question.  
Though, as Bradley argued in the case of death, it does seem that when we are wondering 
if Fred was harmed, it does not seem that the emphasis is on the cause of that harm, but 
rather the fact that the harm happened at all.   That is, the importance of Fred being 
harmed seems to be that his leg is broken not so much who broke it.  Thus, it seems 
reasonable to suppose that my counterfactual question relies on the preferred similarity 
relation versus Hanser’s. 
 
 
88 
Multiplication of Harms 
 Hanser argued that the counterfactual account interprets a single harm as multiple 
distinct events and thus multiple distinct harms.  Just as in preemptive harm, I think 
Hanser is relying on a similarity relation that emphasizes cause.  Recall that in the case of 
Claire shooting Harry, Hanser identified four distinct events: Claire pulls the trigger, the 
gun goes off, the bullet enters Harry’s body, and Harry becomes paralyzed.  If Hanser 
considers those four distinct events that cause four distinct states of harm, then there must 
be four counterfactual questions.   
1.Was it bad for Harry that Claire pulled the trigger? 
2. Was it bad for Harry that the gun went off given that Claire pulled the trigger? 
3.Was it bad for Harry that the bullet entered Harry’s body given that Claire pulled  
  the trigger and the gun went off? 
4.Was it bad for Harry that he became paralyzed given that Claire pulled the  
  trigger, the gun went off, and the bulleted entered his body? 
 Each of these counterfactual questions assumes a similarity relation that holds the 
past fixed, which in turn emphasizes the cause of the harm.  That is, he assumes, for 
example, that the closest possible world in which Harry did not get paralyzed may be the 
one in which Claire did pull the trigger, the gun went off, the bullet entered his body, but 
it did not paralyze him.  Hanser wants an account that isolates the harm from their causal 
antecedents.  That can be achieved through Ben Bradley’s account with a different 
similarity relation.   
 Suppose we ask “was it bad for Harry that he was paralyzed by a bullet rather 
than living a longer life free of paralysis?”  This counterfactual question emphasizes the 
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timing of the event.  That is, the closest possible world is on in which either Harry is not 
paralyzed or is not paralyzed until several years down the road.  That closest possible 
world does not hold the past fixed, meaning that some of the “backtracking” 
counterfactuals come out true.  For example, had Harry not been paralyzed, then the 
bullet would not have entered his body before paralyzing him.  Because the past need not 
be fixed, there is no reason to assume that each of those four distinct events need happen 
in the closest possible world, which means we can isolate the harm done to Harry from 
the causal antecedents.   
 
Beneficial Harm 
 One additional problem for counterfactual accounts is instances where a person is 
harmed without being made worse off.  Bradley considers two cases.  First, a woman is 
raped, becomes pregnant, and raises the child.  Even with taking into account the trauma 
of the rape, the woman’s life is better due to the value of her relationship with her child 
than it would have been had she not been raped.  Second, a man is imprisoned in a Nazi 
concentration camp.  During his time in the camp, the man’s understanding of life is 
deepened and his character is deepened, so much so that his overall life was better off 
than it would have been had he not been imprisoned in the camp.   Both are cases that 
seem to involve harm, but it is stipulated that both individuals are better off as a result of 
the harm.  Based on DMPH neither of those two cases seem to be a harm since the 
victims are left better off than they would have been had the event not occurred. 173   
                                                
173 Bradley, Well-being and Death, 65-66. 
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 To solve this problem, Bradley distinguishes between two different types of harm: 
all-things-considered and prima facie.  All-things-considered harms are harms that are 
bad for a person taking into account all the harm’s consequences for the person.  DMPH 
is that kind of harm.  Prima facie harms, on the other hand, are harms that are bad for a 
person in one way, but may be good for a person in another.  Bradley endorses the 
following account of prima facie harm, which he calls PFH: “[s]omething is a prima facie 
harm for a person if and only if either (i) it is intrinsically bad for that person, or (ii) it 
brings about something intrinsically bad for that person, or (iii) it prevents something 
intrinsically good for that person.”174  The rape victim and Nazi prisoner suffer harm 
according to PFH but not DMPH.  Even though the harm inflicted on the rape victim and 
Nazi prisoner is not all-things-considered harm does not mean that the perpetrators did 
not do anything wrong to the rape victim and the Nazi prisoner or that the perpetrators do 
not deserve punishment for their actions.  The perpetrators certainly tried to commit an 
all-things-considered harm, and also committed prima facie harm against the will and 
without the consent of the victims.  The rights of the victims were also certainly violated.  
Bradley argues that any of those facts could be grounds for saying the actions committed 
in those two cases is wrong. Thus, it is false to say that an action is wrong only if it 
causes an all-things-considered harm.175 
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Comparative Exploitation as an All-Things-Considered Harm 
 
Changing the Counterfactual Question 
 Let us return to the Surfaxin drug trial case.  Would the infants in the trial be 
harmed?  If we understand the question through Hanser’s construction of counterfactual 
harm, then the answer seems to be no.  That is, because the closest possible world is one 
in which the past is held fixed for the infants but the trial never takes places.  Since in the 
actual world with the trial the infants’ chances of receiving treatment are boosted by 50% 
whereas there is 0% chance of receiving medication in the closest possible world where 
the trial does not take place, the actual world is preferable to the closest possible, which 
means the infants are not harmed.   
 In order for cases comparative exploitation to be harmful, then, the exploitee must 
be left worse off all-things-considered then they would have been had the exploitative 
transaction not taken place.  Note that under that view it does not matter how much less A 
(the exploiter) offers B (the exploited party) than C (the unexploited interactor with A), 
so long as B ends up better than she would have had A not interacted with her, B is not 
being harmed.    
 However, as I have described, Bradley argues that Hanser’s construction assumes 
the closest possible world is one in which the past is fixed is only one kind of similarity 
relation, one which emphasizes the cause of the harm.  That is, the important fact to 
remain constant in the closest possible world is one in which A is the cause of said 
harmful interaction versus some other individual under some other scenario.  In the 
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surfaxin example, by holding the past constant, the emphasis is on Discovery Labs being 
the interactor with the potential trial participants.   
 Other similarity relations do exist which place the emphasis elsewhere.  Another 
closest possible world is one in which the transaction between A and B is not 
exploitative.  Perhaps B is offered the same conditions as C or is in a position such that 
they will receive the same conditions as C.  For example, a closest possible world for the 
Surfaxin trial could be one in which the Brazilian children receive the same benefits that 
a child of a developed nation would have had the trial been run in a developed nation.   
Another closest possible world is one in which the Brazilian children do live in a 
developed nation rather than a developed and as a result of their country’s economic 
standing do receive the same benefits as any other developed nation participant.  
 At the very least, under Bradley’s framework, there is no reason to prefer the past-
fixed possible world over the two possible worlds I have suggested.  They simply rely on 
different similarity relations. That being said, it seems that one of the two possible worlds 
I have suggested are preferable to one that holds the past fixed.  A being the cause of the 
exploitative transaction, versus some other potential actor, seems less important as to 
whether B is suffering a harm than the actual transaction between A and B.  In other 
words, what makes a transaction exploitative is not the specific individuals involved, but 
rather the details and terms of the transaction.  For example, Margaret sells Billy a house.   
Billy is particularly not well informed about the housing market.  Margaret, having lots of 
knowledge about the value of her house and being aware of Billy’s lack of housing 
market knowledge, charges him $50,000 more than the house’s market worth.  Margaret 
has clearly exploited Billy.  However, what makes that transaction exploitative is not that 
93 
Margaret exploited Billy, for surely if any other individual had done as Margaret had, the 
transaction would still be exploitative.  Rather, it is the terms of the transaction, that the 
house was unfairly sold at too high of a price, that make it exploitative. 
 If the root of what makes a transaction exploitative is the transaction itself, or the 
terms of the transaction, then it seems only natural in determining whether the transaction 
is harmful, the emphasis should be placed on the transaction.  Thus, it seems that the 
appropriate comparison is between the exploitative transaction and the same transaction 
conducted nonexploitatively.  That is, the closest possible world to the actual world that 
we should use is one in which A transacts with B but does not exploit B.  The 
counterfactual question would look something like the following: “Was B harmed in the 
exploitative transaction with A given that A could have transacted nonexploitatively with 
B?”  In the cases that are often thought to be mutually beneficial exploitation, B is not 
receiving the benefits that he would have received had A transacted nonexploitatively 
with B.  Because B is being denied a benefit in the actual world that she would have 
received in the closest possible world where A transacted nonexploitatively with B, B is 
being harmed. 
 For comparative exploitation, to understand what the nonexploitative transaction 
with B may look like, we need only look to A’s interaction with C, which as stipulated in 
the definition of comparative exploitation as nonexploitative.  The counterfactual 
question may look something like “was B harmed in the exploitative transaction with A, 
given that B should have received the same terms as C?”  Thus, any benefits that B did 
not receive in his transaction with A that C did receive or would have received had she 
had the same transaction with A counts as a harm to B.   
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 For clinical drug trials in developing nations, the comparison for harm for 
participants should not be the consequences of the trial occurring versus the trial not 
occurring, but rather the consequences of the trial run under its current terms versus the 
consequences of the trial run with the terms offered in developed nations.  Primarily, as 
described in the introductory chapter, the two main items that trial participants and host 
nations are not receiving is availability of the current market drug through an active-
controlled trial (versus a placebo-controlled) and access to the drug being tested at an 
affordable price once it passed through the FDA and is available on the market.  Because 
researchers are preventing trial participants from receiving those additional benefits, 
which they would have received had they lived in a developed nation, those participants 
are being harmed  
 Given this new counterfactual framework, let us look once again at the surfaxin 
trial.  When determining if the infants in the proposed Surfaxin trial would be hurt, rather 
than comparing the consequences of the trial to the consequences of not having the trial, 
we ought to compare the consequences of the trial with the consequences of the trial if it 
were to be run nonexploitatively.  As described in the last chapter, the appropriate C's for 
clinical drug trials run in developing nations are trial participants in the developed world.  
That means we ought to compare the consequences of the Surfaxin trial with the 
consequences of that trial being run in the developed world.  The counterfactual question 
may be like the following: “would the infants be harmed in the clinical drug trial, given 
that they ought to receive the same terms as potential participants in developed nations?”  
Since the proposed Surfaxin trial would use a placebo, which would not be allowed in the 
developed world for ethical reasons, the infants are being harmed.  That is, the 
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appropriate comparison is not a 50% chance of receiving the experimental drug (and not 
a placebo) versus 0% if the trial does not occur, rather the comparison ought to be a 50% 
chance of receiving the experimental drug (and not a placebo) versus 100% chance of 
receiving medication be it existing market medication or the new experimental drug.  
Thus, because the infants are not receiving the benefits that they ought to be (an increased 
chance of medication), they are being harmed. 
 
Creating a Climate of Harm 
 Even if we do not adopt Bradley’s framework for the counterfactual question, 
comparative exploitation can still be harmful all-things-considered with the traditional 
counterfactual question.  That is, it is more harmful for B to engage in a comparatively 
exploitative transaction with A then to not interact with A at all.  The source of that harm 
lies in the harmful attitudes A projects when engaging in an exploitative interaction with 
B, and the effect that has on other members in A’s social group.   
 In his book Shared Responsibility, May analyzes the relationship between harm, 
harmful attitudes, those responsible for harm, and groups.  He writes 
 [t]he kind of behavior we engage in does not arise overnight but is normally a 
 function of many successive layers of choosing over the course of a life.  For this 
 reason, responsibility is not confined to those isolated actions which have effects 
 on others, but also includes those decisions that form the self into the kind of 
 agent it is and that influence the way that self then acts in the world.176 
 
Thus, to understand the domain of responsibility, one must understand agency and how 
one’s identity is created.  May conceives of agency in terms of social existentialism.  
                                                
176 Larry May, Shared Responsibility (Chicago: The University of Chicago Press, 1992), 
17. 
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That is, May “stresses the way that our choices are greatly affected by the groups of 
which we are members.”177 The attitudes and actions of one’s community influence one’s 
sense of identity and agency.    Likewise, the attitudes and actions one contributes to the 
community affect the identity and agency of others.  Because of the relationship between 
groups and attitudes, May identifies three cases where responsibility for a harm should be 
shared by each member of a group and not one single member.  The case I am concerned 
with is where a person does not cause harm, but increases the likelihood that harm will 
occur. 178 
 May argues that harmful attitudes can lead to an increased likelihood of harm 
For example a parent might have a careless attitude towards his child’s safety.  Such an 
attitude may lead the parent to drive a car in an area where his child is playing, thereby 
increasing the child’s likelihood of being hit by a car.  The careless attitude could also 
increase the risk of harm by others.  The careless parent might omit various precautions, 
such as removing a rusty nail from the child’s play area, which results in an increased 
likelihood of the child harming herself.179   
 Other such harmful attitudes include risk takers.  Risk takers share in the 
responsibility for a harm their behavior may cause, even though they may not directly 
cause it.180  For example, Bob and Tom both drink alcohol and drive afterwards.  One 
night Tom hits and kills Mary, a pedestrian, while driving home drunk from the bar.  May 
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of moral luck.  
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considers Bob to be partially responsible for Mary’s death because he engages in the 
same risk taking behavior. 
 May offers two reasons why risk takers like Bob are responsible for harms they 
did not directly cause.  First, May argues that the agent who merely risks harm, Bob, and 
the agent who did in fact cause harm, Tom, act in morally similar ways.  May elaborates, 
“[w]hen two people both have increased the likelihood of harm and both are equally 
knowledgeable that their actions increased the likelihood of harm, then their risky 
behavior creates a greater likelihood than previously existed that harm will occur,  and 
they should share in the responsibility for the harms that result.”181  Second, risk takers 
contribute to a climate of risk and/or harm which makes harm more likely to occur.   
 In order to motivate the argument that an agent is morally responsible for 
contributing to a climate of risk, May needs to connect harmful attitudes and behavior.  
Harmful attitudes, for May, are not just mere thoughts or cognitive states.  They are also 
“affective states in which a person is, under normal circumstances, moved to behave in 
various ways as a result of having a particular attitude.”182  May justifies this claim by 
asserting that when one wants to test an agent for a particular attitude, the test is behavior, 
or involves some counterfactual behavioral analysis. 
 May chooses to focus on racism as the prime example of attitudes that create an 
environment or climate of harm.  Racist agents are risk takers concerning racial violence.  
                                                
181 May, Shared Responsibility, 45.  This first reason of acting in morally similar ways 
does seem a little weak and requires more explanation, which May does not offer in the 
remainder of his book.  However, his model of shared responsibility in cases of risk does 
not weigh heavily of this reason.  In my opinion, the strength of May’s argument rests on 
his second reason of increasing the climate of risk. 
182 May, Shared Responsibility, 46. 
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His aim is to show that “the members of a community who share racist attitudes also 
share in responsibility for racially motivated harms produced by some of the members 
because of this climate of racist attitudes.”183  That is, the production of racist attitudes is 
similar to a joint venture.  No single person can create a climate in which harm is likely. 
 Moreover, May argues that those agents who hold racist attitudes but do not harm 
directly participate in racial harms in society in two ways.  First, they causally contribute 
to the production of racial violence by others.  They do this by contributing to a climate 
“that influences others to cause harm.”184  May looks to the example of Thomas Becket, 
the archbishop of Canterbury, and King Henry II as evidence.  Henry II’s knights killed 
Becket after “the king created a climate of opinion simply by asking aloud why he had no 
followers loyal enough to rid him of the false priest.”185  By publicly announcing his 
hatred of Becket Henry II’s words created an attitude of hatred in others that influenced 
their behavior to harm.   Though Henry II did not order his knights to kill Becket and as 
May notes may not have even intended his knights to kill Becket, he still causally 
contributed to Becket’s death.  The idea being that the knights would not have killed 
Becket had Henry II not publicly expressed an attitude of hatred, which in turn created a 
climate in which harm was more likely. 
 May offers another hypothetical example of two groups, group A and group B.  
Several members of group A speak out negatively against group B with full knowledge 
that their public statements may cause violence against group B’s members.  While one 
person of group A who speaks out may not directly cause a violent act to be taken against 
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a member of group B, as in the Becket and Henry II case, the person may still be 
responsible for contributing to a climate that made violence against members of group B 
more likely.186   
 The second way agents who hold racist attitudes but do not harm directly 
participate in racial harms in society is “by becoming, like the reckless observer..., people 
who choose to risk harm and yet do nothing to offset this risk.”187  These are cases where 
the agent does not publicly express their racist attitudes.   May contends that by the agent 
merely holding the same attitude that is known to cause violence and harm to others, the 
agent runs the risk of being a harm producer.  As mentioned before, May believes that 
risk takers who may be morally lucky in their actions or attitudes not leading to harm 
share responsibility for harms caused by others who engage in those same actions and 
attitudes.   In some cases, May contends that by merely holding the racist attitudes, one 
reinforces or legitimizes the racist attitudes for those who do act out in violence.  For 
example, university faculty members and administration can have a strong impact on 
students as they are in a position of authority over them.  If those faculty members and 
administrative officials hold racist attitudes, students may feel their own racist attitudes 
that incite them to violence vindicated.188   
 Furthermore, even if those who hold racist attitudes do not have any part in the 
causal chain that led to violence, they share in the responsibility for the harm.  May 
argues, “insofar as these people do not try to decrease the chances of such violence by 
changing their own attitudes, given that similar attitudes in others have produced harm, 
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they demonstrate a kind of moral recklessness, similar to that of the reckless observer, 
which implicates them in the racially motivated violence.”189  May likens these cases to a 
sort of Russian roulette scenario.  Consider the following hypothetical.  Bob tries to kill 
Fred by aiming the gun at him and pulling the trigger.  However, unbeknownst to Bob, 
the chamber was empty and the gun never went off.  Ted takes the same gun, aims it at 
Fred, and pulls the trigger.  This time the gun goes off because there was a bullet in the 
chamber, and Fred dies.  May contends that even though the gun did not go off for Bob, 
Bob still shares the responsibility for the death of Fred.  As May states, “[b]oth people 
who act recklessly share responsibility not just for the risk but for the actual harm.”190 
 Returning to comparative exploitation, when A exploits B by offering B lesser 
terms, A is behaving in a way that projects the attitude that B is exploitable and is not 
deserving of equal terms as others, C.   That attitude, which I will call the exploitative 
attitude, can lead to harmful consequences for B, or those like B, in the same two ways 
that racist attitudes do.   First, exploitative attitudes create a climate of harm.  That is, 
when A exploits B, particularly in a public venue, A lets others know that B is 
exploitable.  That, in turn, may lead others to believe B and those like B are exploitable, 
which may lead to those other individuals exploiting B.   
 Within the clinical drug trial debate, much of the rhetoric put forth by 
pharmaceutical companies and researchers is pro-placebo-controlled trials in developing 
nations even if an alternative medication exists.  Dr. Paul S Kelly ran a study in Luksaka, 
Zambia for the drug nitazoxanide, which treats crypto, an infectious diarrhea, in children.  
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Despite alternative drugs, such as albendazole, being available on the market, a PCT was 
used.  Of the 48 children who received placebos, 8 died as a result of crypto.191  Kelly 
defended the use of placebos, stating, 
 [t]here is no other way of being absolutely sure that the stuff actually works...It is 
 very very important to do this in third world countries for two reasons.  One, 
 because if you misguide people into thinking that your drug works when it 
 doesn’t work, you’ll be responsible for diverting precious resources away from 
 something else which may also be important.  Two, we cannot assume that 
 something which works in other countries will work here...There are geographical 
 differences and we have to be sure that it works where we’re planning to use it.192 
 
Additionally, a researcher for Schering, who ran a trial for Shigella using a PCT,193 
laments, “I was criticized for doing a Shigella trial.  They said you are taking advantage!  
But without the trial, those children would be dead!”194 
 Note the rhetoric in those two pieces.  They create several black and white 
dichotomies: either we run the trial as is to make sure the medicine actually works or we 
run it differently and will never know; that country is different from our country, which 
means we should run the trial differently or we don’t run it at all; and either we run the 
trial as is and children don’t die or children die.  These white or black distinctions not 
only eliminate possibilities of gray areas, but also shift the focus of the actual criticism.  
The debate is no longer about PCTs versus active control, but rather saving children, as if 
the only alternative to PCT is no trial.  Furthermore, this kind of hyperbolic language 
masks the actual concern about PCTs and encourages others to engage in similar 
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behavior.  That is evident with the growing number of trials run overseas.  From 2001 to 
2003, the number of investigators hired to run trials in the United States dropped by 11 
percent, while overseas investigators increased by 8 percent.195  Pharmaceutical 
companies and hired researchers have created a climate that justifies trials run in 
developing nations without actually addressing the criticisms, which in turn causes more 
trials to be run with similar standards in developing nations. 
 The second way those holding exploitative attitudes but do not harm directly 
participate in racial harms in society is “by becoming, like the reckless observer..., people 
who choose to risk harm and yet do nothing to offset this risk.”196 Recall the example of 
Bob failing to kill Fred with a gun that Ted then uses to kill Fred.  A similar analogy can 
be made for comparative exploitation and even exploitation more generally.  Assume A 
exploits B with no negative consequences to B.  C exploits B in the same manner as A, 
but this time there are negative consequences for B.  Both A and C acted recklessly with 
regards to B’s welfare, and as a result, according to May, both A and C are responsible 
for the harmful consequences B suffers.   Thus, even if an instance of mutually beneficial 
exploitation does not harm the exploitee, the exploiter is still morally responsible for any 
harm that results from that kind of exploitative behavior.  For clinical drug trials, that 
means that even if trial participants in a single trial are not harmed in any meaningful way 
from a PCT, the pharmaceutical company still bears responsibility for instances when 
trial participants are harmed.  
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 We can imagine scenarios where comparative exploitation leads to incredibly bad 
consequences, perhaps even death.  Because of that, under a traditional counterfactual 
account, we might say that it is better for B and individuals like B for A not to mutually 
beneficially exploit B because of the increased likelihood of harm. 
 
Conclusion 
 In this chapter I crafted ways in which we can understand how not only 
comparative exploitation, but also cases of mutually beneficial exploitation, may be 
viewed as harmful.  First, we should reject the standard counterfactual comparison 
theory, which is often used by supporters of PCTs and existing standards in overseas 
clinical drug trials.  Rather, the question of harm depends on the selection of the closest 
possible world.  I argued that the relevant factor for comparative exploitation is choosing 
the closest possible world where the exploitative interaction is nonexploitative.  This 
differs from the standard counterfactual comparison, which would argue that the closest 
possible world is one which no interaction took place.  For comparative exploitation that 
means comparing A and B’s interaction with A and C’s interaction.  The difference 
between the two is what counts as harm to B. 
 Even if one does not support my framework switch for harm questions, I argued 
that comparative exploitation is still harmful under the traditional counterfactual 
comparison account.  That is, when A comparatively exploits B, A is promoting an 
exploitative attitude, one that publicizes B’s vulnerability to exploitation.  That attitude 
creates a climate of harm under which B, and individuals like B, are more likely to get 
exploited, which increases the likelihood that B will get harmed.  Furthermore, even if A 
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does not harm B in their exploitative transaction, the likelihood of severe harm increases.  
Thus, under a traditional counterfactual comparison, it is better for A and B to not 
interact than for A to mutually beneficially exploit B.   
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Chapter 4: Standard of Care 
 
Introduction 
 In the previous two chapters, I have argued that trial participants from developing 
and developed nations ought to be treated similarly.  The most common argument against 
equal treatment is the standard of care argument, which justifies the violation clinical 
equipoise in international trials.  That is, the restraints for the trial, specifically the control 
group, be set by the usual “standard of care” of the host country.  In this chapter, I will 
challenge that argument.  First, I will explore the definitions of “standard of care” and lay 
out some of the arguments for different standards of care.  This section will also identify 
international and FDA guidelines that discuss the standard of care used in clinical trials.  
Next, I will generally dispute the argument supporting different standards of care and 
identify its weaknesses.  Then, Ruth Macklin identifies three faulty assumptions 
proponents of standard of care hold.  I will address each one in turn.  The second section 
addresses the use of placebo control trials (PCTs) as the gold standard assumption.  I will 
argue that active control trials (ACTs) provide a reliable alternative, particularly when 
there is an ethical dilemma, to PCTs.  The third section addresses the assumption that the 
only relevant research question is whether the experimental drug is better than the 
‘nothing’ now available in the host country.  Not only will I contend that the 
experimental drug is not better than the ‘nothing,’ but that another relevant research 
question concerns the risk-to-benefit ratio for trial participants as mandated by 
international and FDA guidelines.  The final section addresses the assumption that the 
only way of attaining affordable drugs is by testing cheap alternatives.  I will contend that 
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pharmaceutical companies are not fulfilling their burden of making the drug available to 
the tested population, and that it is conceivable for those companies to sell the drug at a 
cheap price.  In each section I will begin by explaining what the international and U.S. 
domestic guidelines mandate on that topic.  I will specifically look at the Declaration of 
Helsinki, the Council for International Organizations of Medical Sciences (CIOMS), and 
the Food and Drug Administration (FDA)  
 
Standard of Care 
 The concept of “standard of care” lacks formal definition and has several 
meanings depending on the context.   According to Nicole M. Deming, a mental health 
professional, the phrase “standard of care” refers to “those practices, procedures, and 
quality of treatments that a patient should be accorded and a health care provider is 
obligated to make available.”197  It may also refer to “the evaluation of a provider’s 
actions compared to what should have been done in a given situation.”198  Because 
medicine is constantly evolving with our knowledge increasing, the current standard of 
care must also change and evolve.  While clearly defined guidelines do exist in some 
fields, they can easily be outdated if they reference a specific practice rather than a 
general principle.  Though it may be difficult to clearly define standard of care given the 
dynamic medical climate, Deming argues that we ought to view the standard of care as “a 
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level of care below which providers cannot go rather than an aspirational ceiling or level 
of care to reach.”199   
 Within the legal context of malpractice, a doctor’s negligence is determined in 
relation to the standard of care in that specialty.  As Ralph Peeples, Catherine T. Harris, 
and Thomas B. Metzloff describe, 
 [i]n medical malpractice cases, the liability of a defendant-physician is a function 
 of negligence and causation.  If the defendant-physician has been negligent, and if 
 the proximate cause can be established, then the defendant-physician will be held 
 liable for the plaintiff-patient's injuries.  “Negligence,” in turn, is a function of 
 standard of care; failure by a defendant-physician to meet the relevant standard of 
 care constitutes negligence.  The standard of care expected of physicians is 
 usually described in terms of  “custom”: what is the accepted practice among 
 other physicians practicing in the same specialty?200 
 
 The National Institute of Health developed the following expanded concept of 
standard of care for international research: 
• Provision of the same access to research, expenditure on the total care of each 
subject, and therapeutic drugs shown to be most effective in other locations 
• Provision of the same “hotel” facilities, access to technology, general medical 
care, and other external influencing factors during the trial that were associated 
with and contributed to the “best proven” use of the drugs elsewhere 
• Provision of the same follow up facilities for subjects after completion of the 
study and the same access to ongoing care 
• Research undertaken by a team of the same culture and language group as the 
subjects, so that the same degree of effective communication, trust, and genuine 
informed consent is achieved through a legitimate informed decision making 
process 
• Care provided by a research team with equivalent qualifications, training, and 
expertise201 
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 The ambiguity in all three of these explanations of standard of care, which is at 
the center of the standard of care debate for international research, is determining the 
meaning and intent of the “best proven” treatment available.  Defending the differing 
clinical standards, pharmaceutical companies and researchers argue that the standard of 
care for trial participants be determined by the host nation.   Researchers and bioethicists, 
who are supported the use of a placebo in the AZT trials, maintain that they need only 
provide the “highest standard of care practically attainable in the host country.... There is 
no obligation to provide study participants with the highest standard of care attainable 
elsewhere in the world.”202  In 2000, UNAIDS released a guidance document agreeing 
with that position.203 
 Franklin G. Mill and Howard Brody argue that there is a difference between 
clinical trials and clinical medicine;  
 [p]hysicians in clinical practice have a duty to promote the best interests of 
 patients by offering optimal medical care.  In [randomized controlled trials], 
 however, physician-investigators are not offering personalized medical therapy 
 for individual patients.  Rather, they seek to answer clinically relevant scientific 
 questions by conducting experiments that test safety and efficacy of treatments in 
 groups of patients.204 
 
  Because of that difference, Miller and Brody maintain that the ethics ought to be 
different for clinical medicine and clinical trials.  Specifically, in clinical trials, 
investigators do not have an obligation to provide optimal medical care, but rather they 
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have the obligation to not exploit research participants.  To avoid exploitation, 
investigators need only to ensure that the research participants are not being exposed to 
excessive risk and that they understand that they are volunteering to participate in an 
experiment rather than receiving personalized medical care.205206  
 Industry scientists maintain that the obligation to provide the most optimal 
treatment to be too onerous.  Merck’s Laurence Hirsch and Harry Guess make the 
following arguments against that obligation 
 [f]irst, none of the methods used in the study may be found to be suitable. . . .  
 Secondly, a single study can rarely identify “best” treatment. . . . Thirdly, a new 
 drug or device may not be approved until several years after the end of a trial.  
 Consequently, providing as yet unapproved treatment to trial participants on 
 completion of the study may conflict with local regulations.  Finally, an offer to 
 provide treatment that is otherwise unavailable on completion of the trial might be 
 considered an undue inducement to potential participants.207 
 
That sentiment is supported by a 2001 paper issued by the Pharmaceutical Research and 
Manufacturers of America; 
 [i]t is unrealistic and misleading to suggest that [drugmakers] can ensure access to 
 drugs for an given populations. . . .  Only local governments, not pharmaceutical 
 companies, can make decisions about initial, and particularly ongoing, access to 
 new drugs. . . . There  is a need first to establish an appropriate infrastructure (e.g. 
 roads, transportation,  electricity, and water supplies).208 
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 Admittedly there are practical challenges to providing the best-proven therapies.  
Some developing countries do not have access to intensive care units, clean needles and 
equipment to provide some medications intravenously, etc. However, if pharmaceutical 
companies are willing to spend the money on appropriate infrastructure such as roads and 
transportation, as will be discussed later in this chapter, should they not also provide the 
necessary medical equipment for the best proven medical, especially when lives are at 
stake? In many of the cases talked about throughout this dissertation, such as the Surfaxin 
case, the best-proven treatment does not involve providing expensive equipment, but 
rather providing a medication.   Moreover, as will be discussed on in the second to last 
section of this chapter concerning providing cheaper drugs, pharmaceutical companies 
have the financial means to provide medical treatments and research but choose not to in 
the interest of profit. 
 Additionally, proponents of differing standards of care, from now on referred to 
as the standard of care position, maintain that several key health documents justify it.  
First, the 2008 revision of the Declaration of Helsinki, the most up-to-date version, states,   
 [t]he benefits, risks, burdens and effectiveness of a new intervention must be 
 tested against those of the best current proven intervention, except in the 
 following circumstances:  
• The use of placebo, or not treatment, is acceptable in studies where no 
current proven intervention exists; or 
• Where for compelling and scientifically sound methodological reasons the 
use of placebo is necessary to determine the efficacy or safety of an 
intervention and the patients who receive placebo or no treatment will not be 
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subject to any risk of serious or irreversible harm.  Extreme care must be 
taken to avoid abuse of this option.209 
  
Individuals such as Robert Levine interpret “best current proven intervention” to mean 
what would have otherwise been available to the subjects in their locale.210  For example, 
in the proposed Surfaxin trial, existing market medications were not available on the 
medical markets of Mexico, Ecuador, Bolivia, and Peru.  Since participants would not 
have access to those medications if they were not enrolled in a trial, the standard of care 
for those participants would be zero treatment.  Thus, the trial would not be doing 
anything worse than what the participants would have experienced if they did not enroll 
in the trial.     
 Second, proponents of standard of care point out that in the guidelines to avoid 
exploitation in developing nations as developed by Council for International 
Organizations of Medical Sciences (CIOMS), there is no mention of testing a new drug 
against existing medications that are available in the developed world but not the host 
country.  Specifically, proponents point out Guideline 10: Research in populations and 
communities with limited resources, which states, 
 [b]efore undertaking research in a population or community with limited 
 resources, the sponsor and the investigator must make every effort to ensure that: 
• the research is responsive to the health needs and the priorities of the 
population or community in which it is to be carried out; and 
• any intervention or product developed, or knowledge generated will be made 
reasonably available for the benefit of that population or community.211 
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The guideline seeks to avoid exploitation in research by ensuring that the research not 
only serves to help in the health needs the tested population, but also to ensure lasting 
beneficial effects through the sharing of knowledge.   This latter stipulation, as discussed 
in the introduction, is often ignored by pharmaceutical companies.  Drugs are not made 
readily available at an affordable rate for the tested populations.  This topic will be 
discussed in further detail later in this chapter.   
 Note, also, that the guideline makes no mention of trial procedures.  That is, the 
guidelines do not include a requirement that the trial’s procedural standards be the same 
as those run in developed nations.  Ruth Macklin also recognizes that gap in the 
guideline, and sees it as a gateway for abuse by researchers.  To bolster that point, 
Macklin refers to a commentator on the guideline who, while embracing the general aim 
against exploitation in research, uses an example that is open to precisely the opposite 
charge.  The commentator states, 
 [t]he purpose of this guideline seems to be to prevent exploitation of poor 
 communities for research purposes when the research is unlikely to benefit them.  
 This aim should be supported but at the same time research in developing 
 countries should not be inhibited but encouraged as a means of developing greater 
 international collaboration.  The test is whether in the country or territory 
 concerned research subjects would be deprived of an effective intervention solely 
 on account of the proposed research.  If so it would be unethical but not 
 otherwise.  For example, a randomised trial of an inexpensive and simple method 
 of cervical screening (e.g. a blood test) could be compared with no  screening in 
 parts of India where there was no screening at all.212 
 
Despite agreeing with CIOMS’s general condemning of exploitation in developing 
nations, this commentator, like some others, are missing an obvious avenue of 
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exploitation - testing against no treatment when a viable one exists in a developed nation.  
As Macklin rightly argues 
 [n]one of the women in this study in India would receive the best current method 
 of screening for cervical cancer, some would receive the experimental screening 
 method, and others would not be screened at all.  An ethically superior research 
 design would  compare the proposed inexpensive method with the best current 
 method - the pap smear - to determine whether the proposed new method is as 
 good as, or almost as good as, the best diagnostic method.213  
 
In sum, CIOMS Guideline 10, while providing some necessary regulations, does not offer 
a sufficiently full account of what an ethically sound clinical trial requires to prevent 
exploitation.  By not directly addressing trial procedures, specifically the use of PCTs and 
defining “best current method,” researchers and pharmaceutical companies use the 
loophole to their advantage and argue that their PCTs trials are ethical  
 There are many reasons to reject the standard of care argument.  While this entire 
chapter will argue that there should not be differences in care, let us argue against the 
structure and merits of the argument here. First, it seems wrong to interpret the 
Declaration of Helsinki to intend the best-proven method in the host country.  Had the 
framers intended to contextualize best proven method, it seems that they would have 
rewritten that paragraph to say “best proven method in the host country,” or to use the 
phrase “the standard of care in the host country.”  Since there is no context, a more 
natural interpretation seems to be best proven method, period.  That is, the best proven 
method in existence.  This exact debate over interpretation has a long history for the 
Declaration of Helsinki leading to its many revisions.  Its current phrasing is in part a 
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reflection of the ethical controversy over the use of a placebo in the AZT trial.214  Despite 
the World Medical Association’s efforts to clarify, the wording remains ambiguous as to 
intent. 
 If, however, we are to assume that the Declaration intends the former, the best-
proven method in the host country, the declaration becomes more ambiguous.  How does 
one determine what the “standard of care” is in a country?  Does that include available 
pharmaceuticals, commonly used procedures, sanitary conditions, ethical regulation, 
consent guidelines, etc.? As Macklin argues, the phrase standard of care, “invites 
confusion because of its ambiguity and the many different interpretations placed upon it 
by commentators.  Despite the widespread use of the phrase ‘standard of care’ in 
discussions and debates, there has been little conceptual clarity.”215  Adding to the 
confusion, as Macklin points out and as I have suggested in this section, the phrase 
“standard of care” does not appear in any international declarations or guidelines.  With 
no strict guidelines or regulations, researchers are afforded the ability to interpret 
standard of care in any manner that they like.  A simpler solution is to assume that the 
Declaration intends best-proven method in existence, which is less ambiguous. 
 A second reason to reject the standard of care argument is, as Macklin argues, the 
argument is the lowest-common-denominator basis for determining ethical obligations.  
That is, providing the same standard of care to trial participants that they would be 
receiving from their country anyways if the trial were not to take place, seems to be the 
absolute minimum that researchers could do.  Surely, we ought to do more, if for no other 
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reason that out of our adherence to the principle of beneficence.  Applying beneficence to 
research, Macklin and others suggests entails maximizing benefits while minimizing 
harm to the trial participants.216  Surely that demands more of researchers than the bare 
minimum.  Because as Macklin asserts, “[s]ince the research subjects themselves are 
surely among those who should be counted in seeking to maximize benefits, it follows 
that providing a higher standard of care during the research, when that is feasible, is 
ethically preferable to providing the minimal standard dictated by background conditions 
in the country or region.”217 
 Furthermore, a third reason to against the standard of care argument is that under 
this framework, the amount of care a patient receives depends upon economic conditions 
of the host country rather than a normative concept.  The standard of care argument is an 
interpretation of guidelines concerning how trials ought to be run and how trial 
participants ought to be treated in order to prevent exploitation.  If one wants to frame a 
normative concept on economic affairs, a normative justification for doing so is needed.  
However, there is little normative justification for the standard of care arguments offered 
from its supporters.  As Peter Lurie and Sydney M. Wolfe explain,  “[i]n developing 
countries, the standard of care ... is not based on a consideration of alternative treatments 
or previous clinical data, but is instead an economically determined policy of 
governments that cannot afford the prices set by drug companies.”218  Lurie and Wolfe 
also reveal a deeper worry: the perpetual cycle of limited care created by the drug 
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companies.  That is, as discussed in the introduction and in the next section, it is to drug 
companies’ financial advantage to use PCTS and offer as little care as possible to trial 
participants.  According to the standard of care argument, they need not provide the best 
alternative treatment because it is not available in the host country.  However, the reason 
host countries do not have access to the best alternative treatment is because drug 
companies do not sell it to the host countries at an affordable price.  Thus by keeping the 
prices of drugs and treatments high, drug companies are preventing host countries from 
adopting new treatments as the standard of care for its citizens, which then allows drug 
companies to save money by not offering it to trial participants when they run a future 
trial in that host country.  Drug companies have created the best possible outcome for 
themselves.  They are justifying their treatment of trial participants through appeal to 
conditions that the drug companies, themselves, have created. 
 Not only do drug companies save money by not offering alternative therapies to 
participants in developing nations, but also the use of a PCT allows them to run the trial 
more quickly and move the drug through the FDA approval process faster.  As Macklin 
explains, “[i]n addition, the US Food and Drug Administration prefers a placebo-
controlled study whenever that design is ethically defensible . . . To industry’s advantage, 
the ability to compare a new drug with placebo shortens the time of the study and  makes 
the data more readily acceptable to the FDA, both of which lead to quicker profits for 
experimental products that prove to be efficacious.”219  Thus, it is the pharmaceutical 
industry’s benefit monetarily to argue that PCTs are ethically defensible, hence, the 
standard of care argument. 
                                                
219 Macklin, Double Standards in Medical Research in Developing, 8. 
117 
  Defenders of the standard of care argument, according to Macklin, are making 
three flawed assumptions.  First, PCTs are the gold standard even in circumstances where 
using that methodology compromises ethical standards.  Second, the only relevant 
research question responsive to the health needs of the host countries is “Is the 
experimental product being studied better than the ‘nothing’ now available to the 
population?”  Third, the only way (or best way) of obtaining affordable products is to test 
cheap alternatives to replace the expensive ones used in developed nations.220  In the 
following sections, we will discuss each of the assumptions in turn. 
 
Assumption 1: PCTS as the Gold Standard 
 Proponents of the standard of care argument, as discussed, contend that in 
countries where there is no existing therapy, a PCT is ethical as the placebo is not worse 
off than the treatment participants would be receiving had they not enrolled in the trial.   
If one does not accept that argument, proponents then make reference to the second bullet 
point in the Declaration of Helsinki: “[w]here for compelling and scientifically sound 
methodological reasons the use of placebo is necessary to determine the efficacy or safety 
of an intervention and the patients who receive placebo or no treatment will not be 
subject to any risk of serious or irreversible harm.”221  That is, the PCT is needed for 
scientifically sound methodological reasons, and trial participants are not being subjected 
to any additional risk due to the trial.  If they receive the placebo, they are only enduring 
the risk they are already facing from the illness if they do not enter the trial.   
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 In order to understand the need for researchers to set PCTS as the gold standard 
for optimal trial results, let us look at the regulations and guidelines the FDA sets for 
control choices.  As many drug companies seek FDA approval to market their drug in 
U.S., the regulations and guidelines put forth by the FDA are often the foundation for 
procedure choices.  Refusing to adopt the 2001 revision the Declaration of Helsinki, the 
FDA’s regulations and guidelines concerning PCTs are even vague and lax.222   
Regulations concerning preference of control can be found in the Code of Federal 
Regulations.  Title 21 Part 314 Section 126 discusses the choice of ACT over PCT. 
 (iv) Active treatment concurrent control.  The test drug is compared with known 
 effective therapy; for example, where the condition treated is such that 
 administration of placebo or no treatment would be contrary to the interest of the 
 patient.  An active treatment study may include additional treatment groups, 
 however, such as a placebo control or a dose-comparison control.  Active 
 treatment trials usually include randomization and blinding  of patients or 
 investigators, or both.  If the intent of the trial is to show similarity of the test and 
 control drugs, the report of the study should assess the ability of the study to have 
 detected a difference between treatments.  Similarity of test drug and active 
 control can mean either that both drugs were effective or that neither was 
 effective.  The analysis of the study should explain why the drugs should be 
 considered effective in the study, for  example, by reference to results in previous 
 placebo-controlled studies of the active control drug.223 
 
At best this regulation is vague.  It states that an ACT should be used where the placebo 
or no treatment would be contrary to the interest of the patient, but does not unpack what 
they intend by “interest of the patient.”  Furthermore, the regulation goes on to say that 
you can also use a placebo control in addition to an active control.  The key part of this 
regulation, however, which is echoed in much of the pro-PCT literature, is the emphasis 
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on effectiveness and demonstrating a difference between the existing therapy and the new 
therapy.   
 In their article “When placebo controlled trials are essential and equivalence trials 
are inadequate,” Martin R Tramér et al. analyze the value of ACTS versus PCTS in 
ordansetron trials.224  They found that in many of the ACTS, there was no difference 
between ordansetron and its active control, but as they argue no difference does not 
necessarily mean equivalence.  As they contend, 
 [t]he only conclusions that can be drawn if both drugs show similar efficacy are: 
 (a) both drugs are effective to a similar degree; (b) both drugs are equally 
 ineffective; or (c) the  trial design was inadequate - for example too small - to 
 show the real difference between the two treatments.  In equivalence trials we 
 need to know that both treatments were indeed effective in an A versus B 
 comparison of two active drugs.  To meet this criterion we need to know the 
 extent of the placebo response and that it does not vary.225 
 
In other words, ACTs only allow for a comparative claim: how effective is the new drug 
as compared to how effective the old drug is.  As Tramér et al. argue, there needs to be 
some evaluation of the new drug on an absolute scale.  That is how effective is the drug 
versus no other drug being given. 
 In his comparison between PCTS and ACTS, Mario Castro identifies the five 
most common arguments made by PCT supporters.  First, a double blind, randomized 
PCT is the most rigorous test for treatment efficacy.  This is the line of argumentation 
used by Tramér et al.  Second, because a PCT offers the opportunity to compare 
                                                
224 Ondansetron is a drug used to prevent nausea and vomiting caused from cancer 
chemotherapy, radiation therapy, and surgery. “Ondansetron,” MedlinePlus, accessed 
April 18, 2013. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601209.html. 
225 Martin R. Tramèr, D. John M. Reynolds, R. Andrew Moore, and Henry J. McQuay, 
"When placebo controlled trials are essential and equivalence trials are inadequate," 
BMJ: British Medical Journal 317, no. 7162 (1998): 876-877. 
120 
outcomes under maximal “treatment separation”, fewer patients are needed than would be 
required for an ACT.  This, in turn, increases the likelihood of detected benefit and/or 
harmful treatment-related effects.  Third, “a placebo group can be used as an ‘add on’ to 
standard of care in comparison to an investigational treatment added to standard of 
care.”226 That allows researchers to evaluate the true benefit or risk of a new therapy.  
Fourth, a PCT is justified if there is a high rate of placebo response or if the standard 
treatments are only partially effective.  Fifth, PCTs prove essential in determining trial 
endpoints when typically subjective measures are used due to variation in perception and 
reporting of patient-reported outcomes.227   
 Let us consider each of those arguments in turn.  First, I will address the first 
argument - PCTs are the most rigorous test for treatment efficacy- and the third argument 
- a PCT allows the placebo group to be used as an ‘add on” to standard of care versus 
added to standard of care.  Both arguments boast that PCTs are the best at determining 
the efficacy and benefits of a new therapy.  While there is no denying that a placebo 
control group maximizes the tested treatment’s efficacy as it is being compared to no 
treatment, there are other important measures that can only be achieved with an active 
control group. 
 Though in the cases we are examining where the studies take place in developing 
nations where no existing treatment exists, the tested drug will be sold in the developed 
world where alternative treatments do exists.  Thus, it would seem preferable to 
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understand how a new treatment would function in a general population where alternative 
treatments do exist.  ACTs provide that kind of data.  As Castro explains, ACTs “work 
well in late phase II and III trials where the goal is to test a new therapy in the planned 
manner of use in the general population.”228    
 In order to understand Castro’s argument, let us briefly examine the four phases 
of a clinical trial.  In phase I, the drug is tested on a small number of healthy volunteers 
(between 20 and 80) to determine dosage, identify acute side effects, and document how 
the drug is metabolized and excreted.  In phase II, the drug is tested on a larger set of 
participants (between 100-300) who have the disease that the drug could potentially treat.  
The goal of phase II is for researchers to gather safety data, preliminary evidence of the 
drug’s effectiveness, and to refine research methods for future trials of this drug.  If the 
results of phase II indicate that the drug may be effective and the risks are considered 
acceptable, the drug moves on to phase III.  In phase III, the drug is tested on a larger 
number of participants with the disease intended to be helped by the drug (between 
1,000-3,000).  The drug’s effectiveness is further tested, side effects are monitored, and 
the drug is sometimes compared to a standard treatment if one is already available.  Since 
this phase involves more individuals being tested over longer periods of time the less 
common side effects are more likely to surface.  Finally, in phase IV, the drug is 
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approved and on the market, and trials are conducted to determine the long-term benefits 
and risks of the drug.229 
 Returning to Castro’s argument, since phase II and phase III focus on the drug’s 
effectiveness and identifying risks and side effects, it makes sense to make the conditions 
of the trial such that they mirror the actual kinds of populations where the drug is 
intended to be used.  In most cases, that is in developed nations, where alternative 
treatments exist.  Furthermore, by comparing existing treatments with the new treatment, 
researchers will be better able to identify unique side effects of the tested treatment.  For 
example, perhaps all medications of a certain type cause dry mouth, but the new 
experimental drug has higher incidences of headaches.  Comparison amongst treatments 
is necessary in order to determine if the new medication is an improvement in terms of 
minimizing side effects. Overall, it seems that to best understand how effective a drug 
will be in developed nation populations, that ACTs be used.  Castro fine tunes this point, 
[t]he use of best-available-therapy control groups also provides pivotal evidence of 
efficacy and provides further information with regard to potential side effects from that 
medication.  This allows one to weigh the balance between efficacy versus side effects 
between two different therapies.”230 
 The second argument is that PCTs require fewer patients, which in turn subjects 
fewer patients to potential harmful effects of treatment.  The strength of this argument 
relies on the assumption that the tested treatment is potentially more harmful than no 
                                                
229 “Inside Clinical Trials: Testing Medical Products in People,” U.S. Food and Drug 
Administration, updated April 12, 2013, 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm. 
230 Castro, “Placebo versus Best-Available-Therapy Control Group in Clinical Trials for 
Pharmacologic Therapies Which Is Better?,” 572. 
123 
treatment at all.  In many of the trials under question for ethical violations, the treatment 
being tested is not an entirely new drug where researchers have no idea of the potential 
harmful consequences.  In the AZT trial, a lower dose of the existing treatment was being 
tested, and in the surfaxin trial, a new surfactant drug was being tested when many others 
already existed on the market.  In those trials, the harm posed to the those individuals 
receiving the new medications is by far outweighed by the harm undergone by those 
receiving no treatment in the placebo control group, where harm and potential death of 
aids and respiratory distress syndrome is guaranteed.   
 Additionally, while PCTs may require fewer patients, the dropout rate is much 
higher for PCTs as compared to ACTs.  In a study performed to compare dropout rates 
for PCTS and ACTS for antipsychotic drugs, George Kemmler, et al. reviewed 31 trials - 
11 PCTS and 20 ACTS.  They found the dropout rates to be notably higher for PCTS 
than ACTs.  For all antipsychotics trials (classical and second-generation), PCTS had a 
mean dropout rate of 48.9% while ACTS had a mean dropout rate of 30.3%.231   
Kemmler et al suggest that one reason for the higher PCT dropout is that patients’ 
willingness to participate is negatively affected upon finding out that the control will be 
receiving a placebo.232  Regardless of the cause, empirically PCTS have higher dropout 
rates than ACTs, which has two implications: either more patients have to be involved in 
the PCT to maintain enrolled numbers, or the dropout is so high that an additional trial is 
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needed to prove efficacy.  Either way, more participants are needed which means more 
participants are being subjected to potential harmful treatment-related effects. 
 The fourth argument is a PCT is justified if there is a high rate of placebo 
response or if the standard treatments are only partially effective.  The first part of this 
argument-high rate of placebo response- was addressed under the first and third 
arguments concerning the testing of efficacy.  The latter part of that argument - standard 
treatments are only partially effective - is unclear.  First, what constitutes a standard 
treatment being only partially effective?  If it improves the quality of life of the patients, 
some treatment is preferable to no treatment.  So long as there is health benefit to be had, 
there seems no reason to treat partially effective standard treatments any differently that 
wholly effective standard treatments.  Moreover, if what is at issue is the efficacy of the 
tested treatment, assuming the tested treatment is significantly more effective than the 
standard treatment, then ACTs would seem to show that statistical difference.  That is, 
the margin of effectiveness of the tested treatment would be of statistical significance 
over the standard treatment.  Finally, those cases that cause the most ethical concern do 
not have partially effective treatment, but rather wholly effective treatments.  Thus, this 
argument has little weight in our current discussion. 
 The fifth argument is PCTs prove essential in determining trial endpoints when 
typically subjective measures are used due to variation in perception and reporting of 
patient-reported outcomes.  Trial endpoints are a “measurable outcome that indicates an 
intervention’s effectiveness.”233   Since using a placebo control compares the 
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experimental drug to no treatment, the effectiveness is more easily noticeable, as any 
change in those taking the experimental drug is either a direct benefit or side effect of the 
drug.  As just discussed, there are more factors and questions surrounding a drug’s 
efficacy.  However, I am willing to grant that PCTs may be more helpful in determining 
trial endpoints.  Despite this concession, this argument is not enough to solidify the use of 
PCTs versus ACTs particularly when clinical equipoise is violated.  That is, there is 
guaranteed harm from disease for patients who are in the placebo control.   
 As a final note on the topic of PCTs versus ACTs, research shows that physicians 
show a preference for ACTs over PCTS.  In a study completed by Scott D. Halpern, 
MSCE, et al. in 2002, physicians were asked whether they would refer their hypertensive 
patients to a PCT or an ACT study for a new hypertensive drug.  Of the 651 physicians 
who completed the questionnaire, 67.1% indicated that they would probably or definitely 
encourage their hypertensive patients to enroll in an ACT.  Only 29.7% would encourage 
enrollment in the PCT.  Physicians with prior research participation were more likely 
than those without to encourage enrollment in ACTS. 234  To explain these results, 
Halpern et al. report  
 [p]hysicians viewed the ACT as providing more useful information for their 
 personal practices, as contributing more broadly to a public health benefit, as 
 offering enrolled patients a greater chance for personal benefit and as being less 
 likely to place subjects at unnecessary risks... In open-ended responses, physicians 
 generally offered 2 reasons for preferring ACTS.  Some felt that ‘if the patient has 
 hypertension and is responding to medication, it’s unethical to put him in a 
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 placebo trial.’  Others focused on the value of the information provided by the 
 different trial designs.  As one said, ‘I am interested in [the] benefit of newer 
 medications versus old.  We have already established that antihypertensives are 
 better than placebo.”235 
 
Furthermore, when asked which of ACT or PCT is more justifiable as a means of testing 
new antihypertensive drugs, 67.3% of physicians responded that ACTS were more 
justifiable than ACTS; whereas, only 10.4% thought PCTS were more justifiable.236 
 In this section, I challenged the notion that only PCTs can provide the adequate 
data necessary in testing an experimental drug.  I have also demonstrated that a 
preference for ACTs over PCTs exists in both the minds of participants and physicians 
who recommend trials to their patients.  I want to propose one more challenge for PCT 
supporters.  If PCTs are truly the gold standard, producing the best results for medical 
research, then why are they not run in developed nations?  Recall that in chapter 1, I 
describe how pharmaceutical companies run PCTs in developing nations because it 
would be unethical to run them in developed nations as the standard of care in developed 
nations has existing alternative treatments.  That is, if the trial were to be run in the 
developed nation, it would necessarily have to be an ACT.  Rather than challenge that 
ethical constraint, clinical trials have been exported to developing nations.  One would 
think that if PCTs would as medically and statistically necessary as proponents argue, 
then there would be a strong push to allow PCTs in developed nations, but there is not. 
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Assumption 2:  The only relevant research question responsive to the health needs of the 
host countries is “Is the experimental product being studied better than the ‘nothing’ now 
available to the population?” 
  I interpret this assumption as asking the question whether the only relevant 
research question responsive to the health needs of the host countries is “Is the 
experimental product being studied better than the ‘nothing’ now available to the 
population?”  My answer is no.  There are other relevant questions and considerations 
that ought to factor into the equation of whether the researchers are being responsive to 
the participants’ health needs.  Specifically, in this section, I will argue that guideline 
precedent calls on researchers to examine the risks and benefits to the research 
participants, and if we do so, then we find that for developing nation participants, the 
risks exceed the benefits. 
 The comparison of risks undergone by participants and the benefits received by 
the participants and other communities is mentioned many times in the various guidelines 
governing clinical research.  The Declaration of Helsinki states, 
 [e]very medical research study involving human subjects must be preceded by 
 careful assessment of predictable risks and burdens in the individuals and 
 communities involved in the research in comparison with the foreseeable benefits 
 to them and to other individuals or communities affected by the condition under 
 investigation.237 
 
The Declaration goes on to explain, 
 [p]hysicians may not participate in a research study involving human subjects 
 unless they are confident that the risks involved have been adequately assessed 
 and can be satisfactorily managed.  Physicians must immediately stop a study 
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 when the risks are found to outweigh the potential benefits or when there is 
 conclusive proof of positive and beneficial results.238 
 
CIOMS identifies three general ethical principles that all research involving human 
subjects ought to be conducted in accordance with: respect for persons, beneficence, and 
justice.  The latter two specifically discuss risks and benefits to participants.  In regards to 
beneficence,  
 [b]eneficence refers to the ethical obligation to maximize benefits and to 
 minimize harms.  This principle gives rise to norms requiring that the risks of 
 research be reasonable in light of the expected benefits, that the research design 
 be sound, and that the investigators be competent both to conduct the research and 
 to safeguard the welfare of the research subjects.239 
 
Under the principle of justice, the Council argues that concerning human subject 
research, the principle primarily refers to distributive justice, “which requires the 
equitable distribution of both the burdens and the benefits of participation in research.”240 
 Guideline 8 under CIOMS’ International Ethical Guidelines for Biomedical 
Research Involving Human Subjects goes on to address the risk-to-benefit ratio directly; 
 [f]or all biomedical research involving human subjects, the investigator must 
 ensure that potential benefits and risk are reasonably balanced and risks are 
 minimized. 
• Interventions or procedures that hold out the prospect of direct 
diagnostic, therapeutic or preventive benefit for the individual subject 
must be justified by the expectation that they will be at least as 
advantageous to the individual subject, in the light of foreseeable risks and 
benefits, as any available alternative.  Risks of such ‘beneficial’ 
interventions or procedures must be justified in relation to expected 
benefits to the individual subject. 
• Risks of interventions that do not hold out the prospect of direct 
diagnostic, therapeutic or preventive benefit for the individual must be 
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justified in relation to the expected benefits to society  (generalizable 
knowledge).  The risks presented by such interventions must be reasonable 
in relation to the importance of the knowledge to be gained.241 
 
Note that if benefits for the individual are not realizable, then there must be proven 
benefit to society as in generalizable knowledge.  As we have discussed in the 
introduction and will discuss in the next subsection, that generalizable knowledge is only 
made available to the developed world. 
 The FDA addresses the balance between risk and benefit in its criteria for 
Institutional Review Boards (IRB) approval of research; 
 [r]isks to subjects are reasonable in relation to anticipated benefits, if any, to 
 subjects, and the importance of the knowledge that may be expected to result.  In 
 evaluating risks and benefits, the IRB should consider only those risks and 
 benefits that may result from the research (as distinguished from risks and 
 benefits of therapies that should would receive even if not participating in the 
 research).  The IRB should not consider possible long-range effects of applying 
 knowledge gained in the research (for example, the possible effects of the 
 research on public policy as among those research risks that fall within the 
 purview of its responsibility.242 
 
Though vague in detail, the common go-to human research guidelines all offer rhetoric of 
maximizing the benefits and minimizing the risk for the human participants - a favorable 
risk-benefit ratio. 
 In an effort to clarify what is intended by a favorable risk-benefit ratio Ezekiel J 
Emanuel, David Wendler, and Christine Grady offer explanations of the ratio.  They 
argue, 
 [c]linical research can be justified only if, consistent with the scientific aims of 
 the study and the relevant standards of clinical practice 3 conditions are fulfilled: 
 the potential risks to individual subjects are minimized, the potential benefits to 
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 individual subjects are enhanced, and the potential benefits to the individual 
 subjects and society are proportionate to the or outweigh the risks.243 
 
The last condition of proportionality continues to be a vague area and a center for debate 
in the literature.  In general terms, Emanuel et al. intend,  
 the more likely and/or severe the potential risks the greater in likelihood and/or 
 magnitude the prospective benefits must be, conversely, research entailing 
 potential risks  that are less likely and/or of lower severity can have more 
 uncertain and/or circumscribed potential benefits244 
 
Admittedly, some risks and benefits are unquantifiable, and a more precise standard of 
evaluation is needed, particularly for cases that are not clear-cut.  However, I do not 
believe the case of PCTs in developing nations to be a vague case. 
 In analyzing the risk-benefit ratio for clinical drug trials in developing nations 
(particularly PCTs), let us first look to the risks undergone by participants.    In any 
clinical drug trial, be it ACT or PCT, participants undergo risk, - risk of complications 
from experimental procedures and risk of potential side effects from the experimental 
drug.  For example, in 1996 Pfizer used a Nigerian meningitis epidemic in children to test 
a new drug.  Of those who received the experimental drug, eleven died, and 200 others 
became deaf, blind, or lame.245   
 The risk to participants increases when pharmaceutical companies and researchers 
cut corners in an effort to save money and cut down trial time, as often happens in 
developing nations.  In that same Pfizer study, the experimental drug was given to 
children orally.   In the United States, any treatment of meningitis is normally given 
intravenously - a faster-acting route of administration.  The oral form of the drug had 
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never been tested previous to the trial in Nigeria.  Pfizer took additional short cuts in the 
Nigerian trial.  While industry guidelines mandate that all children in the trial must be 
given a spinal tap a day or so after administering the drug to see if it’s working, Pfizer 
made the spinal tap optional.  Moreover, children were initially supposed to have blood 
tests run on two separate occasions; however, the requirement of the second blood test 
was abandoned due to staff shortage.246    
 One might argue in epidemic situations, where the risks are already high for 
patients, people are willing to take higher risks for a cure than they would have been 
otherwise.  While that argument may justify the patients’ consent to lower standards, as 
they have no other treatment options, it does not, however, justify Pfizer’s lowering of 
standards.  Patients’ willingness to accept inferior treatment does not diminish Pfizer’s 
obligation to provide adequate care.  As will be discussed at the end of this chapter, 
consent does not justify inferior treatment. 
 There are more examples of researcher’s cutting corners in developing nations.  In 
1997 Jay Brooks Jackson ran a trial in Uganda testing the effectives of nevirapine - a 
drug to be used in preventing mother-to-child transmission of HIV.  Since the trial was 
not designed to for FDA approval, but rather as a public health inquiry, several corners 
and FDA guidelines were cut, which exposed trial participants to risk as well as future 
patients.  For example, the drug was supposed to remain at room temperature.  Jackson 
claims that it was, but the temperature wasn’t monitored.  Additionally, researchers did 
not report adverse events as serious if it was managed without hospitalization, even 
though FDA rules would categorize those events as serious.  Jackson argued that though 
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FDA’s requirement for documentation is understandable, as the FDA has seen a lot of 
scams, the hospital in Uganda, Mulago Hospital, does not keep records.  Moreover, there 
was no one available in Uganda to monitor the research to ensure conformity with FDA 
guidelines.247  While Jackson’s plight sheds light on practical problems of guideline 
enforcement, it does not, however, justify the cutting of corners.   
 India has, also, had several incidents of guideline violations.  In 2001, a 
researcher from Johns Hopkins tested an experimental cancer drug on dozens of cancer 
patients, which had not even been proven safe in animals.  In 2003, an Indian 
pharmaceutical company sponsored clinicians who administered an experimental drug, 
letrozole, to over four hundred women, who were told that the drug boosts fertility.  
However, according to the FDA, letrozole is an anticancer agent which is toxic to 
embryos, and moreover, letrozole has yet to be approved for medical use.248  These 
violations no only put participants at a higher risk level than is outlined in international 
guidelines, but at a higher risk level than participants would have been had the trial been 
run in a developed nations where there is a greater level of ethical enforcement.   
 In addition to the increased risk from cutting corners, participants are put at higher 
risk with the use of a PCT versus an ACT.  Many argue that there is little risk to the 
placebo control in developing nations, as they would be receiving no care had they not 
enrolled in the trial.  Recall that in the last chapter, I argue that this is the wrong 
comparison to be made.  Rather than comparing the developing nation participant’s 
actual world with one in which he did not enroll in the trial, we ought to compare the 
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participant’s actual world with the world in which they lived in a developed nation.  
Because as described in the introduction, many of the PCTs in developing nations would 
be run as ACTs in developed nations, we ought to compare the risk of using a PCT over 
an ACT.   
 Assuming that the cutting corners risks just described would be the same for a 
PCT versus an ACT, the primary risk for a PCT over an ACT is for the control group that 
is receiving the placebo.  Let us look at some of the harm endured by the placebo group 
in specific cases.  In March 1999, the Center for Disease Control and Prevention (CDC) 
announced results of their PCTs of AZT run in Côte d’Ivoire and Thailand.  They wanted 
to compare the HIV transmission rate when a mother is given a few weeks of AZT versus 
a placebo.  The short course of AZT halved the transmission rates, and of the over three 
hundred women receiving the placebo, nearly seventy of their babies were born HIV-
positive.249  This case is particularly troubling for a couple of reasons.  First, as seen with 
many other drugs, one of the major reasons why we are testing AZT at shorter courses is 
because the host countries, which are most in need of AZT, cannot afford the medication.  
For those infants who were born HIV-positive despite their mothers’ receiving the short 
course, roughly half of the tested group, their HIV status is in part the result of 
pharmaceutical companies keep the prices too high for AZT.   As a result of pricing, 
rather than running trials for new medications, the CDC must run trials to see if AZT can 
be used at lower doses to reduce costs.  A much easier solution would be for 
pharmaceutical companies to lower prices so such trials would not have to be run. 
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 Second, the CDC unnecessarily ran a PCT when there was an option of an ACT.  
Those fetuses in the placebo group had no improved chance of not being born HIV-
negative.  A commonly described scenario analogous to this one is the woman who walks 
by a baby drowning in a puddle of water.  Should not the woman turn the baby over when 
it would cost the woman so little and benefit the baby so greatly.  Instead of a puddle of 
water in the AZT case, the babies are in a puddle of HIV.  
 Third, perhaps most disturbing is that the CDC would not have been able to run 
the trial in the United States or any other developed country where AZT is available on 
the market because it would have been unethical.  As Macklin describes, 
 [o]nce it had been shown to be effective in reducing the transmission of HIV from 
 mother to child, the expensive AZT treatment became the standard therapy for 
 HIV-positive pregnant women in the US and other industrialized countries.  It 
 would surely be unethical to withhold form women in a research study an 
 effective treatment they could obtain as part of their routine medical care.  But 
 since women in the developing countries did not have access to any treatment 
 whatsoever, they would not be made worse off by participating in the study than 
 they would otherwise have been.250 
 
In other words, the woman does not have to turn over the baby drowning in the puddle 
because the baby would have died anyways had she not come along. 
 These arguments apply to the following situations as well.   In the early 2000s, 
gastroenterologist Paul S. Kelly, hired by Romark, in collaboration with the University 
Teaching Hospital ran a trial in Zambia for nitazoxanide, a drug to treat crypto, diarrhea, 
in both children who were HIV-negative and children who were HIV-positive.  Even 
though alternative drugs such as albendazole existed, a placebo control was used.  
Twenty-five of the HIV-negative children with crypto were given a three-day course of 
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the experimental drug, all of which improved.  Twenty-two HIV-negative children with 
crypto were in the placebo group.  Four of them died a week later.  For the HIV-positive 
children with crypto, twenty-five were given a three-day course of nitazoxanide, even 
though evidence suggested that such a short course would not work.  Five children died.  
Twenty-four of the HIV-positive children were in the placebo control, and four died.   
 Sonia Shah describes the heightened risk these children underwent because of the 
placebo control, 
 [i]t would be useful to know how the surviving children and the relatives of the 
 dead felt about the experiment after it was all over.  Did they know, as their 
 doctors must have, about the evidence that better cures for their children could 
 have been had with antiretroviral therapy, lengthy treatment with nitazoxanide, or 
 alternative drugs, such as albendazole?  Was the history of the drug and the 
 experiment - the facts that patients in the United States had refused to be involved 
 in an experiment such as this, and that it was designed to launch a drug aimed at 
 societies far distant from their own - made clear to  them?  These are unknowns.  
 Their experiences, save perhaps for a few lines of technical  data, went 
 unrecorded.  Like so many experimental subjects in poor countries, they melted 
 back into a social sphere that science rarely penetrates.251 
 
 In the proposed Surfaxin trial, half of the 650 participating babies would be 
assigned to a placebo group when four other known treatments exist on developed 
nations’ markets.  That is putting 325 babies with respiratory distress syndrome in serious 
danger of dying when they are in an environment that could provide them the care they 
need.  There are many more cases of developing nation trial participants in the placebo 
control group succumbing to their illnesses.  While it may seem there is no additional risk 
as that would have been their fate had the trial not taken place, that position assumes the 
wrong counterfactual question.  If we compare the risk of a developing nation participant 
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with the risk of a developed nation participant, we can see that the developing nation 
participant has the additional risk of being place in a placebo-controlled trial. 
 Let us now look at the benefits trial participants receive.  Just as in clinical trials 
in the developed world, developing world participants that are not in the control group 
receive the experimental medication that may aid in combatting their illness.  Both 
participants in the control group and experimental groups receive over all general medical 
care.  For example in SmithKline Beecham’s Havrix trial, a hepatitis A vaccine was 
tested on 40,000 children in Thailand.  All of the children in the trial would receive a 
hepatitis B vaccine and a hepatitis A vaccine if it proved effective.  Additional medical 
services were augmented; “[t]he research team contracted with community public health 
workers to examine all enrolled children absent from school at their homes, to provide 
necessary care, and, if appropriate to arrange transfer to the district or provincial 
hospital.”252   
 Moreover, there were benefits for the populations.  New refrigerators were 
provided to public health stations that did not have adequate refrigeration to store 
vaccines medicines and blood specimens.  Those public health stations that lacked FM 
wireless network access linking them to provincial hospital consultants were given 
access.  When the source of the hepatitis A’s rapid spreading was linked to deficiencies in 
toilet facilities, hand-washing facilities, and water storage, the researchers contracted to 
have the improvements implemented.  Public health workers were provided with an 
unlimited supply of disposable syringes and needles and were given training on how to 
reduce the incidence of blood-borne diseases.  All interested government personnel 
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working on the trial, including 2,500 teachers, public health workers, nurses, technicians 
and physicians, were given the hepatitis B vaccine.  In the process of tracking the deaths 
of all enrolled participants, researchers identified motor vehicle accidents as a major 
cause of mortality in the region and recommended corrective measures.  Finally, the 
training and experience the Thai researchers garnered through the Havrix trial may have 
facilitated subsequent trials.253 
 While it may seem that the SmithKline Beecham went above and beyond to help 
the participating children and the Thai community, it should be noted that, the same 
measures would be taken if the trial were to be run in the developed world.  The 
difference is that much of the infrastructure- including wireless networks, access to 
disposable syringes and needles, and the population receiving the hepatitis B vaccine - 
already exist in the developing world so there is no need for SmithKline Beecham to 
provide it.  This is true of clinical drug trials run abroad in general.  The health care in 
developing nations is so poor that any additional medical care offered would be 
considered part of appropriate medical care in the developed world.  If we view these 
benefits through my counterfactual lens, described in the previous chapter, then the 
developing world participants are not receiving any additional benefit than the developed 
world participants would have received had the trial been conducted there.   
 It is important to note which benefits developing nation participants are not 
receiving that developed nations participants are receiving, specifically technology and 
research garnered from the study and the availability of the tested drug should be proven 
effective at an affordable rate. The next subsection of this chapter will address this topic 
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at length.  However, for now, what is important to note is that, as discussed in the 
introduction, the tested drugs are only be made available at a reasonable rate in developed 
nations.  That was a chief complaint of several Thai scientists in the Havrix trial.  There 
was no provision that ensured that if proven safe and effective the vaccine would be 
made available to Thailand at a reduced cost.  There was, also, an insufficient transfer of 
technology.  Specifically, Thai researchers were not trained to conduct testing for 
antibody to hepatitis A and other laboratory skills.  Most importantly, the scientists 
argued that Thailand had no interest in the vaccine or expectation of deploy it.  As a 
consequence, the trial did not address a health need of the country, but rather a health 
interest of the US Army.  As the scientists argued, “Thai children who participated were 
used as ‘testing material’ for the benefit of the U.S. Army and others from developed 
countries.”254 
 As discussed in the last chapter, Thomas Pogge points out that one might say that 
all participants in a trial are benefiting with a placebo control as their chance of receiving 
effective treatment increases by enrolling in the trial.  For example in the Surfaxin case, if 
half of those enrolled received the Surfaxin treatment and the other half received the 
placebo, all infants enrolled have had their survival prospects boosted by a 50% chance 
of receiving the Surfaxin treatment.255  In the last chapter I argue why this argument uses 
the wrong counterfactual question; however, Pogge provides an additional argument on 
why this analysis fails.  He argues that the harms can be detached from the benefits, but 
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that those who argue in favor of overall benefit assume that the harms and benefits cannot 
be detached from each other. 
 Consider the following analogy: 
 a rich eccentric is eager to play a paint-bomb prank but wants to make sure it is 
 morally justifiable.  So she prepares two gift packages.  One contains a paint 
 bomb rigged to open with a loud bang and to splatter the recipient’s clothes.  The 
 other contains $30,000.  She  fills in labels with the names of two persons and 
 assigns the labels to the packages by the flip of a coin.  This satisfies our eccentric 
 that she is not harming either recipient.  In fact, she is benefitting both by giving 
 each a huge beneficial fifty-fifty chance of $30,000 or splattered clothing.256 
 
One can see the similarities between this analogy and the Surfaxin case.  The trial 
participants are randomly assigned just as the package recipients are.  Each has a fifty-
fifty chance of receiving a benefit (the Surfaxin treatment or $30,000) or a non-benefit 
(placebo or paint bomb, assuming that the paint bomb is not particularly harmful).   
 Pogge argues that there are cases where harms cannot be detached from the 
benefits.  In a mandatory vaccination program, we can neither identify which recipients 
will have an adverse reaction nor alter the vaccine so that it has the same benefit and no 
one has an adverse reaction.  In that case, Pogge maintains “[w]e can then defend the risk 
of harm to which we expose each child as an undetachable side effect of a program that 
brings each child an expected net benefit.  We can justify this risk to each child.”257  That 
justification does not work in the paint bomb scenario.  The eccentric’s claim that “she is 
probabilistically benefitting both package recipients appeals to an uncertainty that is 
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entirely of her own making and easily avoidable.”258  The eccentric could detach the 
harms from the benefit and give money to both individuals. 
 Similarly, Pogge maintains that the uncertainty of which infants will receive the 
Surfaxin treatment and which will receive the placebo is entirely of D-Lab’s own making, 
and is, thus, easily avoidable.  The harm is detachable form the benefit because D-Lab 
could give Surfaxin to everyone or use an ACT.  Pogge admits that using an ACT might 
make the trial more expensive by dispensing more medication and enrolling more 
subjects, the moral complaint of those infants receiving the placebo is not invalidated.  
Pogge argues, “it merely shows how this complaint can perhaps be answered by reference 
to some other good.  While the mandatory vaccination program can be justified as 
treating each child as best we know how, the Surfaxin trial cannot be so justified  to the 
infants in the placebo control group.”259 
 When evaluating the risk-to-benefit ratio, developing nation participants are 
taking on more risk than benefits when entering a trial.  That is, they are taking on the 
risks of potential side effects from the experimental drug, potentially being placed in the 
placebo control, and have their health put at risk by researchers who cut corners.  While 
there is some benefit in infrastructure and in health for those who do receive the 
experimental drug, the large benefit of improving society’s health through the availability 
of a new drug at a reasonable price is only garnered by the developed world, not the host 
nation.  More importantly, the developed nations are receiving the benefit of a new drug 
without taking on any of the risk.   
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 This tip in balance violates the guidelines used for international research.  Recall 
that both the Declaration of Helsinki and the FDA calls for the benefits to outweigh the 
risks.  CIOMS has two principles that the negative risk-to-benefit ratio violates.  These 
trials violate beneficence, which calls for benefits to be maximized and harms to be 
minimized, and they violate justice, which calls for the distribution of risks and benefits 
to be equitable.  Even if you do fully accept my risk and benefit analysis for developing 
nation participants, it is easy to see how the developed world benefits - having access to a 
new drug - without undertaking any of the risk.  This inequitable distribution alone 
violates CIOMS.  However, if you do adopt my counterfactual analysis under which to 
view risk and benefit, one can see that more risk is being undertaken by developing 
nations than benefit when we compare the trials to those run in developed nations. This is 
an additional violation of CIOMS. 
 Thus, supporters of the standard of care argument are wrong in their assumption 
that the only relevant research question responsive to the health needs of the host 
countries is “Is the experimental product being studied better than the ‘nothing’ now 
available to the population?”  First, international guidelines argue that we must evaluate 
the risk-to-benefit ratio.  In doing so, we can see how problematic developing nation 
trials are.  Furthermore, even if we do accept that the only relevant research question is  “ 
Is the experimental product being studied better than the ‘nothing’ now available to the 
population?”, the answer to that question is no.  With my risk analysis, we can see that 
the product being studied is not necessarily better than the nothing now available to the 
population.  
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Assumption 3: the only way (or best way) of obtaining affordable products is to test 
cheap alternatives to replace the expensive ones used in developed nations. 
  To understand researchers’ obligation to provide research garnered from the trial 
and the experimental drug should it prove effective, let us begin by examining 
international guidelines.  The Declaration of Helsinki makes mention of participants’ 
benefits from research results in two separate sections.  In paragraph 17, the Declaration 
states 
 [m]edical research involving a disadvantaged or vulnerable population or 
 community is  only justified if the research is responsive to the health needs and 
 priorities of this population or community and if there is a reasonable likelihood 
 that is population or community stands to benefit from the results of the 
 research260 
 
The lynchpin phrase in that paragraph is “reasonable likelihood.”  It does not say that the 
researchers must guarantee that the community benefits from the results of research, but 
merely that there is a reasonable chance that the community may benefit.  Not only is 
“reasonable likelihood” a vague phrase that many philosophers and medical experts argue 
over the meaning, but it allows for a community to not benefit from the results, even if 
that chance is low, and for at trial to be justifiable.  The Declaration goes on to state that 
participants are entitled to resulting benefits in paragraph 33, 
 [a]t the conclusion of the study, patients entered into the study are entitled to be 
 informed about the outcome of the study and to share any benefits that result from 
 it, for example, access to interventions identified as beneficial in the study or to 
 other appropriate care or benefits.261 
 
Just as in paragraph 17, paragraph 33 does not make any guarantees that the host 
community will benefit.  Rather, it maintains that participants are entitled to that 
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information; specifically, they are entitled to access to interventions.  Access does not 
mean that pharmaceutical companies must guarantee their receipt of such benefits.  It also 
does not mean that pharmaceutical companies must make that access easy or affordable.    
 Guideline 10 of CIOM’s guidelines directly addresses human research in 
populations and communities with limited resources; 
 [b]efore undertaking research in a population or community with limited 
 resources, the sponsor and the investigator must make every effort to ensure that: 
• the research is responsive to the health needs and priorities of the 
population or community in which it is to be carried out; and 
• any intervention or product developed, or knowledge generated, will be 
made reasonably available for the benefit of that population or 
community.262 
 
Similar to the Declaration of Helsinki, CIOMs relies on a vague phrase, “reasonable 
availability.”  What does it mean to make a drug reasonably available to a population?  Is 
allowing the country to buy it, whether they can afford it or not, making the drug 
reasonably available? While the comments on Guideline 10 go on to describe some of the 
relevant factors that figure into the calculus, they continue to remain vague on the 
meaning of “reasonable availability.”  
 As discussed in the introduction, there is a great disparity between the location of 
the highest prevalence of disease, developing nations, and the location of where the most 
apt drugs are available, developed nations.  With few medical resources and growing 
epidemics, developed nations are desperate to have access to existing proven medical 
treatments.  As South African bioethicist Solomon Benatar notes, 
 [t]here are many millions of people around the world who don’t have access to the 
 scientific advances of the last hundred years.  In fact, if you go to any developing 
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 country and ask the people there, they’d say ‘Well, we’re not so much interested 
 in doing research.  We’re interested in having access to the things that you have 
 already found that work!  Why come here to ask research questions when actually 
 what we need is what has already been discovered!  Why should we believe this 
 new research is going to benefit us if the old research doesn’t benefit us?’263 
 
In response to developing nations’ pleas, pharmaceutical companies have launched trials 
to see if existing medications are effective at lower doses, as a lower dose would be 
cheaper.  This was a motivating factor in the 1997 AZT trial that tested AZT at lower 
doses, which was responding to the surging AIDS epidemic.   
 Are lower doses the right solution, or are pharmaceutical companies able to sell 
existing treatments as a lower rate?   In her book The Truth About the Drug Companies, 
Marcia Angell closely examines the drug industry, looking particularly at the price of 
drugs and the research and development of new drugs.  Pharmaceutical companies argue 
that drug prices are priced high in order to cover the research and development costs.  In 
2001, pharmaceutical companies claimed that they spent $802 million for each new drug 
that they bring to the market.264   
 Angell makes many arguments challenging those claims, including the accuracy 
of the $802 million figure.  I want to focus on her arguments against the tie between 
research and development costs and drug prices. She argues that there is no reason to 
believe that research and development costs have anything to do with drug pricing.  In 
reference to the $802 million figure, the president and CEO of Merck stated, “[t]he price 
of medicines isn’t determined by their research sots.  Instead it is  determined by their 
                                                
263 Solomon Benator quoted in Sonia Shah, The Body Hunters: Testing New Drugs on the 
World’s Poorest Patients (New York: The New Press, 2006), 166. 
264 Marcia Angell, The truth about the drug companies: How they deceive us and what to 
do about it (New York: Random House Trade Paperbacks, 2005). 37. 
145 
value in preventing and treating disease.  Whether Merck spends $500 million or $1 
billion developing a medicine, it is the doctor, the patient, and those paying for our 
medicines who determine its true value.”265  As Angell points out, what is important 
about that remark is Mr. Gilmartin’s admission that the price of drugs would remain the 
same even if research and development costs were to change.   
 Moreover, pharmaceutical companies are not producing as much original research 
through their clinical trials as one may think.  For example, Burroughs Wellcome, the 
company that patented AZT, did not develop the technology or provide the first 
application of that technology that was used to determine if AZT would successfully 
suppress the HIV virus in human cells.  They were also not the first group to run a 
clinical trial with AIDs patients.  All of that was completed by the National Cancer 
Institute working with staff at Duke University.266  That story is not uncommon.  
According to Angell at least a third of the big pharma’s drugs are licensed or acquired 
from an outside source.267 
 If developing nations are unable to afford brand name drugs, what about generics?  
To understand the lack of availability of generics, we must examine drug patent law.  A 
patent on a drug lasts twenty years after filing with the U.S. Patent and Trademark 
Office.268  Once the patent expires, other companies may create generics of the drug.  
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When generics enter the market, the price of a generic medication can fall as low as 
twenty percent of the brand-name drug with brand name companies almost never 
lowering their prices.  That combined with the pharmacist's ability to substitute a brand 
name with a generic unless the doctor specifies otherwise cause brand-name sales to 
plummet.269 
 The loss of profit is a great motivator to extend the patents any way possible. 
Roger L. Williams, former FDA director of pharmaceutical science, observed that there 
are between ten and twenty different tactics used by pharmaceutical companies to protect 
their products.270  One of the major aides in their fight is the Drug Price Competition and 
Patent Term Restoration Act.  It was intended to enhance the generic medications market 
by simplifying the FDA approval process for generic companies.  They did not have to 
test their products in clinical trials; rather, they had to prove that their drug had the same 
active ingredients as the brand name and that it would act the same way in the body.   
 While it accomplished its intended job, increasing generic prescriptions from 
twenty percent in 1984 to fifty percent in 2004, it also created loopholes which 
pharmaceutical companies have sine taken advantage of.  The Act had several provisions, 
which extended patent life.  A patent could be extended up to five years if clinical testing 
and FDA approval created long delays in the drug appearing on the market.  Additionally, 
if a brand-name company sues a generic company for patent infringement, FDA approval 
of the generic drug will automatically be delayed for thirty months, no matter what the 
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merits of the suit are271.  As Angell explains, these provisions have led to increased 
efforts to extend their monopoly on a drug, 
 brand-name drug companies routinely file not just one patent on their 
 blockbusters but a series of them spread throughout the life of the first one.  These 
 patents are on every conceivable feature of the drug - never mind usefulness, 
 novelty, or non-obviousness, or how remote from the originally approved drug 
 and its approved use.  And remember patents are easy to get.  The result is the 
 generic companies are routinely charged with infringement of one of these 
 secondary patents, which immediately triggers thirty months of additional 
 exclusivity.272 
 
Thirty extra months of exclusivity translates into thirty more months, in addition to the 
already twenty years, that developing nations have to wait for generics to become 
available. 
 In desperate need of HIV medications at an affordable rate, in 1997 the South 
African legislature amended its Medicines Acts to allow the health minister to break 
patents and buy cheaper generics during health emergences or when patented medicines 
were unaffordable.  In response to the amendment, thirty-nine major drug companies 
went to court to prevent the amendment from being implemented.  The trade group 
Pharmaceutical Research and Manufacturers of America (PhRMA) argued that the law 
was arbitrary and gave the health minister too many powers.  Once again, Angell argues, 
western interests blocked Africans from accessing lifesaving medicines.273 
 If developing nations cannot afford brand-name drugs and the brand-name 
pharmaceutical companies attempt to prevent generics from being manufactured and sold 
in developing nations, then pharmaceutical companies have not met their burden of 
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providing the research, technology, and experimental drug to the tested community.  This 
tips the risk-to-benefit ratio in favor of developed nations - they receive the benefit 
without being burdened with the risk.   
 In order to fulfill that burden, as mentioned, pharmaceutical companies have 
turned to developing the drug at a lower dose, thus making it more affordable.  Not only 
does that take time, leaving countries without medication for even longer periods of time, 
but also there is no guarantee that the drug with be effective at the lower dose.  Their 
efforts may be for not.  It seems more reasonable and more ethically responsible for 
brand-name companies to sell their drug at a more affordable rate at the very least for the 
host country. 
 
Conclusion 
 In this chapter, I have argued against using the standard of care in the host country 
as tool by which we design clinical trials.  Rather, as I argue throughout, trial participants 
ought to be treated the same in both developed and developing nations, specifically on 
the issues of PCTs and the availability of research and the experimented drug after the 
trial.   
 There is one objection that I want to address.  Some argue that the standard of 
care gauge is justified because trial participants consent to the terms of the trial.  As 
discussed in the introduction there are major problems with consent in developing 
countries, but for the purposes of this objection as I have throughout, I will grant all 
conditions of informed consent are met.   
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 Pogge provides the most compelling argument for why, even under perfect 
informed consent, the clinical trials designed by the standards of care of the host 
countries would not be justified or permissible.  Consider the following scenario: a 
successful U.S. filmmaker uses radio equipment waiting for distress calls.  She finally 
hears one; a fishing vessel far out at sea has sprung a leak and is sinking in calm waters.  
The crew of three from no Bangladesh has no flotation devises and will try to survive by 
treading water.  As Bangladesh is a very poor nation, they will not make any efforts to 
save the crew.  Very rarely do ships pass through that part of the sea, and even if another 
ship heard the call, the ship would be unlikely to make the large detour.  The filmmaker 
radio backs a proposal.  She will helicopter to the scene and flip a coin.  If it comes up 
heads, she will rescue the crew and fly them to safety at no charge.  If it is tails, she will 
film whatever happens to them “naturally”, which is most certainly their slow deaths, and 
promises to save the next crew of fishermen that is in mortal danger.  The filmmaker 
intends to use the footage to make a documentary, which will be filmed in wealthier 
countries so that audiences may be educated on panic behavior and its effect on human 
survival in the sea.  The crew accepts her offer.  It is rational to do so as a fifty percent 
chance at being saved is far better than guaranteed death.  Thus, the filmmaker flips the 
coin.  It comes up tails, and she films their deaths. 
 Pogge argues, “[t]he case of the filmmaker shows vividly that a recipient’s prior 
fully informed and rational consent may not justify the treatment he receives as 
permissible when such consent is exacted as a condition for giving him some chance of 
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being saved from a horrible predicament.”274  In other words, consent does not justify the 
filmmaker’s actions as the crew was placed in a situation where they had no bargaining 
power to change the conditions of the agreement.  Under those circumstances, the 
filmmaker could have taken even worse actions - making the fishermen promise to give 
her all savings - and so long as her conditions were better than death, the fishermen are 
rational to agree.   
 The filmmaker case is analogous to the clinical trials situation.  Trial participants 
are suffering from diseases and infections with no hope of treatment.  Most would be 
willing to make great sacrifices for a chance at getting treatment.  Their consent does not, 
however, justify using placebos or withholding the experimental treatment after the trial 
is completed when pharmaceutical companies have the means to save them.   
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Chapter 5: Conclusion 
 I have argued that the double standard in clinical research between those run in 
developing nations versus developed nations is exploitative to the developing nation 
participants and host countries.  Trials run in developing nations continue to increase.  
Pharmaceutical companies and other research bodies are attracted to developing nations 
for many reasons including: financial benefit, high numbers of volunteers, and low 
dropout rates.  By looking at cases such as AZT and Surfaxin, we saw the many double 
standards between trials run in developing nations versus developed nations.  
Particularly, researchers are using a placebo control when a known effective treatment 
exists and is available to the general public in developed nations.  This violates clinical 
equipoise which demands that a trial end when it is known which treatment - the control 
or experimental - is more effective.  Additionally, pharmaceutical companies and 
researchers are not providing the experimental treatment to the host developing nation if 
the treatment is proven effective.  This is unfair to developing nations given that the risks 
and benefits of a trial are to be balanced for participants.  Since drug prices are too high 
for developing nations to afford, they do not have access to the benefits of the trial.  Thus, 
developing nations are taking all the risk but are not being afforded the benefits.   
 The best lens under which to view the wrongdoing of the double standards in 
clinical research is exploitation.  In its most minimal sense, exploitation means to take 
advantage of something or someone.  Intuitively it seems that pharmaceutical companies 
are taking advantage of developing nations and their lack of access to healthcare.  
Exploitation, also, provides a lens that is able to unify many research concerns.  Finally, 
the language surrounding the clinical research double standards centers heavily on 
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exploitation.  Therefore, it seems only appropriate to use the language and model already 
accepted in the literature.   
 Once we accept exploitation as the appropriate lens, we can see the difficulty 
existing theories have in explaining why the double standard is exploitative.  This 
difficulty arises from viewing clinical research in developing nations as mutually 
beneficial.  That is, both the researchers and trial participants benefit.  Trial participants 
benefit as they are left better off than they would have been had the trial not taking place.  
That is, they receive medical care in the trial versus the no treatment if the trial does not 
take place.  I look at three different approaches to exploitation.  Alan Wertheimer argues 
that exploitation is when A gains from a transaction or action that is harmful to B, where 
harm is defined in terms of an appropriate baseline.  Mutually beneficial exploitation is 
when A unfairly gains or gains in an excessive amount from a transaction that is 
beneficial to B.  Though he initially defines the baseline in terms of the competitive 
market value, he later rejects that in favor of an appropriate normative standard to be 
chosen.  The problem with Wertheimer’s account is that he offers no mechanism for 
determining what the normative standard ought to be, especially in the case of clinical 
research.  
 John Lawrence Hill argues that an interaction is exploitative if it 
 1) consist of an offer of benefit, never a threat 
2) which is made intentionally, knowingly or recklessly on the part of the offeror, 
such that it is likely to involve, implicate or take advantage of; 
3) a psychologically recognized vulnerability or weakness on part of the offeree; 
4) where the vulnerability or weakness characteristically results in a significant 
impairment of the rational-emotional capacity of the individual; 
5) that the offer actually has the effect of impairing the rational-emotional 
capacity of the offeree; 
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6) such that, but for the impairment of this capacity, the offeree would not have 
accepted the offer.275 
 
Hill’s account is problematic for many reasons, the primary of which is that it stipulates 
that it is not rational for the victim to enter into an exploitative transaction.  However, in 
the case of clinical research is seems perfectly rational for the developing nation citizen 
to enter the trial.  He has a chance of receiving lifesaving treatment by entering versus the 
zero treatment he receives if he does not.   
 Finally, Ruth Sample maintains that exploitation “involves interacting with 
another being for the sake of advantage in a way that degrades or fails to respect the 
inherent value in that being.” 276  Sample’s theory is very broad and relies on the phrase 
“to take advantage.”  Such broadness leads to many cases of wrongdoing that do not 
seem exploitative to be categorized as exploitation, such as murder. 
 Because I am dissatisfied that any single theory can account for all cases of 
exploitation, I proposed defining the necessary and sufficient for a type of exploitation 
rather than for exploitation as a whole.  I call the type of exploitation I am interested in 
comparative exploitation.  In comparative exploitation, A exploits B in interaction I iff 
 1. A does x to B in interaction I; and 
 2. there is a possible world in which C exists such that (1) B and C ought to be 
 treated equally; (2) if A and C engage in I under similar circumstances, A does  
not do x to C; (3) it is feasible for A to not do x to B; and 
 3. A treats B less equally than A has treated, treats, or would treat C in interaction 
 I for the sake of benefit. 
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The problem of clinical research is one of comparative exploitation.  The A is the 
researchers, the B is developing nation participants, and the C is developed nation 
participants.  Researchers are exploiting developing nation participants because 
developing nation participants and developed nation participants ought to be treated 
equally; it is possible for researchers to treat both groups equally; and researchers are 
treating developing nation participants less equally than developed nation participants.  
 Under my vision of comparative exploitation, clinical research exploitation, 
like many other cases of mutually beneficial exploitation, is erroneously considered 
mutually beneficial.  Under the traditional counterfactual account of harm, to suffer a 
harm is to come to be worse off than one otherwise would have been.  In an effort to be 
charitable to counterfactual account defenders, Matthew Hanser provides the following 
formulation of the counterfactual comparison of harm: “a person suffers harm if and only 
if there occurs an event e such that had e not occurred he would have been better off in 
some respect for some interval of time.”277  Two of the problems Hanser identifies with 
this account are preemptive harms and excessive multiplication of harm.   
 Ben Bradley offers a different account of harm that is not only able to solve the 
problems of preemptive harms and excessive multiplication of harm, but also explains 
why exploitation in clinical research, along with many other exploitation cases 
erroneously labeled as mutually beneficial, is harmful.  For Bradley, in order to 
understand the value of an action, we should focus on the following counterfactual 
conditional: “if X were to have happened, Y would have happened.”278  He understands 
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that statement to mean “to say that if X were to have happened, Y would have happened 
is to say that at the closest possible world in which X happens, Y happens.”279  In 
determining which possible world is closest to the actual world, one must adopt a 
similarity relation.  Because different similarity relations change which possible world is 
closest to the actual world, the value of an action must be relativized to that particular 
similarity relation. 
 I accept Bradley’s account of harm and argue that for comparative exploitation, 
specifically clinical research exploitation, we ought to ask a counterfactual question using 
a similarity relation in which in the closest possible world is one in which the interaction 
is nonexploitative.  Because developing nation participants would receive benefits in that 
possible world that they do not receive in the actual world, developing nation participants 
are being harmed. 
 If we do not accept Bradley’s account of harm, I argue that comparative 
exploitation is still an all-things-considered harm and would be deemed harmful under 
the traditional counterfactual account.  When A comparatively exploits B, A is promoting 
an exploitative attitude, one that publicizes B’s vulnerability to exploitation.  That 
attitude creates a climate of harm under which B, and individuals like B, are more likely 
to get exploited, which increases the likelihood that B will get harmed.  Furthermore, 
even if A does not harm B in their exploitative transaction, the likelihood of severe harm 
increases.  Thus, under a traditional counterfactual comparison, it is better for A and B to 
not interact than for A to comparatively exploit B. 
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 One challenge to claims of exploitation in clinical research is that participants 
in developing nations and developed nations should not be treated similarly.  Rather, the 
restraints for the trial, specifically the control group, ought to be determined by whatever 
the “standard of care” is for the host country.  Thus, if the known effective treatment is 
not available in the host country, it is acceptable to use a placebo control.  I argue that 
while international guidelines are vague, they do not necessarily support the standard of 
care argument.  Furthermore, those who support the different treatment are making three 
faulty assumptions, as identified by Ruth Macklin: placebo-controlled trials are the gold 
standard even in circumstances where using that methodology compromises ethical 
standards; the only relevant research question responsive to the health needs of the host 
countries is “Is the experimental product being studied better than the ‘nothing’ now 
available to the population?”; and the only way (or best way) of obtaining affordable 
products is to test cheap alternatives to replace the expensive ones used in developed 
nations.  In response, I argue that active-controlled trials provide a reliable alternative to 
the placebo control.  I also contend that the experimental drug is not better than the 
‘nothing,’ but that another relevant research question concerns the risk-to-benefit ratio for 
trial participants as mandated by international and FDA guidelines.  Finally, I maintain 
that pharmaceutical companies are not fulfilling their burden of making the drug 
available to the tested population, and that it is conceivable for those companies to sell 
the drug at a cheap price. 
 In sum, researchers are comparatively exploiting developing nation participants 
by offering them less than they would had the participants lived in a developed nation.  
That exploitation is not only morally wrong, but it is harmful to the participants and the 
157 
host nation.  In order to avoid that exploitation, we must move towards universalizing the 
standards for clinical trials. 
 
One More Problem 
 If we accept my account to be true, clinical research is exploitative and we ought 
to universalize conditions for trials in developed and developing countries, there still 
exists one major worry: there will no longer be an incentive for trials to be run in 
developing nations.  Thomas Pogge elaborates on this worry using Discovery Lab’s (D-
Lab) Surfaxin trial.  He argues that D-Lab has no good reason to run the trial in Bolivia 
unless it can use a placebo control.  Thus, D-Lab has three feasible options for testing 
Surfaxin.280  They are ranked as follows in nonmoral, cost-benefit terms: 
 Placebo-Poor: use a placebo-control design and conduct the test in a poor   
 country; 
 Active-Rich: use an active-control design and conduct the test in a rich country; 
 Active-Poor: use an active-control design and conduct the test in a poor   
 country.281 
 
As described in Chapter 4, placebo controls are economically advantageous for 
pharmaceutical companies, hence why the Placebo-Poor option ranks first.  Moreover, it 
is cheaper for a company to run an active control design in a rich country, as they would 
not have to provide the additional infrastructure and supplies that is often required in 
developing nations.  Recall the Havrix trial where researchers provided medical supplies, 
training, and wireless networking to the community in Thailand.  Those items need not be 
provided by the sponsoring research company in developed nations, as they are already 
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apart of existing infrastructure.  Thus, the Active-Rich option is more financially 
attractive than the Active-Poor option.   
 Pogge notes that “[w]hen morality places constraints on what an agent may 
demand from needy people in exchange for improving their situation, may such agents 
tend to ignore the plight of the needy people.”282  Therefore, as Pogge suggests, even 
though developing nations are in desperate need of medical attention that clinical trials 
can afford, we can reasonably expect fewer trials to be run in developing nations if 
standards are universalized.  The benefit at stake for developing nations is huge.  Even 
though the host nation and trial participants, particularly those in the placebo control, are 
being exploited, those receiving the experimental drug are receiving beneficial medical 
treatment that may prevent death.  In the Surfaxin example, if the trial is not run in 
Bolivia, then those infants in the experimental group are not receiving the Surfaxin and 
will surely die of respiratory distress syndrome.  And, that is exactly what happened.  
After receiving international criticism, D-Lab ran an active control trial in the United 
States.283   
 Agreeing with Pogge’s assessment, Alan Wertheimer suggests that to interfere 
with the exploitative interaction between developed nation researchers and developing 
nation trial participants may be better for no one.  He is not arguing that it is morally 
permissible for researchers to exploit trial participants, but rather that it is wrong to 
prevent such a transaction, where both parties benefit in some way, on the grounds that 
such transactions are unfair.  Wertheimer calls that argument the Permitted Exploitation 
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Principle (PEP).284  There are arguments for rejecting PEP, Wertheimer admits, including 
appeals to justice or ethical obligations.  However, there are plausible justifications for 
PEP, including the welfare of the exploited party.  Wertheimer believes that the question 
of whether to permit the exploitative interaction in clinical drug trials is an empirical 
question of effects. If developing nation participants are going to be significantly worse 
off without the trial, then there seems to be a justification for permitting the interaction.285   
 I disagree with Pogge and Wertheimer’s assessment.  While there is a possibility 
of clinical trials declining in developing nation with the universalization of standards, 
there are additional reasons beyond the cost effectiveness of placebo controls for 
researchers to run trials in developing nations.  These were identified in Chapter 1 and 
include: cheaper labor costs, rapid recruitment of participants, low dropout rates and 
participant complaints, and lower risk of drug interactions.  While D-labs may have 
altered their plan in the face of criticism, it is unclear whether it will be empirically true 
of all researchers and pharmaceutical companies given those listed advantages.   
 Moreover, the deeper concern is whether to permit such exploitation in light of 
the potential decline of trials in developing nations.  I, firmly, disagree with PEP within 
this context.  First, as I argued in Chapter 3, it is a misconception to believe that trial 
participants are not being harmed through the exploitative transaction.  Since there are 
benefits that developing nation participants are not receiving that developed nation 
participants are, developing nation participants are being harmed when we conceive of 
harm under Bradley’s lens.  Additionally, as Larry Mays argues, when researchers exploit 
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trial participants, even if those trial participants are not harmed, the researchers are 
creating a climate of harm that increases the likelihood of harm to developing nations.  
Thus, while in the short term it may be agreeable to allow exploitative drug trial practices 
to continue, in the long term developing nations may suffer extensive harm.  That 
justifies intervention of exploitative transactions even if there is a low probability of harm 
from that transaction. 
 Second, even if we disregard my harm analysis and accept that trial participants 
are benefited from the exploitative transaction, a moral wrong is still being done when 
the participants are exploited.  As a society, it seems we ought to intervene out of a 
deeper sense of justice.  Do not the trial participants deserve to be interacted with in a fair 
nonexploitative manner?  If we deem the exploitative transactions to be permissible then 
society is in a sense being held hostage by the exploiter, the pharmaceutical companies.  
In essence, the threat is to withdraw potentially lifesaving drug trials from developing 
nations if we hold them morally accountable for their actions.  Not only is this a bad 
practice for determining what we ought or ought not to do, but also it creates a dangerous 
slippery slope.  If we adopt a policy of allowing morally wrong actions that seemingly 
benefit the victim, then what prevents society from giving in on other moral wrongs, 
where the harm to the victim is more evident, when in similar hostage type situations?  In 
other words, where do we draw the bright line on permissibility of morally wrong 
actions?   
 Third, there is a need to intervene in exploitative clinical trials because, as Pogge 
argues, pharmaceutical companies are partly at fault for why quality healthcare is not 
available in developing nations.  Recall that in Chapter 4, I explain how pharmaceutical 
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companies, through manipulation of patent law and lobbying efforts, keep the price of 
drugs high.  A major consequence of which is that developing nations are unable to 
afford such medication and go without.  Moreover, the persistent impoverished state of 
many developing nations is also in part a result of the existing global economic order.  As 
Pogge explains, “insofar as the existing global economic order, through its strong 
centrifugal tendencies, contributes to the persistence of severe poverty in many poor 
countries, the most powerful states and their corporations and citizens, playing the 
dominant role in designing and imposing this order, share responsibility for such 
poverty.”286  As members that both contribute to and benefit from the global economic 
systems, pharmaceutical companies are excluding most people in poor countries from 
accessing lifesaving medications before even entering the country to run a trial.  As 
Pogge rightly suggests, while exploitation through clinical trials is morally wrong, that 
moral wrongness is made worse when the exploitation is able to occur as the result of an 
injustice the pharmaceutical companies help create. 287 
 Furthermore, though moral constraints may create the permissible exploitation 
dilemma, morality can provide the solution.  As Pogge argues,  
 [m]orality can hold that people with ample resources (money, time, etc.) ought to 
 make some effort toward preempting and reducing such root causes of severe 
 distress.  If most affluent people, corporations, and governments gave a little of 
 their wealth toward reducing severe poverty or toward beefing up emergency 
 services (hospitals, ambulances, coast guard, fire brigade), then we could avoid 
 and preempt most of the desperate needs and emergencies that agents such as D- 
 Lab . . . are tempted to take advantage of.288 
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Such a position is aimed towards achieving basic health care across all nations.289  This 
would in turn eliminate the injustice that pharmaceutical companies are taking advantage 
of when they exploit developing through clinical drug trials. 
 Pogge’s solution is an ideal one that reflects a deeper worry over economic 
disparity between nations.  That is not very helpful with our current dilemma over 
whether to allow exploitative clinical trials in developing nations because if we prohibit 
them, then trials may not be run in developing nations at all.  Accepting the overarching 
ideal of health care equality to frame the issue, Pogge also suggests practical solutions. 
 Pogge admits that holding pharmaceutical companies to a moral responsibility to 
alleviate the medical disaster among the global poor is a large task for a single company.  
As he describes, 
 [i]f one of them lived up to its moral responsibility - by making a major research 
 effort targeted at poor-country diseases, for example, or through a  massive 
 initiative of offering proprietary drugs cheaply to poor people in developing 
 countries - then it would quickly encounter the discipline of the market.  It would 
 face declining revenues with which to fund its research, gradually lose ground 
 against its competitors, and eventually end up in bankruptcy.290 
 
However, an effort made by pharmaceutical companies together may be create effective 
change in developing nation while not overburdening the companies.291 
 Assuming a public-good strategy, that is aiming reformations at what is good for 
the public, Pogge offers three practical reforms on how we may achieve that change.  
First, “the results of any successful effort to develop (research, test, and obtain regulatory 
approval for) a new essential drug are to be provided as a public good that all 
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pharmaceutical companies may use free of charge.”292  This suggestion counteracts the 
problem of high drug prices brought on by drug patents.  That is, if research is available 
to all, other companies may produce the drug.  This, in turn, creates competition, which 
drives the price of drugs down close to their cost of production.293   
 If we were to accept the first reform in isolation, there would be little incentive for 
pharmaceutical companies to spend money and effort in research.  This leads to Pogge’s 
second reform,  
 inventor firms should be entitled to take out a multiyear patent on any essential 
 medicines they invent, but during the life of the patent, should be rewarded out of 
 public funds, in proportion to the impact of their invention on the global disease 
 burden.294 
 
This reform restructures the incentive structure for such firms.  As Pogge describes, 
 any inventor firm would have incentives to sell its innovative treatments 
 cheaply. . . in order to help get its drugs to even very poor people who need them.  
 It would have  incentives also to ensure that patients are fully instructed in the 
 proper use of its drugs (dosage, compliance, etc.) so that, through wide and 
 effective deployment, they have as great an impact on the global disease burden 
 as possible.295 
 
Pogge also suggests that this would encourage pharmaceutical companies to work with 
generic producers, as the copying of the drug by generic producer increases the number 
of patients receiving the drug, which would, in turn, increase the favorable impact on the 
global disease burden.   
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 An additional advantage of such a model is that it would encourage companies to 
research diseases that are predominantly in poorer nations, such as tropical diseases.296  
Little research is conducted on such diseases, as there is little profit margin for the 
pharmaceutical company.  However, it is reasonable to think that the financial gain for 
improving the global disease burden would lead companies to research more tropical 
diseases.    One might think that this would, thus, reduce research on medical conditions 
that add little to the global disease burden.  In anticipation of such a concern, Pogge 
limits the new incentive scheme to essential drugs.  Drugs for other medical conditions 
would remain under the existing incentive model.297    
 Because the second reform requires a funding source for the incentives, Pogge 
suggests a third reform, “to develop a fair, feasible, and politically realistic allocation of 
these costs, as well as compelling arguments in support of this allocation.”298  In order for 
implementation to be successful the majority of the burden of cost will rest on developed 
nations’ shoulders.  Pogge offers give prudential reasons justifying developed nations’ 
shouldering the majority of the financial burden.  First, taxpayers in developed nations 
substantially benefit from the lower drug costs and/or insurance premiums.  Second, “by 
giving poor populations a free ride on the pharmaceutical research conducted for citizens 
in the affluent countries, we are building goodwill in the developing countries by 
demonstrating in a tangible way our concern for their horrendous public health 
problems.”299  Third, medical-research jobs in would be created in developed nations.  
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Fourth, the reform would rapidly increase medical knowledge with a broader array of 
medical interventions, which would enable developed nations to better respond to public 
health emergencies.   Fifth, better human health globally reduces the threat developed 
nations face from invasive diseases.300 
 It is not my intention to advocate or defend Pogge’s reforms.  Even he admits that 
his proposed reforms need to be better developed and more thought through.301  I merely 
want to show that there are possible solutions to maintaining clinical research in 
developing nations without sacrificing our moral standards for clinical trials.  Thus, rather 
than continuing to center on morally evaluating the double standards in clinical research, 
the future debate should focus on crafting reformative plans that can equalize the playing 
field between developed and developing nations.   
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